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ABSTRACT 
The trend in new vaccine development is directed towards the use of antigens 
with better immunogenicity/risk ratio and away from the use of inactivated or attenuated 
pathogens. However, in many instances, purified antigens are poorly immunogenic 
particularly in the form of a simple solution. Various particulate delivery systems with 
or without immunological adjuvants have been investigated in recent past to enhance the 
immune responses against purified antigens but very few of the investigated particulate 
vaccine delivery systems have been successful in overcoming regulatory and/or 
commercial hurdles. The principle objective of this research project was to develop and 
characterize a biodegradable nanoparticulate vaccine formulation for induction of 
enhanced antibody and/or cell-mediated immune responses against a model protein 
antigen.  
Many of the immunological adjuvants explored in the past were pathogen 
derived such as heat labile toxin of enterotoxigenic Escherichia coli, the B-subunit of 
cholera toxin or the Freund‟s complete adjuvant, which could become a possible risk 
inducing factor. Immunoglobulin-A (IgA) is an endogenous antibody recently reported 
to have an immunomodulatory effect after being taken up by lymphoid tissue probably 
through IgA specific receptors on M cells in mice and humans. The development and 
evaluation of a chitosan-dextran sulfate (CS-DS) nanoparticulate vaccine delivery 
system, with or without incorporation of IgA as an immunological adjuvant with M-cell 
targeting potential, was undertaken in this thesis work to serve the need and importance 
of research in the field of delivery of newer vaccines (proteins, nucleic acids, 
polysaccharides and synthetic peptides). 
In this investigation, CS-DS nanoparticles were prepared using a complex 
coacervation (polyelectrolyte complexation) technique. The optimized nanoparticle 
formulation was loaded with a model protein antigen (pertussis toxin) and/or IgA. This 
formulation system was evaluated for in-vitro (particle size, zeta potential, electron 
microscopy, entrapment efficiency, release profile and stability) and in-vivo 
immunological parameters.  
 2 
CS-DS blank nanoparticles of size and zeta potential in the range of 150 to 400 
nm and -40 to +60 mV respectively, were obtained. The ratio of chitosan to dextran 
sulfate, order of mixing and pH of nanoparticle suspension were identified as important 
formulation factors governing size and zeta potential of nanoparticles, which in turn 
affect stability and entrapment efficiency of the formulation. An optimized blank CS-DS 
nanoparticle formulation with particle size 314.7 ± 9.2 nm, zeta potential +53.2 ± 4.4 
mV and prepared with CS to DS weight ratio of 3:1 was used to load pertussis toxin 
(PTX) and/or IgA. An entrapment efficiency of higher than70%) was obtained for PTX 
and IgA in CS-DS nanoparticles and all loaded nanoparticle formulations showed less 
than 15% of initial release  followed by no significant release of IgA or PTX in release 
studies.  
The in-vivo uptake study of IgA-loaded CS-DS nanoparticles in nasal epithelia 
of Balb/c mice indicated the preferential uptake of nanoparticles in nasal associated 
lymphoid tissue (NALT) probably by M-cells. The in-vivo comparative immunological 
evaluation of detoxified pertussis toxin (PTXd)-loaded CS-DS nanoparticle formulations 
by subcutaneous (a parenteral route) versus intranasal (a mucosal route) administration 
highlighted the significance of route of administration. The PTXd-loaded CS-DS 
nanoparticle formulations were found to induce higher immune responses when 
administered through subcutaneous route compared to intranasal route. The 
immunological evaluation of developed formulations in female Balb/c mice groups 
showed that CS-DS nanoparticles formulations induced significantly higher serum IgG 
and IgG1 titers (p < 0.05) compared to conventional alum adjuvanted PTXd formulation, 
administered by the subcutaneous route. However, the IgG immune response induced by 
PTXd-loaded CS-DS nanoparticle formulations by intranasal administration were not 
significantly different (p < 0.05) compared to solution the PTXd solution formulation. 
The difference in level of immune response induced by different routes of administration 
highlighted the role of antigen-dose optimization for particular administration route, 
development of specific delivery devices for mucosal administration of vaccines 
especially for animal studies and the need of individualistic formulation research for 
different antigens. 
 3 
This study indicated the potential of CS-DS nanoparticles as a simple and 
effective particulate delivery system with in-built immunological adjuvant property for 
acellular protein antigens. The study also indicated the potential relevance of IgA as a 
novel immunological adjuvant for particulate vaccine delivery systems. The research 
embodied in this thesis highlights the need for further research in the field of vaccine 
delivery systems with greater emphasis on defining a correlation between 
pharmaceutical factors and in-vivo immunological responses. 
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CHAPTER 1 
LITERATURE REVIEW AND GENERAL 
INTRODUCTION 
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1.1. VACCINE DELIVERY SYSTEMS 
Vaccination has become the most effective strategy for prevention, control and 
eradication of infectious diseases. The research related to vaccines is often focussed on 
the identification and application of novel antigens. In the last few decades, advances in 
pharmaceutical delivery systems, the emergence of purified subunit antigens, emergence 
of new infectious diseases such as AIDS and the evolution of antibiotic resistance in 
microorganisms have resulted in the development of various novel vaccination 
strategies. One of these novel vaccination strategies is the use of pharmaceutical vaccine 
delivery systems for manipulation and enhancement of immune responses. 
Vaccine delivery systems have become more important with the continuous 
expansion of immunization programs as increasing the number of „stand alone‟ vaccines 
is problematic. Firstly, participation in the vaccine program may decrease when children 
need to receive more injections. Secondly, more injections pose a higher threat of 
infections in developing countries during immunization. Lastly, „stand alone‟ vaccines 
can significantly increase the cost of immunization programs. Development of 
combination vaccines containing two or more antigens solves the problem of the number 
of injections to some extent, but incorporation of a large number of antigens in a simple 
formulation can be risky and increases the risk of immunological and/or pharmaceutical 
interferences.
1
 The use of an appropriate delivery system may reduce or even overcome 
these problems. 
Delivery systems are also of great importance for the delivery of vaccines via 
routes other than the parenteral routes currently in practice for most infectious diseases. 
The delivery of an antigen to the mucosal surface can be achieved by several routes 
including oral, rectal, intranasal, pulmonary, or vaginal. Organized lympho-epithelial 
structures associated with the gut, upper respiratory tract and nasopharyngeal tissue are 
termed gut associated lymphoid tissue (GALT), bronchus-associated lymphoid tissue 
(BALT) and nasopharynx associated lymphoid tissues (NALT) respectively. These are 
the prime inductive sites for mucosal immunity.
2-4
 Mucosal immunization is an 
attractive alternative to parenteral administration of vaccines as it may offer advantages 
 6 
in the immunity generated and provide a non-invasive needle-free option for vaccine 
delivery. However, the advantages offered by mucosal routes are usually negated by 
possible degradation of antigens by enzymes or acid, rapid clearance or elimination of 
antigens due to ciliary or peristaltic movement and inefficient permeation of antigens 
across mucosa.
5
 Therefore, although mucosal sites are potentially immunologically 
active, specialized delivery systems with a higher dose of antigen are necessary for 
induction of effective immune responses. 
Clearly the success of vaccination is not only dependent on the nature of 
vaccine‟s immunogenic components (epitopes), but also on the delivery system.6, 7 
Various particulate delivery systems and fewer non-particulate systems have been 
reported in literature as carriers for antigens with many also showing immunostimulant 
effects.  
1.1.1. Particulate Delivery Systems 
The overall objective for pharmaceutical researchers has been to develop 
particulate nonliving delivery systems that have dimensions comparable to 
pathogens and may be efficiently taken up by antigen presenting cells (APCs), 
thereby generating and enhancing immune responses. Delivery systems promote the 
interaction of both antigens and adjuvants with the key cells of the innate immune 
system such as APCs including macrophages, dendritic cells and B cells, while 
facilitating generation of memory B- and T-cells in the adaptive immune effector 
arm of the immune response.
8
 Delivery systems, especially particulate ones, 
facilitate presentation of an ordered and repetitive array of B-cell epitopes, which 
result in more efficient B-cell activation through their antigen receptors.
9, 10
 
Although it is thought that the primary function of particulate delivery systems is to 
promote the antigen depot and enhanced uptake by APCs, it is still possible that the 
delivery system may have direct immunostimulatory/adjuvant effects on APCs. 
The adjuvant effect of particulate delivery systems has been suggested to 
be largely a consequence of their uptake into dendritic cells and macrophages 
following parenteral administration.
11
 In the case of mucosal delivery of vaccines, 
 7 
particulate structures potentially facilitate the specialized uptake by M cells present 
in organised lympho-epithelial structures. M cells can internalize the particles, 
microbes or antigen by various mechanisms such as clathrin-mediated endocytosis, 
fluid-phase pinocytosis, actin-dependent phagocytosis, and macropinocytotic 
engulfment involving disruption of the apical cytoskeletal organization.
12-15
 The 
antigen can then be actively transported to APCs. Moreover, particulate delivery 
systems can increase the retention time of antigens in local lymph nodes.
16
 The 
adjuvanticity of particulate delivery systems has also been ascribed by some to their 
ability to protect the antigen within the biological environment.
17
          
The potential benefits of particulate delivery systems in vaccination have 
resulted in the use of some conventional particulate drug delivery systems (e.g. 
microparticles, liposomes) for vaccine delivery along with the development of 
various novel particulate vaccine delivery systems. 
1.1.1.1. Microparticles and Nanoparticles 
Microparticles (1-100 µm) and nanoparticles (< 1 µm) have been 
studied by various groups
18-21
 as vaccine delivery systems via almost all routes of 
administration. It is generally accepted that particles in the nano-size range are a 
more efficient carrier with immunostimulant properties, when compared to larger 
size particles,
18, 21, 22
 but no definite particle size limits have been established 
from the current literature, as particles of different size ranges may follow 
different endocytic pathways and be preferentially taken up by different 
phagocytic cells.
23
 If uptake and processing of different sized particles occurs via 
different mechanisms, this may bias immune responses to generate a specific 
type of immunity. Particles in the size range of 20–200 nm are usually taken up 
by receptor-mediated endocytosis and elicit a cellular biased response, whereas 
particles with the size between 0.5 µm and 5.0 µm are predominantly taken up 
by phagocytosis and/or macropinocytosis and elicit a humoral response.
23, 24
 
However, the effect of particle size on the immune responses after vaccination 
has not been consistent therefore the use of a particular particle size for delivery 
system must be trailed on a case-by-case basis in combination with variations 
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such as route of administration, schedule of delivery, preparation method and the 
nature of the antigen and main excipients in the delivery system. 
   The availability of multiple natural and synthetic materials and versatile 
preparation procedures make polymeric micro- and nano-particles potential 
vaccine delivery systems which warrant further research evaluation.
25
 
1.1.1.1.1. Synthetic Polymers 
Poly-(lactide co-glycolides) (PLG) and poly-(lactic acid) (PLA) 
are the principal synthetic polymers investigated for incorporation of 
antigens, primarily because of their biodegradable and biocompatible 
nature.
18, 26
 These polyester polymers have also been extensively used as 
controlled release vehicles and suture material. The method most commonly 
used for the preparation of polyester based particulate vaccines is the double 
emulsification-solvent evaporation method using dichloromethane or ethyl 
acetate as the polymer solvent.
27, 28
 The aqueous antigen solution is 
emulsified into the polymer solution in organic solvent by sonication 
followed by homogenization of the first emulsion in poly-vinyl alcohol 
(PVA) or sodium cholate solution. Other methods, such as nanoprecipitation 
and simple emulsification (o/w) have also been reported for entrapment of 
antigen.
29
 However there are some problems commonly encountered during 
the encapsulation of antigens in synthetic polymers such as exposure of 
antigens to high shear, organic solvents, cavitation and localized elevated 
temperature, leading to antigen denaturation.
30
 Degradation of antigens may 
also occur following encapsulation and during the release from PLG particles 
when the polymer breaks down and releases an acidic component.
31
 To 
overcome some of these problems, alternative approaches such as adsorption 
of antigen on empty polymeric particles and use of more hydrophilic 
derivatives of synthetic polymers (e.g. PLA-PEG) for incorporation of 
antigens have been investigated.
32, 33
 Jabbal-Gill et al.
34
 reported an 
interesting strategy for adsorption of antigens to the surface of polymeric 
lamellar substrate particles (PLSP) that were produced by a non-solvent 
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induced precipitation of PLA or another suitable semi-crystalline polymer. 
Potential advantages of this technique include lack of antigen exposure to 
organic solvents, high shear stresses and low pH. The adsorption of antigen 
onto PLSP is dependent on antigen characteristics such as hydrophobicity, 
surface charge and conformation, as well as pH of the suspension and 
incubation period. Intranasal or parenteral administration of PLSP adsorbed 
antigens, induced a significantly higher systemic immune response in 
comparison to corresponding solution formulations administered at the same 
dose. The angular lamellar morphology of PLSP and good antigen stability 
during manufacturing are thought to be additional features of PLSP 
compared to spherical or plain PLA particles.
35-37
 Cationic PLG 
microparticles with adsorbed DNA enhanced the protective efficacy of a 
DNA-based tuberculosis vaccine and increased antibody and cellular immune 
responses to hepatitis B antigen.
38, 39
 The adjuvant effect of microparticles 
and nanoparticles has been suggested largely to be a consequence of their 
uptake into dendritic cells and macrophages or M-cells following parenteral 
and mucosal administration respectively.
11
 In addition, the acidic moieties of 
lactic or glycolic acid monomers liberated during erosion of the PLG or PLA 
polymers can assist in acidification of the endosomes of antigen presenting 
cells that will trigger antigen presentation via the MHC class-II pathway.
24, 40
 
PLG microparticles have been shown to be effective for the induction of 
cytotoxic T lymphocytes in addition to systemic and secretory mucosal 
immunity.
27, 41, 42
 The amount and sequence of the antigen that initiates the 
response may also influence the differentiation of CD4
+
 T cells into distinct 
effector subsets, that is, Th1 or Th2 cell responses.
43, 44
 Hence, when stability 
of the encapsulated antigen is compromised, this might result in the Th1 or 
Th2 skewing of the immune response, since the relative accessibility of 
different epitopes might change.
24
  
Various other synthetic polymers have also been investigated as 
carrier materials for vaccine candidates including sodium polystyrene 
sulphonate, polystyrene benzyltrimethylammonium chloride, 
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polyphosphazenes, polycaprolactone, polymethyl methacrylate and 
polydimethylsiloxane.
42, 45
 
One interesting multi-functional polymer which has been 
investigated for vaccine delivery is polyglutamic acid (PGA). PGA is a 
highly anionic polymer used to form antigen-loaded nanoparticles for 
induction of antigen specific immune responses.
46, 47
 While α-PGA is 
generally synthesized by an established chemical synthesis, various strains of 
Bacilli have been suggested for the microbial production of γ-PGA.48, 49 The 
γ-D-PGA capsule has been recognized as one of the important virulence 
factors of B. anthracis and is essential for establishment of a lethal anthrax 
infection.
50
 While not acting as an antigen on their own, γ-PGA nanoparticles 
can act as a vaccine delivery system with in-built immunostimulant effect for 
other antigens incorporated in a vaccine formulation.
51, 52
 
1.1.1.1.2. Natural and Semi-synthetic polymers 
Alternative biocompatible polymers have been widely evaluated 
for particulate delivery systems for antigens because of their aqueous 
solubility, biodegradable and bioadhesive properties. Much of the work 
undertaken with biopolymers has focused on their potential for mucosal 
delivery of vaccines. Chitosan and its derivatives have been used for vaccine 
delivery both in particulate and solution dosage forms.
53-55
 Chitosan and its 
derivatives form nanoparticles by a precipitation/coacervation method using 
a precipitating agent. Chitosan has very low toxicity and is soluble in 
aqueous acidic environments. In solution, the amine functional groups of 
chitosan are protonated which allows chitosan salts to bind strongly to 
negatively charged materials such as cell surfaces and mucus. This binding 
delays the clearance of chitosan formulations from the mucosal sites.
56
 The 
range of properties of chitosan and chitosan derivatives has resulted in a 
number of recent studies of chitosan and its derivatives in the delivery of 
peptides, proteins, drugs, genes and vaccines.
57-61
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Alginate is another biodegradable natural polysaccharide which 
has been widely studied through both the mucosal and parenteral route as 
delivery system component for vaccines. It is an algae derived anionic 
polysaccharide which can be used to prepare micro- or nano-spheres by 
ionotropic gelation using divalent or trivalent cations. Ajdary et al. 
62
  
reported that oral vaccination of Balb/c mice with BCG vaccine encapsulated 
in alginate microspheres resulted in higher proliferative and delayed-type 
hypersensitivity (DTH) responses and IFN-γ production in comparison with 
results of mice immunized orally with BCG alone. Following systemic 
infection with BCG, mice vaccinated with encapsulated BCG had lower 
mean bacterial counts compared to those vaccinated orally with BCG alone.
62
 
Rebelatto et al.
63
 reported high levels of anti-pig serum albumin (anti-PSA) 
IgG antibodies in serum and nasal secretions of Holstein female calves after 
intranasal vaccination with PSA encapsulated in alginate microparticles 
compared to the corresponding solution formulation, but no significant 
increase of PSA specific IgA. On the other hand, Tafaghodi et al.
64
 reported 
that intranasal immunization with alginate microspheres encapsulated with 
tetanus toxoid, results in strong systemic IgG and mucosal IgA response in 
rabbits. In a few recent studies researchers have reported that alginate coated 
chitosan nanoparticle are an effective subcutaneous or oral delivery system 
for hepatitis B surface antigen with in-built adjuvant properties.
65, 66
 
Many other natural and semi-synthetic polymers have been 
proposed to prepare microspheres for antigen delivery e.g. polyacryl starch, 
gelatin, cross-linked chondroitin-4-sulfate, modified collagen derivatives, and 
hyaluronic acid derivatives.
67-69
 
1.1.1.2. Vesicular Particulate Delivery Systems 
 The interest in vesicular systems for vaccines has given rise to various 
potential novel vaccine delivery systems in the last two decades. 
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1.1.1.2.1. Liposomes 
Liposomes are artificial closed vesicle structures composed of 
lipid bilayers separated by aqueous compartments. They are prepared from 
phospholipids similar to those naturally occurring in cell membranes and 
therefore are generally regarded as biocompatible. Liposomes can be 
prepared by suspending a mixture of desiccated lipids in an aqueous buffer. 
The lipid mixture should usually contain a large proportion of a neutral lipid 
such as phosphatidylcholine, and lipids used as either tracers or protein 
anchors, and the suspension is made by either sonication or extrusion through 
polycarbonate filters of defined pore size.
70
 Liposomes are conventionally 
divided into three types mainly based on the size and number of bilayers 
present in the liposome. Concentric layers of phospholipids with aqueous 
phases in-between form multilamellar vesicles (MLV) with an average size 
of 1-50 μm. Liposomes with a single bilayer in a size range of 100 – 500nm 
and 10-100nm are called as large unilamellar vesicles (LUV) and small 
unilamellar vesicles (SUV) respectively.
71
 As a consequence of the presence 
of both hydrophilic and lipophilic structures, a wide spectrum of antigens can 
be entrapped into or adsorbed on liposomes. Although most work with 
liposomes has involved systemic administration of vesicles, various studies 
in the last few decades have shown their usefulness for mucosal 
immunization. Liposomes have been identified as effective immunological 
adjuvant and delivery systems but formulation parameters such as surface 
charge, antigen density, site of antigen incorporation in liposomes, liposomes 
size and rigidity of bilayers need to be optimized for individual cases of 
antigens.
72-74
 The enhanced immune response obtained with administration of 
a liposome-antigen formulation is probably due to increased uptake and 
presentation of antigen, by both the particulate nature of liposomes as well as 
their ability to fuse with the epithelial cells of the mucosa.
71
 Liposomes are 
preferentially endocytosed by macrophages due to their ability to 
accommodate multiple copies of antigenic epitopes and this may also 
contribute to the adjuvant effect of liposomes.
75, 76
 The adjuvanticity of 
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liposomes has also been ascribed to their ability to protect the antigen within 
the biological environment and effects on the intracellular processing of 
antigen following uptake.
25
 
Although conventional liposomes have been reported as a 
promising delivery system for vaccines; instability on storage, sensitivity to 
host enzymes and rapid removal from the blood by the reticulo-endothelial 
systems limit their potential.
77, 78
 In the last few decades, scientists have 
reported various modifications in liposome delivery system to improve 
stability and further enhance the efficiency of liposomes as a vaccine delivery 
system. Microencapsulated liposome systems (MELs) have been investigated 
as a potential immunisation carrier for recombinant HBsAg.
79
 MELs were 
prepared by first entrapping the HBsAg particles within liposomes composed 
of phosphatidylcholine:cholesterol (1:1 molar ratio), which were 
subsequently encapsulated in alginate-poly(L-lysine) hydrogel microspheres. 
The study reported significant anti-HBsAg titres in mice subcutaneously 
administered with HBsAg in MELs, and indicated that MELs were relatively 
more efficient than conventional liposomes or alum in eliciting higher and 
prolonged antibody levels. The superior adjuvanticity of MELs is related to 
the increased residence of HBsAg in MELs at injection sites and the 
sustained delivery of the liposomal antigen from these systems.
80
 In the case 
of conventional liposomes, it is suggested that, a large fraction of the 
liposomes are degraded by phospholipases, resulting in liberation of the 
naked HBsAg particle to the surroundings, which is less efficient in eliciting 
the humoral immune responses.
79
  
Selective combination of the lipid components used in liposome 
formulation can achieve controlled stability of the liposomal membrane and 
selective release of encapsulated antigens in specific environmental 
conditions.
25
 One approach involves the use of pH sensitive lipids such as 
phosphatidyl-β-oleoyl-γ-palmitoyl ethanolamine. The liposomal membrane 
containing these lipids can destabilize at the slightly acidic pH of endosomes, 
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resulting in their fusion with the endosomal membrane and the release of 
peptide and protein antigens.
81, 82
 These type of liposomes have been reported 
to promote cell-mediated immune responses.
83
 
1.1.1.2.2. Proteoliposomes 
Proteoliposomes are nano-vesicles containing major outer 
membrane proteins and lipopolysaccharides representing selected pathogen 
associated molecular patterns. The term was formerly used to designate 
multi-molecular vesicles formed of highly hydrophobic outer membrane 
proteins of meningococci and other Neisseria species.
84
 In the literature the 
terms „outer membrane vesicle‟, „proteosome‟ and „proteoliposome‟ have 
been used interchangeably.
77, 84
 Proteoliposomes exert an adjuvant effect over 
antigens and have demonstrated an ability to induce potently enhanced 
immune responses against antigen with a modulation towards Th1 response. 
The proposed mechanism of action is that proteoliposomes contains several 
pathogen-associated molecular patterns (PAMPs) which are delivered as 
danger signals to immune competent cells (dendritic cells and macrophages) 
along with the antigen incorporated within.
85
 The mucosal application of 
proteoliposomes has been restricted to the nasal route, perhaps due to low 
stability of preteoliposomes in aqueous solutions with varying pH.
77, 86
 
Monovalent 
87
 and trivalent 
88
 influenza A/H1N1-proteosome (no LPS) 
vaccines administered IN produced high antibody titers in serum as well as in 
nasal secretions, suggesting that IN delivery of proteosome based vaccines 
may be able to produce both systemic and mucosal immunity. Furthermore, 
preclinical studies have shown that such a vaccine is capable of protecting 
mice upon challenge with the infective pathogen.
89-91
 
The proteoliposome technology has been successfully utilized in 
some commercial products such as VA-MENGOC-BC™ vaccine and 
Protollin™ mucosal adjuvant.92, 93 
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1.1.1.2.3. Virosomes 
Virosomes are small unilamellar vesicles, containing viral 
envelope glycoprteins embedded into the membrane.
78, 94
 Using preformed 
liposomes and hemagglutinin and neuraminidase, purified from influenza 
virus, Almeida et al.
95
 were first to report successful generation of membrane 
vesicles with spike proteins protruding from the vesicle surface. Due to the 
resemblance to native influenza virus, the system was named Virosomes.
96
 
The majority of methods employed to reconstitute influenza viral membranes 
are based on three steps: (a) detergent solubilisation of the viral membrane, 
(b) sedimentation of the internal viral proteins and the viral RNA genome by 
ultracentrifugation, and (c) reconstitution of the phospholipids and membrane 
proteins into a biological membrane by selective removal of the detergent.
96
 
Immunopotentiating reconstituted influenza virsomes (IRIVs) are spherical 
unilamellar vesicles with an average diameter of about 150 nm. They are 
reconstituted empty influenza virus envelopes and have been evaluated as a 
vehicle for trivalent inactivated influenza vaccine in humans and many 
animal models by the intranasal route.
97, 98
 Figure 1.1 depicts the schematic 
structure of an IRIV.  
 
Figure 1.1. Graphical structural representation of an 
Immunopotentiating Reconstituted Influenza Virosome (IRIV).
99
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Since the first description of influenza virosomes, virus envelopes 
have been reconstituted from a diversity of viruses. The viral component in 
virosomes enhances their efficiency in APC binding and promotes cytosolic 
delivery that enhances antigen presentation over MHC class-I.
100
 In addition, 
virosomes containing specific glycoproteins, such as those extracted from 
human parainfluenza viruses, also possess the ability to induce membrane 
fusion with cell surfaces.
101
 This suggests that incorporation of the membrane 
fusion glycoprotein in the design of particulate delivery systems is a useful 
feature for increasing the uptake of the antigen incorporated in the delivery 
system by APCs.
78
 Virosomes are already approved for human vaccination in 
two commercial products, Epaxal® with hepatitis A and Inflexal V® with 
influenza antigens.
102
 
1.1.1.2.4. Transferosomes and Vesosomes 
Transferosomes are highly deformable liposomes or vesicles 
developed mainly for transdermal delivery system of bioactives.
72
 
Transfersomes are composed of phospholipids such as phosphatidylcholine, 
but also contain surfactants, such as sodium cholate, deoxycholate, Span 80, 
Tween 80 and dipotassium glycyrrhizinate. The surfactant acts as an edge 
activator that destabilises the lipid bilayers and increases the deformability of 
the vesicle.
103, 104
 The serum IgG antibody titre generated in response to 
administration of tetanus toxoid in transfersomes, niosomes and conventional 
liposomes to the shaved skin of rats, and also an alum-absorbed tetanus 
toxoid given intramuscularly, was compared in an immunological study. It 
was reported that two applications of tetanus toxoid in transfersomes 28 days 
apart could induce an immune response that was equivalent to that produced 
by intramuscular injection of alum-absorbed tetanus toxoid. In comparison, 
niosome and conventional liposome formulations induced weaker immune 
responses.
105
 Transfersomes offer two main advantages, first, they are a non-
invasive and second, they give rise to high titer values with respect to other 
vesicular carriers. The transfersomes if suitably designed may have suitable 
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immunoadjuvant action and could be targeted to the APCs also.
106
 The 
transfersome structure offers the advantages of the liposome lipid bilayer 
while incorporating a surfactant that permits elasticity and deformation of the 
bilayer structure. This deformation allows the transfersome to squeeze 
through small spaces; thereby facilitating permeation through skin.
103
 It is 
likely that this ability of transferosomes to permeate the stratum corneum, 
which is the major permeation barrier of the skin, is the mechanism by which 
these vesicles are able to deliver incorporated antigen to APCs but exact 
mechanism of action still needs to get investigated. 
Vesosomes were initially developed as multicomponent or 
multifunctional bilayer vesicular drug delivery systems.
107
 Vesosome is a 
multicompartmental aggregate of tethered vesicles encapsulated within a 
large bilayer.
80, 108
 In the recent past, the vesosomes concept has been utilized 
for enhanced delivery of antigens through the transdermal route.
108
 Mishra et 
al. 
108
 investigated the potential of fusogenic vesosomes (cationic liposomes 
within an outer largely neutral liposomal bilayer) for topical delivery of 
tetanus toxoid antigen. In the immunisation study, the vesosomal systems 
were shown to elicit a combined Th1 and Th2 immune response following 
topical administration, suggesting the effectiveness of vesosomal systems for 
the topical delivery of vaccines. The authors have reported that fusogenic 
vesosomes have potential to microinject entrapped antigen directly into the 
cytoplasm of APCs, via a fusion event at the plasma membrane. The fusion-
mediated delivery of encapsulated antigen to the cytosol of APCs has been 
indicated as the reason for induction of class-I antigen presentation in 
addition to presentation with class-II MHC molecules, due to capture and 
endosomal processing of extracellular antigen encountered after the release 
or exocytic spill of antigen in the vicinity of APCs.
106, 108
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1.1.1.2.5. Archaeosomes and Exosomes 
Archaeosomes are liposomes made from the polar ether lipids of 
Archaea. Archaea is a Domain of prokaryotes, which is phylogenetically 
more related to Eukarya than to Bacteria.
109, 110
 Figure 1.2 represents the 2-
dimensional structure of an archeosome.  
 
 
Figure 1.2. Schematic 2-dimensional presentation of structure of an 
archaeosome.
111
 
 
These lipid structures provide formulary advantages, and 
contribute to the physico-chemical stability of the archaeosomes and their 
efficacy as self-adjuvanting vaccine delivery vesicles. The uptake of 
archaeosomes by phagocytic cells is several folds greater than that of classic 
liposomes. The immunologically important structural features of 
archaeosomes include: ether polar lipid structures leading to 
immunopotentiating interactions with the antigen-presenting cells (APCs), 
the ability to direct antigen cargo for MHC class I processing leading to 
potent induction of CD8+ T cell response, and the stability of archaeal lipid 
cores facilitating profound immune memory.
112
 Archaeosomes are stable to 
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oxidative stress, high temperature and alkaline pH, and resist attacks of 
phospholipases, bile salts and serum proteins.
113
 It appears that archaeosomes 
are taken up in APCs and the antigen is released into both cytosolic and 
phagolysosome compartments for processing, although the exact mechanism 
of antigen delivery has yet to be determined.
114
 It has been suggested that 
archaeosomes are sufficiently degraded in vivo, because internalized as well 
as surface bound BSA was equally able to induce an antibody response. It 
has also been shown that incorporation of the antigens into archeosomes was 
a precondition to achieve high antigen-specific antibody titers, because 
immunizations with antigen only mixed with archeosomes elicited 
significantly lower antibody titers.
115
 The potential of archaeosomes has also 
been reported for development of immunotherapy against cancer and 
infectious diseases in murine models.
116, 117
  
One another vesicle type which has been recently investigated for 
potential use in therapeutic cancer vaccine development is known as 
Exosome. These are 50–100-nm vesicles secreted by APCs, such as dendritic 
cells and B-cells, as well as a whole range of other cell types, including T-
cells, mast cells, tumor cells, and intestinal epithelia.
118-121
 The biological 
role of exosomes in vivo has not been completely elucidated but some 
researchers have suggested that a circulating network of exosomes in animals 
is responsible for distal communication between cells.
122
 This network can be 
suggested as mechanism for enhancement of the immune responses by 
exosomes. Indeed, Raposo et al.
119
 reported that B cell-derived exosomes can 
directly activate CD4+ T cells. Exosomes from different cellular origins bear 
distinct proteins of the producing cell type.
123, 124
 One of the most abundant 
protein families found in exosomes are tetraspanins, such as CD9, CD63, 
CD37, CD53, CD81, and CD82.
118, 123, 125
 Exosomes released from dendritic 
cells have been named dexosomes. They have characteristic protein content, 
incorporating a high number of MHC class I and II molecules and appear to 
be therapeutically and immunologically relevant.
123, 126
 Dexosomes pulsed 
with tumor-derived peptides elicited potent antitumor T-cell responses and 
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tumor regression in mice.
127
 The rationale for the use of dexosomes in cancer 
therapy is mainly founded on protein content of dexosomes and the ability of 
dexosomes to activate distant dendritic cell (DC) by delivering key 
proteins.
126, 128
 The manufacturing or preparation of exosomes for cancer 
immunotherapy purpose involves collection of monocytes from the patient 
followed by cultivation of monocytes in the presence of GM-CSF and IL-4 to 
let them differentiated in dendritic cells. After a specified time of culture, 
dexosomes released from dendritic cells are isolated and purified from the 
cell culture medium. Dexosomes could also be loaded with tumor cell 
derived antigens at different times during this process.
126
 Although, a few 
parenteral vaccine formulations for cancer immunotherapy based on 
dexosomes are under Phase I or II clinical trials,
129, 130
 more detailed research 
is required to understand and effectively utilize this delivery systems in mass 
populations. 
1.1.1.2.6. Niosomes 
Niosomes are unilamellar vesicles made up primarily of non-ionic 
surfactant molecules. They are very similar to liposomes except that synthetic 
amphiphiles are used in place of phospholipids for preparation of vesicles, 
which makes niosomes resistant to oxidative degradation. Initial 
investigations into the immunogenicity of these delivery systems showed that 
niosomes were generally better stimulators of IgG2a than Freund‟s complete 
adjuvant, but poor stimulators of IgG1, and that the adjuvant activity of 
niosomes was dependent on the entrapment of antigen within vesicles, 
mixing free antigen with vesicles was not effective.
131
 A subsequent 
investigation using 1-monopalmitoyl glycerol, cholesterol, and dicetyl 
phosphate in the molar ratio 5:4:1 demonstrated that both 560 nm and 225 
nm vesicle preparations induced higher interferon-γ concentrations than 
inoculation with 155 nm vesicles, in response to restimulation of splenocytes 
with the ovalbumin (antigen).
132
 Niosomes have generally been studied for 
parenteral administration, although they have also shown success through the 
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oral route with some formulation modifications.
133, 134
 The specific 
mechanism of action for niosomes has not been investigated but uptake of 
niosomes by GALT via M-cells on oral administration has been suggested. 
1.1.1.3.  Immunostimulating Complex (ISCOM) and ISCOMATRIX™ 
Immunostimulatory complexes (ISCOMs) are colloidal antigen 
delivery systems composed of antigen, cholesterol, phospholipid and saponin 
mixture Quil A. An ISCOM particle without antigen is called ISCOMATRIX
™
 
which has been reported to comprise an in-built adjuvant property.
17, 76, 135
 They 
are about 40 nm spherical aggregates of ring-like micelles.
1
 ISCOMs are 
prepared by solubilising protein antigen, cholesterol and phospholipids with a 
detergent (usually Triton X-100) which is subsequently exchanged by Quil A.
78
 
The lipid components of the formulation can be removed if the starting antigenic 
material is a virus suspension.
136
 Quil A saponins are derived from Quillaja 
saponaria (soap bark tree) and have been used as adjuvants in veterinary 
vaccines. Quil A saponins form strong complexes with cholesterol and probably 
enhance antigen transport through membranes of APCs by forming pores in 
membranes.
137
  Although initial studies with ISCOMs as vaccine delivery 
systems shown effective antigen delivery by both mucosal and parenteral routes 
resulting in stimulation of Th1 and Th2 CD4+ activity, MHC-I restricted CD8+ 
activity and secretory IgA, local reactions (pain and erythema) at the site of 
injection in human trials as well as difficulty in incorporation of some antigens, 
raised questions about the success of ISCOMs as delivery systems. Recently 
many of these problems have been overcome by use of either some additional 
excipients or physical incorporation of antigens with ISCOMATRIX
™
. ISCOMs 
and ISCOMATRIX
™
 vaccines have now been shown to induce strong antigen-
specific cellular or humoral immune responses to a broad range of antigens of 
viral, bacterial, parasite origin or tumor in a number of animal species including 
non-human primates and humans. The ability of ISCOMs and ISCOMATRIX
™
 
to induce cytotoxic lymphocytes (CTL) in humans makes them ideal for use in 
vaccines directed against chronic infectious diseases as well as for therapeutic 
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cancer vaccines. Additionally, ISCOMs and ISCOMATRIX
™
 also demonstrates 
significant potential as oral and intranasal adjuvants.
17
 
1.1.1.4. Cochleates 
Cochleates are bilayer sheets of stable protein phospholipid-calcium 
precipitates. The calcium ion stabilizes the formed spirals by ionic interaction 
(Figure 1.1).  
 
Figure 1.3. Simplified comparison of structure and properties of a liposome 
and cochleate.
138
  
 
Cochleate vaccines may be beneficial for mucosal administration 
specifically through the oral route because the delivery vehicle is very stable. 
They are prepared through the calcium-induced fusion of liposomes composed of 
negatively charged phospholipids, in particular phosphotidylserines, for example, 
dioleyol phosphotidylserine.
138, 139
 The inclusion of phosphotidylserine in 
liposomes was shown to enhance recognition and processing of liposomal 
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antigen by macrophages.
140
 Gould-Fogerite and coworkers
138
 hypothesized that 
as the cochleate outer structure is calcium rich, a partial fusion event occurs 
between the outer layer of cochleate and the cell membrane, which results in the 
delivery of a small amount of the encochleated antigen into the cytoplasm of the 
APC. Delivery of antigenic material to the cytoplasm allows access to the MHC   
Class-I presentation pathway which facilitates stimulation of CD8þ CTL. Also, 
some endocytic uptake of encochleated antigen leading to MHC Class-II 
presentation probably occurs.
138, 141
 Hoffmann et al.,
142
 however, reported 
contrary to the above results, that phosphotidylserine containing liposomes 
specifically inhibited immune responses to antigen in mice.  Proteins, peptides 
and DNA formulated into cochleates are effective vaccines when given by 
mucosal or parenteral routes.
138, 143
 Additionally, the efficacy and optimization of 
scale-up production of proteoliposome-derived cochleate delivery systems 
containing different antigens for intranasal immunization of Balb/c mice were 
evaluated in a series of studies. Proteoliposome derived cochleates are prepared 
to combine adjuvant properties of proteoliposomes with stability of cochleates 
that make the delivery system capable of inducing both systemic and mucosal 
antibody as well as Th1 type of immunity.
144-146
 
1.1.1.5. Virus like particles and SMBV 
The development of anti-viral vaccines has almost exclusively been 
based on live attenuated virus strains or inactivation of infectious virus. These 
vaccines induce strong immune responses but have some serious drawbacks 
including the possibility of accidental infection before inactivation, reversion of 
inactivating mutation or attenuated virus and potential to cause harm in immuno-
compromised individuals.
147, 148
 Virus like particles (VLPs) are virus-resembling 
particles composed of one or several viral proteins that, when over-expressed, 
spontaneously self-assemble into highly repetitive particles.
102, 149
  VLP vaccines 
combine advantages of whole virus vaccine and recombinant subunit vaccine. 
VLPs are structurally similar to viruses but, because they lack viral nucleic acids, 
are completely non-infectious. VLPs can be made using recombinant techniques 
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in expression systems that do not rely on viral replication. Moreover, VLP based 
vaccines can induce high antibody titers and strong cytotoxic T-lymphocyte 
responses against a target molecule. The superb immunogenicity of VLPs arises 
from the fact that they incorporate key immunological features of viruses such as 
repetitive surfaces, a potent stimulator of B cell responses,
10
 particulate structure, 
and sometimes induction of innate immunity through activation of pathogen-
associated molecular pattern–recognition receptors.150 VLPs can also be used to 
generate antibody responses toward antigens not derived from the VLPs parental 
virus. This is achieved by linking a foreign antigen to the surface of a VLP 
usually by chemical conjugation. This method has been used to couple a diverse 
range of antigens, including proteins, polypeptides, capsular polysaccharides, 
and small organic molecules. In this way, the underlying viral fingerprint of the 
VLP is imparted to the attached epitope, thereby rendering it as potent a B cell 
immunogen as the VLP.
151
 A novel use of this principle is to attach disease-
associated self-molecules to VLPs and to use the resultant conjugate vaccines to 
overcome B cell tolerance and induce neutralizing autoantibodies.
150, 151
 This 
technological innovation is the foundation that underlies Immunodrugs. 
Immunodrugs are therapeutic VLP vaccines designed to induce autoantibodies 
against disease-related proteins. They are comprised of VLPs derived from the 
RNA bacteriophage Qβ to which self-antigens are covalently attached. One 
Immunodrug, AngQb, achieved clinical proof of concept for lowering blood 
pressure in hypertensive patients.
152
 Currently, VLP-based vaccines, 
Recombivax
®
 and Energix
®
 for hepatitis B virus (HBV) have been licensed 
commercially.
151
 
Synthetic Biomimetic Supramolecular Biovector (SMBV) is a 
nanoparticulate system consisting of a positively or negatively charged 
polysaccharide core surrounded by a lipid membrane (dipalmitoyl 
phosphatidylcholine and cholesterol). The diameter of the particles ranges 
between 50 and 100 nm. The similarity to viruses in structure and size (Figure 
1.2) leads to a strong activation of the immune system against the presented 
antigens.  
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Figure 1.4. Schematic comparative presentation of a virus (left) and a 
SMBV™ loaded with antigens (right).153  
The SMBV system is able to deliver a broad range of antigens because 
of its dual character structure, that is, hydrophilic core and lipophilic cover, and 
the ability to adapt the charge within the core.
153
 The SMBV core is usually 
composed of maltodextrin modified with a quaternary ammonium moiety and 
these nanoparticulate structures are generally prepared by high pressure 
homogenization. The loading of antigens can also be undertaken after completing 
the preparation of „„empty SMBV‟‟ and this could be beneficial with the antigens 
that are unstable at high temperature/presssure.
154
 The phase-I clinical studies on 
human volunteers using a nasally administered SMBV-based trivalent influenza 
vaccine were well tolerated and induced mucosal and serum antibodies against 
all three influenza strains.
153, 155
 Whilst it has been hypothesized that the 
mechanism by which SMBV is able to promote humoral as well as mucosal 
immunity is linked to the presentation of antigens to the nasal mucosa,
154
 this has 
yet to be verified. Studies have shown that SMBV are strongly muco-resident in 
the nose of adult volunteers and might allow the direct binding of the antigen to 
the nasal mucosa.
78
 Furthermore, the antigen to SMBV ratio of 1/40 is reported 
as optimal for both systemic and mucosal immune response, probably because 
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this ratio of antigen and SMBV allows efficient binding of antigen to APCs.
154, 
156
 
1.1.1.6. Aquasomes and Dendrimer based delivery systems 
Aquasomes are three-layered structures (i.e., core, coating, and 
antigen/drug) that are self-assembled through noncovalent bonds, ionic bonds, 
and van der Wals forces.
157, 158
 They consist of a ceramic core whose surface is 
noncovalently modified with carbohydrates to obtain a sugar ball, onto which is 
adsorbed the therapeutic agent. The core provides structural stability to a largely 
immutable solid.
159
 Kossovsky et al
160
 demonstrated the efficacy of an 
organically modified ceramic antigen delivery vehicle. These particles consisted 
of diamond substrate coated with a glassy carbohydrate (cellobiose) film and an 
immunologically active surface molecule in an aqueous dispersion. These 
aquasomes (5–300 nm) provided conformational stabilization as well as a high 
degree of surface exposure to protein antigen (muscle adhesive protein). For 
muscle adhesive protein, conventional adjuvants had proven only marginally 
successful in evoking an immune response. However, with the help of these 
aquasomes, a strong and specific immune response could be elicited by 
enhancing the availability and in vivo activity of antigen.
160
 The use of ceramic 
core–based nanodecoy systems was proposed by Goyal et al161 as an adjuvant 
and delivery vehicle for hepatitis B vaccine for effective immunization. Self-
assembling hydroxyapatite core was coated with cellobiose, and finally hepatitis 
B surface antigen was adsorbed over the coated core. The antigen-loading 
efficiency of plain hydroxyapatite core (without cellobiose coating) and coated 
core were reported to be approximately 50% and 21% respectively. The 
preparation was found to be better than the conventional adjuvant alum on 
subcutaneous immunization in Balb/c mice. The nanodecoy systems were also 
found to be able to elicit a combined Th1 and Th2 immune responses.
161
 
 
Dendrimers are well-defined (monodisperse) synthetic globular 
polymers with a range of interesting chemical and biological properties. 
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Chemical properties include the presence of multiple accessible surface 
functional groups that can be used for coupling biologically relevant molecules 
and methods that allow for precise heterofunctionalization of surface groups. 
Biologically, dendrimers are highly biocompatible and have predictable 
biodistribution and cell membrane interacting characteristics determined by their 
size and surface charge. Despite the molecular characteristics of dendrimers, they 
have at present only to a limited extent been used as carrier molecules to enhance 
immunogenicity of antigens for vaccine purposes, with an exception of the 
lysine-based multiple antigen peptides (MAP) carrier dendrons.
162
 Although 
MAP dendrimers are developed specifically for presenting small peptide antigens 
to the immune system, the accommodation of nonpeptidic haptens (e.g., 
carbohydrates) and of several different types of peptides simultaneously (B and T 
cell epitopes) have also been demonstrated. The use of dendrimer based vaccine 
delivery is still in premature stages and further development and immunological 
investigations are needed to evaluated immunostimulant and carrier properties of 
these delivery systems.
163
  
1.1.2. Non-Particulate (Liquid) Delivery Systems 
Simple solutions have always been the first choice as delivery systems for 
vaccines due to simplicity and cost-effectiveness. However, most acellular safer sub-
unit antigens are not sufficiently effective without adjuvants to induce immune 
responses. Many of these vaccines were found effective when formulated in 
particulate vaccine delivery systems, resulting in exhaustive research in the field of 
particulate delivery systems in the last 3-4 decades. On the other hand, non-
particulate delivery systems with in-built adjuvant properties have also been 
developed and are in commercial use. One of the commercially successful non-
particulate delivery systems with in-built adjuvant properties is MF59
TM
, an oil-in-
water emulsion (o/w) consisting of small, uniform, and stable microvesicles, 
consisting of a drop of oil surrounded by a monolayer of non-ionic detergents. The 
oil is squalene, which is obtained from shark liver. Squalene droplets are stabilized 
by addition of two non-ionic surfactants, a low hydrophilic–lipophilic balance (HLB) 
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surfactant, polysorbate 80 (Tween 80), which is widely used as an emulsifier in 
foods, cosmetics and pharmaceuticals, including parenteral formulations, and 
sorbitan triolate (Span 85). The exact mechanism of action for MF59
™
 emulsion is 
not known but administration of MF59
™
 induced a significant influx of macrophages 
at the site of injection, which was significantly suppressed in mice deficient for 
chemokines receptor 2 (CCR2).
164, 165
 Thus, it is likely that one of the effects of 
MF59
TM
 is to trigger the production of chemokines in cells resident at the injection 
site. Ongoing studies show that a local immuno-stimulating environment is 
generated and that human immune cells can be directly activated in vitro by 
MF59
TM
. Irrespective of its mechanism(s) of action, the studies done on mice 
strongly suggest that MF59
™
 enhances functional and protective antibody 
responses
166-168
 and/or induces strong T-cell responses
166, 169, 170
  to several different 
types of antigen including bacterial toxoids (e.g., tetanus toxoid and diphtheria 
toxoid), outer membrane vesicles (e.g., Neisseria meningitidis), polysaccharide 
conjugates (e.g., meningococcal C conjugate vaccines), recombinant antigens (e.g., 
hepatitis B surface antigen, meningococcal B), and viral antigens (e.g., influenza 
antigens). Toxicology studies in animal models and clinical studies ranging from 
phase 1 to 4 have demonstrated the safety with different vaccines. In an extensive set 
of preclinical studies, clinical studies and postmarketing data, the MF59
™
 emulsion 
has been found to be a safe and potent vaccine adjuvant, resulting in the licensure of 
an MF59
™
-adjuvanted influenza vaccine in more than 20 countries.
171
 Furthermore, 
multiple emulsion delivery systems along with an additional immunostimulant have 
been reported as effective in animal models through the oral route of 
administration.
172
 
1.1.3. Live Attenuated Vectors And Edible Vaccines 
Live attenuated vectors are effective vaccine delivery systems because they 
are replicating microorganisms that have inherent adjuvant activity. The ability of 
some microorganisms to colonize in host, and the potential for including genes from 
unrelated microorganisms encoding relevant antigens, represent an attractive 
possibility for use of these microorganisms as vaccine delivery systems. Various 
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bacterial (e.g. Salmonella, Escherichia coli, Mycobacterium, Lactobacillus and 
Listeria monocytogenes) and viral (e.g. Poxviurses, Alphavirus, Adenovirus and 
Poliovirus) species have been investigated as vectors for vaccine delivery.
173, 174
 
Live, recombinant vectored vaccines have the advantage that they can stimulate both 
humoral and cell-mediated immune responses, and have a great potential for 
immunization either alone or in combination with a subunit antigen.
101
 There are a 
few live attenuated vector based veterinary and human vaccines available in 
commercial markets in few countries 
175, 176
 but further investigations are required 
for full utilization of this technology in humans. 
A major hurdle to the successful development of non-replicating oral 
vaccines is the lack of efficiency of the uptake of antigen in the gastrointestinal tract. 
A variety of approaches have been taken to protect antigens from digestive enzymes. 
One of the promising approaches is use of plants as recombinant biofactories to 
express a number of proteins including pharmaceuticals and potential vaccines. The 
use of plants as vectors has been reported advantageous as vaccine antigen 
production in plants is safe and potentially very cheap and infinitely scalable; plants 
can often be used to produce biologically active proteins far more easily than can 
bacteria or yeast; and the use of food plants could allow edible vaccines to be locally 
and cheaply produced in the developing world.
177
 Transgenic plants represent a 
potentially stable and cheap propagation source. However, development and 
selection of a suitable transgenic line can take many months and production at high 
yield is often not attainable or stable, often owing to the phenomenon of post-
transcriptional or siRNA-dependent gene silencing.
178
 Additionally, the potential to 
induce tolerance and the potential for the vaccines to inadvertently enter the food 
chain has been widely reported as possible disadvantages of this technology.
179
 
Overall, there are still major hurdles in the way of routine vaccine production via 
plants and this technology can only be expected to be commercially viable for 
vaccine delivery and development after further research. 
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1.1.4. Challenges and Limitations in the Development of Vaccine Delivery 
Systems 
Despite fast development in the level of sophistication in the design of new 
antigen delivery systems, a number of challenges, such as efficient loading of 
antigen into the carrier, targeted and specific delivery in the body whilst evading 
biological defence mechanisms, and enhancement of vaccine efficacy and safety, 
must be met for these systems to be scientifically and clinically relevant. For 
licensing of new or newly formulated vaccines, non-clinical and clinical data 
regarding safety and efficacy are required, next to pharmaceutical quality data. 
Compliance with the regulatory guidelines and the risks associated with vaccine 
development make it a costly process, urging the protection of Intellectual Property. 
However, licensing of a promising novel vaccine formulation, with demonstrated 
higher efficacy and safety, does not guarantee success. Higher costs and patient 
conservativeness may limit market uptake.
180
 Challenges and limitations in the 
development of vaccine delivery systems can be summarised in following points: 
 The need for increasing subunit vaccine efficacy. 
 The need for improving needle-free delivery. 
 The need for enhancing vaccine safety. 
 Target identification and mapping the need. 
 Lack of animal models which closely resemble human physiology in terms 
of expression of various antigen receptors for targeting purposes. 
 Regulatory hurdles for developing new vaccine delivery systems.  
 Poorly standardized methods for characterization. 
 Potential instability of antigens in delivery systems. 
 The need for simple formulations; easy and cheap to manufacture as well 
as scale up in production. 
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1.2.   IMMUNOLOGICAL ADJUVANTS 
The term “adjuvant” is derived from the Latin “adjuvare” which means „help‟ 
and was first used by Ramon in 1926 for a substance used in combination with a specific 
antigen that produces more immunity than the antigen used alone.
181
 For convenience 
and to avoid confusion  the use of the term “adjuvant” is avoided for vaccine delivery 
systems as not all of vaccine delivery systems show immunostimulant properties and 
simply act as carrier for antigen. Various non-specific and specific 
strategies/components have been investigated as immunological adjuvants for different 
antigens. The strategies or formulation components investigated for enhancing or 
modifying immune responses against antigens range from specific targeting ligands for 
particular receptors/cells to adsorption of antigens on chemical compounds. The 
immunological adjuvants for vaccines can be divided into the following main categories, 
1.2.1. Mineral salts 
Aluminium salts, principally aluminium hydroxide or aluminium 
phosphate, have been the most widely used adjuvants and are commonly referred to 
as alum. These adjuvants are components of several licensed human vaccines, 
including diphtheria-pertussis-tetanus (DPT), diphtheria-tetanus (DT), DT 
combined with Hepatitis B (HBV), Haemophilus influenza B or inactivated polio 
virus, Hepatitis A (HAV), Streptococcus pneumonia, meningococcal and human 
papilloma virus (HPV).
182
 Formulation is achieved through adsorption of antigens 
onto the aluminum hydrogel. The mechanisms of action of the aluminum salts 
frequently cited include: depot formation facilitating continuous antigen release; 
particulate structure formation promoting antigen phagocytosis by antigen 
presenting cells such as dendritic cells, macrophages and B cells and; induction of 
inflammation resulting in recruitment and activation of macrophages, and increased 
MHC class II expression and antigen presentation.
183, 184
 Advantages of aluminum 
adjuvants include their safety record, augmentation of antibody responses, and 
relatively simple formulation for large-scale production. The major limitations of 
aluminium adjuvants include their inability to elicit cell-mediated Th1 or CTL 
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responses that are required to control most intracellular pathogens such as those that 
cause salmonellois, tuberculosis, malaria, leishmaniasis, leprosy and AIDS.
181
 
Moreover, vaccines containing alum cannot be frozen because this leads to loss of 
potency. Accidental freezing is a widespread phenomenon occurring in up to 70% 
of vaccines in developing countries.
185
 Additionally, alum has been occasionally 
associated with serious side effects such as erythema, granulomas and induction of 
IgE and IL-4 (allergy and immediate hypersensitivity).
186-188
 Alternatively, calcium 
phosphate has been used to adsorb antigens which does not induce IgE production 
in animals or humans.
186
 Mineral salts are not suitable for mucosal immunization 
because of their mode of action by formation of antigen depots and reported they 
are to be ineffective when used in conjuction with DNA-based vaccines.
188, 189
 
1.2.2.  Microorganism-derived adjuvants 
Microorganism-derived substances have a high degree of 
immunogenicity and immune enhancing capabilities. Many species of bacteria have 
been used as a source of potential adjuvants such as Mycobacterium spp., 
Corynebacterium parvum, C. granulosum, Bordetella pertussis, E.coli and Neisseria 
meningitides.
190
 Bacteria toxins were the first investigated group of bacteria derived 
substances used as adjuvants. The important bacterial toxins investigated as 
immunological adjuvants include inactivated pertussigen, heat-labile toxin (LT) and 
cholera enterotoxin (CT).
188
 These bacterial toxins showed enhancement of different 
branches of immune responses (mucosal and/or humoral and/or cellular) and have 
been investigated through both mucosal and parenteral routes of administration in 
various animal studies but the toxicity associated with these bacterial toxin 
adjuvants does not allow their use in humans. One important example of toxicity 
linked to bacterial toxins was the withdrawal of heat labile toxin (LT) adjuvanted, 
intranasal trivalent influenza vaccine which was approved for distribution and use in 
Switzerland following successful clinical studies, but was withdrawn following 
reports of Bell‟s palsy in some recipients. The pathogenesis of Bell‟s palsy as 
associated with the intranasal influenza vaccine is unclear although the presence of 
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E. coli enterotoxin in the vaccine was suggested as a possible risk inducing 
factor.
191, 192
 
The toxicity issues related to bacterial toxins derived adjuvants lead to 
investigations for use of more specific and purified microorganism-derived 
components (e.g. muramyl dipeptide, monophosphoryl lipid A, CpG motifs) as 
adjuvants.
193, 194
 Muramyl dipeptide (MDP) is a bacterial derived less toxic 
compounds capable of stimulating both humoral and cellular immune responses.
195
 
DNA containing CpG motifs and synthetic oligodeoxynucleotides containing 
unmethylated CpG motifs are one of the most potent cellular adjuvants.
196
 
Monophosphoryl lipid A (MPL) was the first immunological adjuvant capable of 
activating T-cell effector responses to be used in a licensed vaccine.
197
 MPL in 
various formulations such as in emulsion formulations has been investigated in 
many clinical studies for induction of strong humoral and cellular immune 
responses against different antigens.
198, 199
 The adjuvant activity of most 
microorganism-derived substances is mediated through activation of toll-like 
receptors (TLRs) which mediate the danger signals activating the host immune 
defence system.
200
  
1.2.3.  Miscellaneous adjuvants 
There are various other substances which have been investigated as 
immunological adjuvants but with no commercial success for human use yet. The 
important categories of substances explored as immunological adjuvants include 
cytokines (granulocyte macrophage-colony stimulating factor and interleukin-12), 
polysaccharides (inulin, chitosan and dextran), saponins (Quil-A) and some 
synthetic polymers.
181
 The exact mechanism of action behind these substances 
acting as immunological adjuvants is not known and more in-depth research is 
warranted.  
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1.3. TARGETING LIGANDS  
Targeted delivery of antigen to particular cells or receptors is one of the 
approaches for a vaccine formulation as this strategy has the potential to provide a better 
efficacy to risk ratio for immune responses induced by incorporated antigen. The 
organised mucosa-associated lymphoid tissues (O-MALT) are antigen-sampling and 
inductive sites of the mucosal immune system. At these sites, antigens are transported 
across the mucosal epithelial barrier to prime underlying lymphocytes for a subsequent 
immunological response. Specialised cells termed membranous epithelial (M) cells are 
responsible for this transepithelial antigen transport, and putative M cells have been 
identified at multiple mucosal sites.
201
 M cell specific surface carbohydrates have proven 
invaluable for M cell identification in experimental studies and, since microorganisms 
frequently use carbohydrates as cell surface receptors, they offer a mechanism to 
account for the M cell selective interaction exhibited by many microorganisms. The site 
and role of M cells in the immunological system makes them one of the potential sites 
for targeting of antigen formulations.
202
 
Many lectins such as Ulex europaeus 1 (UEA1) and wheat germ agglutinin 
lectin (WGA) have been used for the targeting of antigen formulations to M-cells 
through the mucosal routes (oral, nasal, rectal) in animal models.
203, 204
 The lectin-
binding characteristics of the M cell apical membranes exhibit considerable species and 
site-related variations, and there is also evidence of heterogeneity among M-cells within 
individual domes which limits the success of lectins as M-cell targeting agents in 
humans. The M-cell specific plant lectins such as UEA-I and WGA have been reported 
to be only effective in a mouse model because L-fucose, the M-cell surface carbohydrate 
to which these lectins specifically bind, is reported to be absent on human M-cell 
surface.
205, 206
  
Another group of sites that has been identified as ideal for vaccine targeting is 
toll-like receptor (TLR) expression implicated in diverse cell types such as airway and 
gut epithelial cells, B-cells, mast cells, NK cells, dendritic cells, regulatory T-cells, 
macrophages, monocytes, neutrophils, basophils and endothelial cells.
207, 208
 TLRs are 
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transmembrane signaling proteins expressed by cells of the mammalian immune system, 
showing specific binding to different ligands of varied molecular nature.
209
 The 
discovery and elucidation of TLR function has provided new knowledge on the host 
pathogen interface, and a more comprehensive view of immunological events and 
pathways.
210
 In addition to microbial interaction and intervention, a number of agents 
that can be used as adjuvants have been associated with specific TLR involvement 
(Table 1.3) in the initiation and qualitative direction of immune responses. With the 
exposition of TLRs and their immunological role, development of a vaccine formulation 
incorporating a ligand/adjuvant for specific targeting of a particular TLR is emerging as 
a promising strategy for efficient and safe delivery of antigens. However the success of 
this strategy will be dependent on the invention/development of safer and specific 
immunological adjuvants for TLRs and further elucidation of immunological roles and 
mechanisms of TLRs. 
 36 
Table 1.1. Selected adjuvants and natural ligands recognized by Toll like receptors 
(TLRs).
190, 210
 
 
TLR type Adjuvant/Natural ligands 
TLR 1 Triacyl lipopeptides, E.coli type II heat labile entertoxins 
TLR 2 Muramyl dipeptide (MDP) derivatives, viral glycoproteins, E.coli 
type II heat labile entertoxins 
TLR 3  Polyinosinic-polycytidylic acid (synthetic dsRNA analog) 
TLR 4 Monophosphoryl lipid A (MPL) and MDP derivatives 
TLR 5 Flagellin 
TLR 6 Diacyl lipopeptides (macrophage-activating lipopeptide-2) 
TLR 7  ss RNA/guanosine analog, Imiquimod 
TLR 8 ss RNA, small synthetic compounds 
TLR 9 CpG oligonucleotides 
TLR 10 Unknown 
TLR 11 Profilin 
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1.4. ROUTE OF ADMINISTRATION  
One important factor which is linked not only to efficiency of a vaccine but also 
to the cost of vaccination and acceptability of a vaccine by population is route of 
administration. Conventionally, most of the vaccines are administered as injections by 
parenteral routes mainly to avoid any potential loss of activity or stability of antigen on 
exposure to mucosal environment and also due to requirement of mostly lesser dose of 
antigen for being effective compared to mucosal administration. But in the past few 
decades with the development of novel vaccine delivery systems and newer 
immunological adjuvants, various other routes such as intranasal, oral, sub-lingual, 
transdermal and rectal have been investigated as promising routes for delivery of 
vaccines. Different delivery systems with or without an immunological adjuvant were 
found useful for particular (type of) antigens and for different routes of administration 
(Table 1.2 and 1.3). 
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Table 1.2. Delivery systems studied (selective examples) for delivery of antigens through mucosal routes. 
Delivery 
System 
Antigen Immunostimu-
lant  
Route of 
Administration 
Pre-clinical 
/ clinical 
Result(s) / outcome(s) Ref. 
PLG 
microspheres 
E. coli surface 
antigen 6 
LTR192G Oral Human Low serological immune 
response were elicited, further 
modifications in delivery 
strategy is required 
211
 
Dry powder 
chitosan 
delivery 
system 
Genetically 
inactivated 
diphtheria 
toxoid CRM197 
None Intranasal Human Effective systemic immune 
response on single dose but 
mucosal immune response only 
on booster dose 
212
 
DOTAP/chole-
sterol 
liposomes 
Human sperm 
surface antigen 
(CD52) 
Diphtheria 
toxoid 
Intranasal Female 
mice 
CD52-specific IgA and IgG 
antibodies in sera and vaginal 
secretions 
213
 
Meningococcal 
Proteosomes 
Shigella flexneri 
2a 
lipopolysaccha-
ride 
In-built  Intranasal Human 
Phase I/II 
Induction of S. flexneri 2a 
LPS-specific IgA, IgG, and 
IgM antibody-secreting cells in 
a dose-responsive manner 
214
 
ISCOMATRIX A/New Caledonia 
20/99 H1N1 
In-built Intranasal Female 
Balb/c mice 
Antibody response in both serum 
(IgG) and nasal secretions (SIgA) 
135
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influenza virus & merino surpassed the levels obtained with 
unadjuvanted vaccine 
administered s.c. 
Virosomes Tri-valent 
Influenza virus 
vaccine 
LTK 63 Intranasal Human 
Phase I  
Induction of higher mucosal 
immune response by nasal 
administration compared to 
parenteral administration 
215
 
Attenuated 
Salmonella 
enterica 
serovar Typhi 
Helicobacter 
pylori urease 
In-built 
adjuvant 
property 
Oral Human  Induction of mucosal IgA 
response against vector and 
strong serological IgG response 
against antigen in fraction of 
volunteers studied   
216
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Table 1.3. Delivery systems studied (selective examples) for delivery of through parenteral routes. 
Delivery 
System 
Antigen Immunostimu-
lant  
Route of 
Administration 
Pre-clinical 
/ clinical 
Result(s) / outcome(s) Ref. 
Monophospho-
ryl lipid A 
containing 
liposomes 
Recombinant 
protein 
(R32NS181) 
Malaria antigen 
In-built and 
Al(OH)3 
Intramuscular Human  Superior systemic immune 
responses compared to 
previously reported vaccines; 
no systemic toxicity. 
217
 
Proteoliposo-
mes 
N. meningitides 
pore protein A 
In-built Information not 
available 
Human 
Phase II/III 
Significantly higher serum 
antibody levels compared to 
control groups 
218
 
Virosomes Hepatitis A In-built Intramuscular Human  Epaxal
®
 is registered and 
available in various 
commercial markets. 
219
 
ISCOMs Influenza 
vaccine 
In-built Intramuscular Human 
Phase I/II 
Induction of strong and rapid 
antibody responses, T helper 
responses and to a certain 
extent cytotoxic T cell 
responses. 
220
 
Virus like Human In-built and Intramuscular Human  Vaccine was found efficacious 
221
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particles papillomavirus 
(HPV-16/18) 
Al(OH)3 Phase III in prevention of incident and 
persistent cervical infections 
with HPV-16/18. 
MF59
™
 
emulsion 
Influenza 
vaccine 
In-built Intramuscular Human Fluad
®
 is a registered vaccine 
product and has been found 
safe and efficient in various 
clinical studies. 
171, 
222, 
223
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Mucosal immunization may offer advantages in the immunity generated and 
provide a noninvasive needle-free option for antigen delivery. If suitable delivery 
strategies can be developed, there is the potential for acceptable and safe modes of 
administration suited for self or mass administration of vaccines. Additionally, 
immunization via mucosal routes has been reported to induce both mucosal and systemic 
immune responses at least in some monogastric species including human.
224
 Of the 
mucosal sites, the oral route of administration is considered to be the most acceptable 
and accessible. In addition, the presence of organized lympho-epithelial structures 
known as GALT (gut associated lymphoid tissue) and NALT (nasal associated lymphoid 
tissue) through oral and nasal routes respectively makes these routes attractive for 
vaccine delivery. Although, mucosal delivery of vaccines may offer some important 
advantages the difficulty of developing mucosal and particularly oral vaccines using 
non-living approaches should not be underestimated. Unfortunately, the advantages 
offered by the oral route of immunization are usually negated by the hostile 
gastrointestinal environment, with a high probability of degradation of antigens by acid 
and enzymes, dilution of the vaccine formulation by the gastrointestinal contents and 
elimination of antigens by peristalsis and ciliary movement, necessitating the use of  
higher doses of antigens and specialized formulations. As a result, oral vaccination has 
tended to produce immune responses that are either poor or none at all compared to 
parenteral vaccination.
225
  
The intranasal route of administration has an advantage over the oral route in that 
lower doses of antigen are required because there is no significant dilution of the vaccine 
formulations by nasal fluids and no exposure to low pH or a broad range of secreted 
degradative enzymes.
30
 Nasal delivery of nonreplicating vaccines such as immunogenic 
proteins, peptides and DNA for mucosal as well as systemic immunity is receiving 
increased research focus as a potentially useful immunological concept.
226
 The 
successful development of economical and safe nasal non-replicating vaccines for 
immunization of human population is directly correlated with the selection and 
development of optimized formulations and delivery systems. Figure1.3 depicts a 
hypothetical simplified overview of pathways eliciting immunogenic responses via nasal 
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immunization 
8, 227-229
 and highlights the potential of particulate delivery systems in 
nasal immunization. 
 
 
Figure 1.5. Hypothetical simplified overview of pathways eliciting immunogenic 
responses via nasal immunization. 
  
NALT, the prime inductive site for nasal mucosal immunity, is arranged on both 
sides of the nasopharyngeal duct in rodents.
230, 231
 The collection of oropharyngeal tissue 
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and NALT equivalent tissues is called Waldeyer‟s ring in humans. The inductive sites 
for nasal immunity in the NALT or the Waldeyer‟s ring are comprised of B- and T-cell 
follicles, specialized M cells (membranous cells) containing follicle associated 
epithelium with intervening antigen presenting cells (dendritic cells and macrophages) 
and regional draining lymph nodes, that is, cervical lymph nodes.
2, 227, 228
 The M cell is a 
specialized antigen sampling epithelial cell consisting of a large basolateral pocket filled 
with T-cells, B-cells and macrophages. When an antigen is present on the nasal mucosa, 
especially an antigen in the form of a particle, it is actively transported, primarily by M 
cells, to reach antigen presenting cells (APCs) including dendritic cells, macrophages, 
B-cells and follicular dendritic cells for processing and presentation. The successful 
development of economical and safe nasal non-replicating vaccines for immunization of 
mass human population is directly correlated with the selection and development of 
optimized formulations and delivery systems for newer vaccines. 
Nasal immunization is also a commercial reality with a nasal influenza vaccine. 
Flumist
®
 (Medimmune, Inc.)  has been available in the United States since 2003 and was 
proven to be safe and efficacious. However, it did not establish a significant market 
share of the total influenza vaccine market. The Flumist
®
 vaccine was initially indicated 
for active immunization of healthy individuals aged 5–49 years which excluded the main 
target group for influenza vaccination (young children and the elderly). In addition, 
Flumist
®
 was available only in a frozen formulation, requiring storage and transport at 
temperatures of -15ºC or below thereby inflating the high retail price and causing 
inconvenience for pharmacies. Recently, a new formulation of Flumist
® 
vaccine, CAIV-
T (cold adapted influenza vaccine-trivalent), which can be stored in a standard 
refrigerator and is indicated for the active immunization of eligible individuals aged 2–
49 years, has gained FDA approval.
232
 The Flumist
®
 experience highlights the potential 
of intranasal route as a mucosal vaccine delivery approach and the need to focus on 
developing novel and/or better scientific approaches for commercial success. To achieve 
the ultimate success in vaccine delivery, one may need to employ multiple strategies to 
meet the challenges in formulation, manufacturing, regulatory, and of course, customer 
acceptance and satisfaction. 
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1.5. SIGNIFICANCE OF THE RESEARCH 
The literature review of vaccine delivery systems highlights the need for further 
research in this field as very few delivery systems have ben successfully developed into 
commercial products. This phenomenon could be due to the research and development 
efforts being focused on the development of individual antigen rather than on delivery 
systems. Despite the efficacy of killed and attenuated vaccines, they do bear the 
potential risk of residual toxicity and might contain toxic components or reversion to 
virulence.
137
 The technological advances in biotechnology have made possible the large 
scale production of highly purified bio-engineered DNA and proteins. However, in many 
instances, purified antigens are poorly immunogenic and induce only antibody responses 
on parenteral administration. A safe and efficient delivery system, preferably with built-
in adjuvant activity, could significantly improve the efficiency and utility of these 
purified antigens.
78
 One more important conclusion which can be drawn on the basis of 
the literature review is need for efficient and safe immunological adjuvants to be 
incorporated in a vaccine delivery system for induction of a strong and wide-range of 
immune responses. Most of the immunological adjuvants recently investigated have 
been derived from pathogens. This makes a vaccine delivery system containing one of 
these immunological adjuvants gaining regulatory approval difficult due to safety issues. 
The selection of the route of administration for vaccines delivery systems has also been 
reported as an important factor affecting type of immune response elicited by a vaccine. 
It is evident that there is an urgent need for a better understanding of the relationship 
between the design and performance of the vaccine delivery systems with consideration 
of the route of administration. 
The development and evaluation of a particulate vaccine delivery system with or 
without incorporation of a non-pathogen derived potential immunological adjuvant with 
M cell targeting potential was undertaken in this research project to tackle some of the 
above issues related to vaccine delivery systems and immunological adjuvants. This 
research project may offer a novel way of achieving strong immune responses against 
the acellular protein antigens with the potential to offer significant advantages for human 
immunization and prevention of infectious diseases. 
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1.6. OVERALL OBJECTIVES 
The principle objective of the research was to design, develop and evaluate a 
biodegradable nanoparticulate delivery system with a non-pathogen derived potential 
immunological adjuvant which has the M-cell targeting prospective. The research 
objectives were sub-divided into following points: 
 Design, formulation and optimization of a chitosan (CS) and dextran sulphate 
(DS) based biodegradable nanoparticulate vaccine delivery system. 
 Development of incorporation method(s) for a subunit protein antigen (pertussis 
toxoid) and/or a potential immunological adjuvant with M cell targeting 
prospective (IgA) into the optimized nanoparticulate system. 
 In-vitro evaluation of the antigen and/or IgA - loaded nanoparticulate system in 
terms of particle characteristics, release profile, entrapment efficiency and 
stability. 
 In-vivo evaluation of M-cell targeting ability of a IgA-loaded (antigen-free) 
nanoparticles via intranasal administration.  
 In-vivo immunological evaluation of the optimized antigen loaded formulation(s) 
in a mouse model. The in-vivo immunological evaluation of formulations was 
conducted to assess, 
 Immunological potential of nanoparticulate delivery system through 
intranasal versus subcutaneous route of administration. 
 Efficiency of IgA as an immunological adjuvant through intranasal and 
subcutaneous route of adminstrations. 
 Differences in type of immune responses produced by the optimized 
formulation(s) through different route of administrations in presence or 
absence of IgA in formulation. 
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1.7. THESIS OVERVIEW 
The research work of the project has been compiled in three main chapters, 
each incorporating an introduction, experimental, results and discussion section. The 
three main research chapters are followed by a general discussion and conclusions 
chapter. The three main chapters of thesis explain three varied parts of my research work 
as explained below, 
 Preparation and optimization of chitosan–dextran sulfate (CS-DS) 
nanoparticles: This chapter describes the preparation method of CS-DS 
nanoparticles and how important formulation factors were optimized to obtain a 
stable and efficient CS-DS nanoparticulate formulation. An optimized blank CS-
DS nanoparticle formulation was then used in later studies which were described 
in further chapters. 
 Preparation and in-vitro characterization of the CS-DS nanoparticle 
formulation loaded with a model antigen and/or potential 
adjuvant/targeting agent: This chapter explains how a model protein antigen 
and/or a novel potential immunological adjuvant (IgA) were loaded into CS-DS 
nanoparticles and what the characterstics of the systems are. The chapter also 
addresses the characterization methods and quantification of antigen and IgA. 
 Immunological characterization of the antigen and/or IgA loaded CS-DS 
nanoparticle formulations in-vivo: The chapter focuses on the in-vivo 
evaluation of the loaded CS-DS nanoparticulate formulations through the 
mucosal (intranasal) and parenteral (subcutaneous) routes of administration. The 
chapter comprises comparison of immunological responses induced by different 
loaded CS-DS nanoparticle formulations with conventional antigen formulation. 
Also, a preliminary study to evaluate M-cell targeting ability of CS-DS 
nanoparticles loaded with IgA by nasal route of administration is reported in this 
chapter.   
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CHAPTER 2 
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CHITOSAN-DEXTRAN SULFATE 
NANOPARTICLES 
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2.1. INTRODUCTION OF CHITOSAN-DEXTRAN SULFATE 
NANOPARTICLES 
2.1.1. Chitosan 
Chitosan is generally produced from crustaceans such as crabs and prawn 
shells but may also be derived from fungal chitins. It is a polysaccharide derived 
from deacetylation of chitin and has structural characteristics similar to 
glycosaminoglycan (Figure 2.1).
57
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Figure 2.1. Chemical structure of the chitosan (A = % degree of acetylation). 
 
Chitosan contains primary amine groups that can be protonated by 
selected acids or pH adjustment as the pKa of chitosan amine is 6.3. This unique 
property renders chitosan some useful features or applications. For instance, the 
interaction of chitosan protonated amine groups with cell membranes results in a 
reversible structural rearrangement of protein associated with tight junctions which 
leads to their opening.
233
 Also, protonation of amine groups of chitosan promote 
adhesion of chitosan formulations to negatively charged mucosal surfaces.
234
  These 
properties aid to stimulate the absorption and/or uptake of therapeutically active 
materials by epithelial cells and M-cells from chitosan-based formulations on 
mucosal administration.
55
 The cationic nature of chitosan in solution has also been 
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exploited by researchers in the formulation of DNA based antigens for mucosal 
delivery as ionic interaction between chitosan and DNA enhances the entrapment 
efficiency of antigen in particulate delivery systems.
61, 235-237
  
The promising properties of chitosan as formulation ingredient has 
prompted the development of its various derivatives such as glycol-conjugated 
chitosans (chitosan conjugated with mannose, galactose, glucose, lactobionic acid or 
glucoseamine), lipid-conjugated chitosans (palmitic or oleic acid conjugated 
chitosan), mono-N-carboxymethyl chitosan and N-trimethyl chitosan (TMC).
55, 238
 
Chitosan has functional groups (amine and hydroxyl) which allow chemical 
modification of the molecule and its physical properties. Thiolated chitosans, 
obtained by modification of the primary amine groups with cysteine, thioglycolic 
acid and 2-iminothiolane, are a class of derivatives that showed improved 
mucoadhesive properties and have been used in mucosal delivery systems.
239-241
 
These derivatives of chitosan have shown in situ gelling properties due to the 
formation of inter- and intramolecular disulfide bonds at physiological pH.  Another 
chitosan derivative synthesized by modification of its amine groups is mono-N-
carboxymethyl chitosan (MCC). MCC is a negatively charged chitosan derivative 
with a property of significantly decreasing transepithelial electrical resistance 
(TEER) of Caco-2 cell monolayers at concentrations of 3-5% (w/v).
242
 Quaternary 
chitosan derivatives are soluble over a wide pH range due to their permanent 
positive charge. Quaternary chitosan derivatives such as N-alkylated chitosan 
derivatives have been reported to possess antibacterial and antifungal properties.
243
 
N-trimethyl chitosan (TMC) is a partially quaternized derivative of chitosan, which 
has been extensively studied for its absorption enhancing and mucoadhesive effects 
for hydrophilic macromolecules, particularly through mucosal routes.
244, 245
  
It is surprising that only a few of chitosan derivatives showed higher 
immunological adjuvant properties in in-vivo studies compared to non-derivatised 
chitosan formulations.
246, 247
 TMC nanoparticles loaded with influenza subunit 
antigen shown higher immunogenicity compared to TMC solution formulation of 
antigen following intranasal vaccination in mice.
245
 The TMC is a water soluble 
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chitosan derivative and provides mucoadhesive as well as absorption enhancing 
effects even at neutral pH.   Sayin et al. prepared negatively charged MCC and 
positively charged TMC nanoparticles for nasal vaccination.
248
 Both tetanus toxoid 
(TT) loaded TMC and MCC/chitosan particles were efficiently taken up by murine 
macrophages regardless of their surface charge but mice that received either TT–
chitosan or TT–TMC nanoparticles intranasally developed higher serum antibodies 
than those that received intranasally TT–MCC particles, and comparable to the 
control mice vaccinated subcutaneously with free TT. TT formulated with soluble 
TMC or MCC induced similar antibody responses as compared to the nanoparticle 
formulations.
248
 
It is clear from the studies that chitosan derivatives have strong 
mucoadjuvant activity and enhance local and systemic immunity upon mucosal 
immunization. Moreover, upon parenteral administration, particulate chitosan 
vaccines are also taken up by APCs and induced high systemic immune responses in 
vaccinated animals.
249
 It is important to note that in the absence of antigen, chitosan 
and its derivatives hardly show immunostimulating effects.
250
 Type and 
immunogenicity of antigens as well as the type and adjuvant activity of chitosan 
also play an important role in the type of immune responses and adjuvant activity of 
chitosan formulations. The differences in physicochemical properties such as charge 
density and molecular structure of chitosan derivatives have a great impact on their 
interaction with APCs and their adjuvant activity, but the mechanisms involved 
need further investigations.
55
 
2.1.2. Techniques for preparation of chitosan nanoparticles 
Chitosan nanoparticles formulations can be prepared by both chemical 
and physical methods. Chemical processes such as the reaction of the primary amine 
goups of chitosan with a di-aldehyde (usually glutaraldehyde) crosslinker, have 
some major drawbacks particularly in the case of proteins and peptides delivery. 
The use of organic solvents and crosslinking agent during the chemical process may 
adversely affect the stability of proteins and peptides.
61
 Consequently, physical 
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methods by which chitosan and its derivatives are crosslinked to yield nanoparticles 
are preferred.
55
 The presence of amine functional groups in chitosan molecule 
enables chitosan to carry a positive charge in acidic aqueous media, which in turn 
allows the interaction of negatively charged macromolecules and polyanions with 
chitosan to form nanoparticles by ionic gelation or complex coacervation.
251, 252
 
Ionic gelation and complex coacervation are very similar methods and sometimes 
used interchangeably as the only difference is use of an electrolyte (e.g. 
tripolyphosphate) in former and of an ionic polymer (e.g. alginate) in later, for 
gelation of chitosan.
253, 254
 These nanoparticle manufacturing techniques have 
advantages of not requiring the use of organic solvents or homogenisation or heat, 
therefore minimizing possible degradation of active ingredient during the prepration 
process. Tri-polyphosphate (TPP) is a most widely investigated polyanion for 
formation of chitosan nanoparticles because of its non-toxic property and quick 
gelling ability. Many researchers have explored the capacity of chitosan–TPP nano-
system for association of peptides, proteins, oligonucleotides, antigens and plasmids 
DNA for potential pharmaceutical usage.
255-257
 Preparation methods by polyionic 
crosslink of cationic chitosan molecules with proteins, nucleic acids and genes were 
particularly useful for carrying and delivering macromolecules as therapeutic 
agents. Aside from its strong electrostatic interaction and binding with negatively 
charged proteins/genes, the chitosan–protein or chitosan–gene system has the ability 
to gel spontaneously on contact with multivalent polyanions due to the formation of 
inter- and intramolecular crosslinkage mediated by these polyanions. Additionally, 
incorporation of highly charged density polyanions onto chitosan nanoparticles can 
improve nanoparticle properties concerning protein association efficiency and 
modulation of active materials release. Other anionic crosslinkers reported to be 
useful in formation of chitosan nanoparticles include sodium sulfate, negatively 
charged cyclodextrins, poly-γ-glutamic acid and dextran sulfate.55, 254, 258 
2.1.3. Dextran Sulfate 
Dextran sulfate (DS) is a biodegradable and biocompatible polyanion 
with negatively charged sulfate groups (Figure 2). The polysaccharide itself is 
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expressed by bacteria, with most research focusing on dextran expressed from 
Leuconostoc mesenteroide. The structure of dextran consists of linear (1-6)-a-D-
glucose, with branches extending mainly from (1-3) and occasionally from (1-4) or 
(1-2) positions accounting for a 5% degree of branching (Figure 2.2). Dextran is 
highly water soluble and easily functionalized through its reactive hydroxyl 
chemistries. Characterization of many types of dextran have indicated that 
branching, average molecular weight, and molecular weight distributions can vary 
widely depending on the conditions and strain of bacteria used for expression.
259, 260
 
Dextran was investigated as a blood plasma replacement in the early 1940s and has 
since become of interest as a biodegradable and biocompatible material. 
Biodegradation occurs through natural enzymatic splitting of saccharide bonds by 
dextran-1,6-glucosidase found in spleen, liver, lungs, kidneys, brain, and muscle 
tissue as well as by dextranases expressed by bacteria in the colon.
261, 262
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Figure 2.2. Chemical structure of the dextran sulfate (DS). 
 
Dextran has been reported as an immunological adjuvant/carrier for 
antigens/vaccines in some studies
263-265
. Diwan et al
265
 used the „pre-formed‟ 
dextran microspheres for intramuscular administration of diphtheria toxoid to rats 
and reported that significantly higher antibody titers (24 times) were obtained 
against diphtheria toxoid compared to immunization with the conventional 
diphtheria toxoid absorbed on alum. They further reported that the immune response 
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was sustained for nine months, with gradual decline of antibody titers thereafter. In 
another study, the same group
266
 reported that cross-linked „pre-formed‟ dextran 
microspheres, containing tetanus toxoid induced serum antibody to tetanus toxoid 
for long periods, eliminating the need for additional booster doses. These studies 
indicate that dextran or its derivatives contain potential adjuvant properties for 
induction of strong humoral immune responses against a co-administered antigen. 
Dextran sulfate is derived by esterification of dextran under mild 
conditions using sulfuric acid. Dextran sulfate has also been investigated for various 
biomedical and pharmaceutical applications. It has been used in the isolation of 
ribosomes and to release DNA from histone complexes. It can also promote 
hybridization of probes with DNA and complexes with fibrinogen. In-situ formation 
of hydrogels is appealing for biomaterial applications and therefore has been 
employed in the formation of dextran hydrogels via addition reactions. Hiemstra et 
al. have investigated gelation of vinyl sulfone-esterified dextrans, with degrees of 
substitution of 2-22, with bifunctional or four-arm PEG-SH.
267, 268
 These materials 
have shown rapid gelation times and are also hydrolytically degradable via 
hydrolysis of the conjugated sulfone. The above dextran conjugated materials have 
been successfully investigated as controlled release delivery vehicles of 
indomethacin (a low molecular weight hydrophobic anti-inflammatory drug), 
bovine serum albumin, lysozyme, and immunoglobulin G.
268-270
 The relatively low 
cost and availability of dextran as well as its hydroxyl functionality for chemical 
modification has increased the utilization of dextran in the field of polysaccharide 
polymer conjugates for biomaterials. 
Dr. Yan Chen research group
57, 254
 have previously reported preparation of 
chitosan nanoparticles by complex coacervation method using dextran sulfate as a 
cross-linking agent. The studies reported the application of chitosan-dextran sulfate 
nanonparticles as a potential protein and peptide delivery system. These in-vitro 
investigations found charge and weight ratio of chitosan to dextran sulfate as an 
important formulation factor affecting particle size, zeta potential, release profile 
and entrapment efficiency. 
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In summary, chitosan and dextran sulfate have the following properties 
which make them a potentially suitable ingredient for a nanoparticulate vaccine 
delivery system: 
 Absorption enhancement and mucoadhesive nature of chitosan. 
 Immunological adjuvant properties of chitosan and dextran. 
 Biodegradability and non-toxic nature of chitosan and dextran sulfate. 
 Large-scale availability of both polysaccharides at cheap cost. 
 Aqueous solubility of both chitosan and dextran sulfate 
 Formation of particles (micro- and nano-particles) by simple and mild physical 
methods. 
 Availability of both chitosan and dextran sulfate in various molecular weights 
and possibility of preparation of wide range of derivatives. 
 Being approved ingredient by regulatory bodies for one or more medical 
applications in human beings. 
2.1.4. Objectives of this section 
The principle objective of this section of the thesis was to prepare chitosan-
dextran sulfate nanoparticles using a simple aqueous method and optimize the 
important formulation factors using particle size and zeta potential as evaluation 
parameters. 
2.2. EXPERIMENTAL 
2.2.1. Materials 
Low molecular weight chitosan (MW ~ 150,000, 75-85% deacetylated, 
Catalogue no. 448869), dextran sulfate sodium salt (MW ~ 5000, Catalogue no. 
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31404), and acetic acid (purum, Catalogue no. 45740) were purchased from Sigma-
Aldrich chemicals Ltd, Australia.  All other chemicals used for experiments were of 
molecular biology grade and used as received unless otherwise specified. Purified 
water (Milli-Q water) was used in all preparations and procedures. 
2.2.2. Methods 
2.2.2.1.  Preparation of nanoparticles 
CS-DS nanoparticles were prepared using the method developed in 
our laboratory with some modifications.
57
 In brief, a known weight of low 
molecular weight chitosan was dissolved in acetic acid and dextran sulfate was 
dissolved in purified sterile water to produce a CS solution and DS solution 
respectively. These solutions (CS and DS) were used for preparation of CS-DS 
nanoparticles by complex coacervation / ionic gelation method. Specifically, CS 
solution and DS solutions were mixed at room temperature under high speed 
magnetic stirring for 15 minutes to form nanoparticles as a result of ionic 
interactions between chitosan and dextran sulfate.  
2.2.2.2. Particle size and zeta potential of nanoparticles 
Particle size of nanoparticles in a formulation was determined using 
photon correlation spectroscopy using a Zetasizer 3000HS (Malvern Instruments, 
Malvern, Worcestershire, UK). Photon correlation spectroscopy uses the rate of 
change of light fluctuations to determine the size distribution of the particles 
scattering light. The measurements were performed at 25ºC with a detection 
angle of 90°, and the raw data were subsequently correlated to Z average mean 
size using a cumulative analysis by the Zetasizer 3000HS software package. 
Each sample was measured 10 times. 
The zeta potential of particles was determined by laser Doppler 
anemometry using a Zetasizer 3000HS (Malvern Instruments, Malvern, 
Worcestershire, UK). The samples were injected into the flow cell chamber and 
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measurements were carried out at 25ºC. For each sample, the mean ± standard 
deviation (SD) of 3 repeat measurements was established. 
2.2.2.3. pH and short-term storage stability study 
The stability of developed nanoparticle formulations was assessed at 
different environmental pH using particle size and zeta potential as evaluation 
parameters. The pH of prepared CS-DS nanoparticulate formulations was 
adjusted to different pH values (3.7, 4.5, 5.5, 6.5, 7.5 and 10.0) by dropwise 
addition of 0.1M NaOH into prepared nanoparticle formulations. The pH 
adjusted nanoparticle formulations were then characterized for particle size and 
zeta potential using Zetasizer as explained in section 2.2.2.2. An optimum 
nanoparticle formulation was selected based on its pH stability and 
immunological rationales (explained in section 2.3.1 of this chapter) for all of 
further studies.  
The short-term stability of optimized nanoparticulate formulation was 
evaluated for one week by measurement of particle size and zeta potential using 
the Zetasizer at specified time periods. The experimental data was statistically 
analyzed using Graphpad Prism software (v5 demo, GraphPad Software, Inc., 
CA, USA). 
2.2.2.4. Characterisation of nanoparticles by electron microscopy  
 The morphology and size of optimized nanoparticulate formulation 
was characterized using focused ion beam field emission electron electron 
microscope (FESEM or FIBSEM) and transmission electron microscopy (TEM). 
For FIBSEM, a clean glass coverslip was taped over an aluminium SEM stub 
using carbon tape and a drop of sample (nanoparticle formulation) was spread on 
top of the glass coverslip. The sample was coated with platinum film using 
sputter coater device and micrographs/pictures were taken with a Zeiss Neon 
40EsB FIBSEM (Carl Zeiss SMT AG, Germany). For TEM, a drop of sample 
was placed on top of the copper grids coated with carbon and allowed to air dry. 
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Electron micrographs were taken with a JEOL JEM2011 transmission electron 
microscope (Jeol Ltd, Japan). 
2.3. RESULTS AND DISCUSSION 
Empty CS-DS nanoparticles were prepared by complex coacervation / ionic 
gelation method which is a simple and aqueous based formulation technique. This 
nanoparticle preparation method is particularly useful for incorporation of proteins and 
peptides because of lack of use of organic solvents and high energy procedures which 
can cause degradation of most biological compounds. Chitosan with a pKa value of ~ 
6.3 when dissolved in an acidic medium becomes polycationic due to protonation of 
primary amine functional groups in its structure.
257, 271
 Dextran sulfate sodium salts 
provide polyanionic solutions of dextran sulfate (Figure 2.2) when dissolved in water as  
one of its pKa value is in negative and another one near 2.
272
 These two oppositely 
charged polysaccharides can form nanoparticles on mixing by ionic cross-linking due to 
electrostatic interactions between oppositely charged ions. Tiyaboonchai et al
273
 
demonstrated the presence of spectral shifts in the sulfate and amine regions in the FT-
IR spectra of CS-DS nanoparticles on comparison with FT-IR spectra of chitosan and 
dextran sulfate. The spectral shifts have been reported as confirmation of existence of an 
electrostatic interaction between the sulfate groups of dextran sulfate and the amine 
groups of chitosan.  
The use of dextran sulfate as negatively charged polymer in formation of 
chitosan nanoparticles by complex coacervation / ionic gelation method has been 
reported to offer advantages. It has been reported that small sized chitosan-
tripolyphosphate (CS-TPP) nanoparticles dissolve very quickly in low pH hydrochloric 
acid solution,
274
 whereas CS-DS nanoparticles were stable in low pH.
275
 It has been 
indicated that CS-DS nanoparticles have enhanced stability and increased mechanical 
strength compared with CS-TPP nanoparticles,
254, 276
 probably because of the larger 
structure of dextran sulfate which provide stronger cross-linking with CS compared to 
TPP. Additionally, Tiyaboonchai et al
277
 have studied that dextran sulfate is capable of 
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reducing the cationic charge-related cytotoxicity of polyethylenimine (PEI) 
nanoparticles in vitro. 
2.3.1. Formulation characterization and optimization 
The previous work done in our laboratory on CS-DS nanoparticles
254
 and 
preliminary experiments helped in identifaction of important formulation factors to 
be optimized for obtaining a stable CS-DS nanoparticles formulation. For 
preliminary studies, particle size and zeta potential were used as characterizing 
parameters. Concentration of chitosan and dextran sulfate in solutions used to 
prepare nanoparticles affected the particle size of particles forming by ionic 
crosslinking / coacervation method. The particles in the range of nanometers (1-
1000nm) were only obtained when low concentrations of chitosan and dextran 
sulfate (0.1% w/v - 0.25%w/v) were used to prepare nanoparticles. The 0.1%w/v 
concentration of chitosan and dextran sulfate solutions provided formulations having 
nanoparticles of less than 500nm size. These results are in agreement with previous 
similar studies
57, 257
 and indicate that the size of coacervation nuclei formed during 
the preparation increases with increase in polymer concentration used. Therefore, for 
all further studies  0.1% w/v chitosan dissolved in 0.2% v/v acetic acid solution and 
0.1% w/v dextran sulfate solution (DS) in purified water were used. The pH of CS 
and DS was recorded as 3.6 and 4.2 respectively. Another formulation factor 
identified as important for optimization of nanoparticle formulation was ratio of 
chitosan and dextran sulfate. Different ratios of volumes of chitosan and dextran 
sulfate solutions (each with a concentration of 0.1% w/v) were used to study the 
effect of chitosan and dextran sulfate ratio on the properties of formed CS-DS 
nanoparticles. Table 2.1 lists the weight and molar ratios of chitosan to dextran 
sulfate in various CS-DS nanoparticle formulations prepared. 
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Table 2.1. The ratio of chitosan to dextran sulfate in various CS-DS 
nanoparticle formulations prepared. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 and Figure 2.3 depicts the effect of weight ratio of CS to DS on 
particle size and zeta potential of nanoparticles. The weight ratio of CS to DS 
decides the overall charge of chitosan-dextran sulfate nanoparticles formed with 
charge of nanoparticles being the charge of that dominant component. It indicates 
that despite the large difference in molecular weight of chitosan and dextran sulfate 
used for nanoparticle preparation, the charge to weight ratio is in similar range for 
chitosan and dextran sulfate. This is also supported by the formation of precipitation 
in case of formulation prepared with 1:1 weight ratio of CS to DS. The presence of a 
high magnitude of zeta potential on the nanoparticles increases the stability of the 
formulation, as charged particles are less likely to form agglomerates due to ionic 
Weight ratio of chitosan to 
dextran sulfate 
Molar Ratio of chitosan to 
dextran sulfate 
1 : 3 
1 : 90 
1 : 2 
1 : 60 
1 : 1.5 
1 : 45 
1 : 1 
1 : 30 
1.5 : 1 
1 : 20 
2 : 1 
1 : 15 
3 : 1 
1 : 10 
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repulsive force.
66
 However, it was noticed that the positively charged nanoparticles 
were significantly larger in size than negatively charged nanoparticles (Table 2.2) 
when size of nanoparticles with a particular CS:DS weight ratio was compared with 
size of nanoparticles with same DS:CS weight ratio (student t-test, p < 0.01). This 
might be because of the larger molecular size of chitosan compared to dextran 
sulfate and increased repulsion between positively charged amine groups of chitosan 
with increase in proportion of chitosan in formulation. This was previously reported 
that charge on macromolecules affect their contraction-extension/folding-unfolding 
which in turn affects their conformational structure and size.
257
  
This study also showed that the order of mixing of chitosan and dextran 
sulfate solutions is important for preparation of a stable formulation i.e. the smaller 
volume solution should be added into larger volume solution to get stable 
formulation. Addition of larger volume component into smaller volume component 
during the preparation of nanoparticles resulted in visible precipitation 
instantaneously or within half an hour of preparation. This might have happened 
because of agglomeration of nanoparticles during charge inversion of nanoparticles 
in the process of preparation. 
Schatz et al.
278
 reported that the formation of polyelectrolyte complexes on 
mixing solutions of polyanions and polycations is spontaneous, entropy driven, and 
can lead to the formation of water-soluble complexes or precipitates, corresponding 
to two extreme cases. Schatz et al.
278
 also compiled the important factors impacting 
the particle formation process; (a) the reactivity of two strong polyions lead to 
insoluble polyelectrolyte complexes and the interaction between strong and weak 
ions should be able to yield stable colloidal complexes, (b) the polymer 
concentrations in the reaction medium, (c) external parameters such as pH, ionic 
strength, order of mixing of reactants, and rate of mixing. Furthermore, it has been 
previously reported in literature
279, 280
 that chitosan is a weak polybase and dextran 
sulfate is a strong polyacid. Drogoz et al.
281
 investigated the various stages of the 
complexation process of chitosan and dextran sulfate and described that colloids 
were positively or negatively charged according to the nature of the polymer in 
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excess. The study conducted for this thesis also shows similar results and further 
confirms that nature of polymer in excess determines the charge of nanoparticles. 
Drogoz et al.
281
 also described that the existence of various mechanisms of colloidal 
polyelectrolytes formation, according to the nature of the polymer in excess, could 
be attributed to the differences in chemical reactivity (strong versus low) of the ion 
in excess and the confirmation and flexibility of the macromolecular chains related 
to their electrostatic potential. 
 
 63 
Table 2.2. The effect of ratio of CS to DS and order of mixing on particle size and zeta potential of CS-DS 
nanoparticle formulations. 
Order of addition 
during 
preparation 
Weight 
ratio of 
CS to DS 
Visual 
observantion 
pH of 
formulation 
 Particle 
size ± 
S.D (nm) 
Polydispersity 
index ± S.D 
Zeta 
potential ± 
S.D (mV) 
CS (0.1%) into DS 
(0.1%)  
1 : 3 Colloidal 3.9 
165.7 ± 
16.2 
0.355 ± 0.064 -38.2 ± 5.2 
CS (0.1%) into DS 
(0.1%)  
1 : 2 Colloidal 3.8 
161.8 ± 
22.7 
0.245 ± 0.149 -34.2 ± 2.1 
CS (0.1%) into DS 
(0.1%)  
1 : 1.5 Colloidal 3.8 
158.6 ± 
15.6 
0.315 ± 0.148 -27.4 ± 1.6 
DS (0.1%) into CS 
(0.1%)   
1 : 1 Precipitation n/a n/a n/a n/a 
DS (0.1%) into CS 
(0.1%)  
1.5 : 1 Colloidal 3.8 
258.0 ± 
1.6 
0.340 ± 0.014 39.1 ± 0.2 
DS (0.1%) into CS 
(0.1%)  
2 : 1 Colloidal 3.8 
300.2 ± 
17.2 
0.253 ± 0.099 47.2 ± 0.2 
DS (0.1%) into CS 
(0.1%)  
3 : 1 Colloidal 3.7 
314.7 ± 
9.2 
0.290 ± 0.212 53.2 ± 4.4 
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Figure 2.3. Effect of weight ratio of CS to DS on particle size and zeta potential 
of CS-DS nanoparticles. 
  
 
To determine the isoelectric pH point of CS-DS nanoparticle formulations 
and to study the effect of pH change on particle size of CS-DS nanoparticles, the pH 
of nanoparticulate formulations was adjusted using 0.1M NaOH and the 
nanoparticles were characterized for size (Figure 2.4) and zeta potential (Figure 2.6). 
In broad sense, an increase in pH especially above pH 7 resulted in abrupt and steep 
increase in particle size of nanoparticles formulated with different weight ratios of 
CS to DS. It indicates the instability of CS-DS nanoparticles in basic pH 
environment. This instability of nanoparticles can be explained by neutralization of 
charge over nanoparticles with increase in pH (Figure 2.4) which increases the 
probability of agglomeration of nanoparticles as electrostatic repulsive force between 
nanoparticles was reduced. During the measurement of particle size of nanoparticle 
formulations using zetasizer higher variability was observed when the particle size 
exceeded 2000nm and accurate measurements could not be obtained (Figure 2.4). 
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This might be due to continuous formation of agglomerates and settling of 
precipitates in formulation.  Also, different formulations showed precipitation or 
significant increase in particle size at different pH values. A correlation between 
initial zeta potential of nanoparticles and pH at which visible precipitation occurred, 
can be made. The nanoparticle formulations which showed initial higher zeta 
potential (positive or negative) produced visible precipitation at higher pH compared 
to those formulations which showed lower zeta potential (Table 2.2 and Figure 2.5). 
The isoelectric pH point for different CS-DS nanoparticle formulations prepared 
from different   CS : DS weight ratios, was calculated assuming linear correlation 
between change in zeta potential of nanoparticles with change in pH of formulation 
(Table 2.3 and figure 2.7).  
This study illustrated that size and zeta potential of CS-DS nanoparticles 
can be modulated by change in pH of residual environment. One has to point out that 
the increased particle size, as a consequence of pH change, is more a reflection of the 
aggregation of nanoparticles, rather than the change of the size of individual 
nanoparticles. Panyam et al. reported that by varying the surface charge, one could 
potentially be able to direct nanoparticles either to lysosomes or to cytoplasm. The 
research group suggested that nanoparticles which show transition in their surface 
charge from anionic at pH 7 to cationic in the acidic endosomal pH (pH 4-5) were 
found to escape the endosomal compartment whereas the nanoparticles which 
remain negatively charged at pH 4-5 were retained mostly in the endosomal 
compartment. Accordingly, easy modulation of particle size and zeta potential of 
nanoparticulate formulations could be important for induction of efficient in-vivo 
immune responses for vaccine delivery. 
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Figure 2.4. Effect of pH adjustment on particle size of CS-DS nanoparticles 
prepared from different CS to DS weight ratios at room temperature. 
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Figure 2.5. Effect of pH adjustment in range of pH 3.5 – 8.0 on particle size of 
CS-DS nanoparticles prepared from different weight ratios of CS:DS at room 
temperature (highlighting modulation of particle size with increase in pH before 
precipitation). 
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Figure 2.6. Effect of pH of final formulation on zeta potential of nanoparticles 
prepared from different weight ratios of CS:DS.  
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Figure 2.7. Determination of isoelectric pH point for CS-DS nanoparticle 
formulations prepared from different weight ratios of CS:DS, using linear 
model. 
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Table 2.3. Determination of isoelectric pH point for CS-DS nanoparticle 
formulations using linear model. 
Formulation 
(CS:DS ratio) 
Slope of linear 
trend line 
Intercept of 
linear 
trend line 
Coefficient of 
correlation (R) 
Isoelectric  
point pH 
1 : 3 5.858 -58.96 0.9723 10.06 
1 : 2 4.964 -47.90 0.9775 9.64 
1 : 1.5 4.576 -40.04 0.9620 8.75 
1.5 : 1 -7.253 59.71 0.9843 8.23 
2 : 1 -8.874 74.01 0.9518 8.34 
3 : 1 -8.230 73.93 0.9308 8.98 
 
 
 
Above results indicate that negatively charged CS-DS nanoparticles have 
smaller particle size and higher isoelectric pH point compared to their positively 
charged counter parts. These initial in-vitro studies suggested that negatively charged 
nanoparticle formulation prepared using 1: 3 ratio of CS and DS should be used as 
optimum and stable formulation for further in-vitro and in-vivo studies. However, 
considering the in-vivo situation, it is more likely that positively charged particles 
have higher possibility and efficiency to interact with negatively charged mucosal 
and epithelial cell surfaces. A high negative charge over the particle surface could 
reduce the interaction of particles with mucosal and epithelial cell (APCs and M-
cell) surface as a result of ionic repulsive forces which can lead to possibility of 
decreased delivery of an incorporated antigen in delivery system to APCs. 
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Sogias et al.
282
 elucidated the mechanisms of interactions between chitosan 
and mucins (mucus gels) and found that electrostatic attraction appears to be the 
major mechanism for CS mucoadhesion but is also accompanied by contributions 
from hydrogen bonding and hydrophobic effects. Sayin et al.
248
 prepared both 
positively and negatively charged nanoparticles using chitosan or chitosan 
derivatives, CS and TMC for positively charged nanaoparticles and MCC for 
negatively charged nanoparticles. On intranasal administration of nanoparticle 
formulations, the group found that CS and TMC nanoparticles which have positively 
charged surfaces induced higher serum IgG titres when compared to those prepared 
with MCC which were negatively charged and smaller in size. Thiele et al. compared 
cationic, polyamine-coated polystyrene microparticles and anionic, protein-coated 
polystyrene microparticles with respect to their phagocytosis and phagosomal fate in 
dendritic cells and macrophages. The group concluded that hydrophilic, cationic 
microparticles were efficiently phagocytosed by dendritic cells and electrostatic 
attraction between the positively charged microparticle surface and the negatively 
charged cell surface is likely to mediate binding and subsequent internalization.  
The above literature reports indicate that hydrophilic CS nanoparticle 
formulation with a positive surface charge has higher potential to be 
immunologically effective in-vivo than negatively charged chitosan nanoparticle 
formulations. Based on this rationale, a positively charged CS-DS nanoparticle 
formulation with higher isoelectric pH point of 8.9, prepared using 3:1weight ratio of 
CS and DS was selected for further studies. In addition to positive charge, higher 
isoelectric pH point provides wider pH range of stable formulation which could be 
important in characterization and in-vivo performance of delivery system. 
2.3.2. Electron microscopy and stability study of selected CS-DS 
nanoparticle formulation 
The morphology and size of selected nanoparticle formulation was studied 
using the focused ion field emission scanning electron microscopy (FIBSEM) and 
transmission electron microscopy (TEM). FIBSEM and TEM micrographs (Figure 
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2.8) confirmed the nanosize of CS-DS particles and show the particle size 
distribution of nanoparticles. Also, it was observed that all the nanoparticles were 
not of spherical shape and shape of nanoparticles irregularly varied along with 
surface morphology. The detailed study of the morphology and structure of CS-DS 
nanoparticles could not be performed by electron microscopy as the nanoparticles 
were unstable under high energy beam in microscopes and it was realised that 
nanoparticles structure (shape and size) was getting affected by internal conditions of 
microscope during the tenure of microscopy. This suggests that the CS-DS 
nanoparticles are not perfect solid bodies but more likely the CS-DS nanoparticles 
are either softer particles or partially / fully made up of gel-like structure when 
dispersed in water which gets affected under the exposure of high vacuum. The 
exposure of nanoparticles to high energy may have also affected the surface 
morphology. Although various research groups
249, 254, 283
 have previously used 
simple SEM and TEM techniques similar to method used in this study, there are 
many recent publications
53, 284
 reporting use of cryo-techniques for sample 
preparation before use of electron microscopy of chitosan nanoparticle formulations. 
It suggests that cryo-sample preparation techniques might be a better tool for stable 
microscopic study of chitosan nanoparticles. Unfortunately, formulations could not 
be studied by cryo-technique due to lack of facility and expertise in Western 
Australia.   
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Figure 2.8. FIBSEM (A and B) and TEM (C and D) micrographs of CS-DS 
nanoparticle(s). 
 
 
The short-term storage stability of selected CS-DS nanoparticle formulation 
was investigated at room temperature using particle size and zeta potential as 
evaluation parameters (Table 2.4). The particle size and zeta potential of selected 
CS-DS nanoparticle formulation didn‟t showed any significant change for 3 days (72 
hours) but on seventh day a significant increase in particle size (One way ANOVA 
followed by post-Dunnet test, p < 0.01) and significant decrease in zeta potential 
(One way ANOVA followed by post-Dunnet test, p < 0.05) of nanoparticles were 
A B 
C D 
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recorded (Table 2.4). The increase in particle size with corresponding decrease in 
zeta potential indicates agglomeration of nanoparticles. As the formulation was 
neither sterile nor preserved, it was expected that the microorganism activities might 
have taken place which could also contribute to the instability of nanoparticles. It 
can be interpreted on the basis of data obtained from short term stability study that 
the vaccine formulation should be prepared fresh for all further studies and any 
unused formulation should be discarded after 48 hours of preparation. The long-term 
stability in aqueous environment and effect of temperature on the stability of 
formulation was not studied assuming that any long-term storage of vaccine 
formulation would be in freeze-dried form. The development and stability study of 
lyophilisation of CS-DS nanoparticle formulation were not undertaken as part of this 
thesis work and could be investigated in the future. 
 
Table 2.4. Short-term stability study of CS-DS nanoparticulate formulation. 
Time 
(days) 
Particle size ± S.D 
(nm) 
Polydispersity 
index ± S.D 
Zeta potential ± S.D 
(mV) 
0 314.7 ± 9.2* 0.29 ± 0.21 53.2 ± 4.4** 
1 320.8 ± 4.1 0.30 ± 0.16 51.2 ± 5.4 
3 334.2 ± 8.5 0.28 ± 0.21 45.8 ± 5.8 
7 358.0 ± 13.5* 0.51 ± 0.22 36.9 ± 8.8** 
*Means are significantly different (p < 0.05), **Means are significantly different    
(p  < 0.01).  
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To conclude, development and optimization of an empty CS-DS 
nanoparticle formulation was undertaken which can be used as potential vaccine 
delivery system for further in-vitro and in-vivo studies.The ratio of chitosan to 
dextran sulfate, order of mixing and pH of nanoparticle suspension were identified as 
important formulation factors governing size and zeta potential of CS-DS 
nanoparticles. These formulation factors could be utilized for manipulation of 
particle size and surface charge of CS-DS nanoparticles. An optimized blank CS-DS 
nanoparticle formulation with particle size 314.7 ± 9.2 nm, zeta potential +53.2 ± 4.4 
mV and prepared with CS to DS weight ratio of 3:1 was found stable for atleast 24 
hours in aqueous environment without any significant change in particle size and 
zeta potential. The particle size range of opitimized empty CS-DS nanoparticles was 
confirmed using electron microscopy techniques but shape and surface properties of 
nanoparticles could not be completely evaluated as the simple electron microscopy 
techniques were found unsuitable. 
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CHAPTER 3 
PREPARATION AND IN-VITRO 
CHARACTERIZATION OF THE CS-DS 
NANOPARTICLE FORMULATION LOADED 
WITH A MODEL ANTIGEN AND/OR 
POTENTIAL ADJUVANT / TARGETING 
LIGAND 
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3.1. INTRODUCTION 
The current trend in new vaccine development is directed towards the use of 
antigenic subunits or highly purified recombinant molecules with better 
immunogenicity/risk ratio for the development of effective vaccines, and away from the 
use of killed or attenuated pathogens.
285-287
 The live vaccine systems (killed or 
attenuated pathogens) have been reported to be associated with adverse reactions in a 
significant percentage of vaccines. These can range from simple headache to 
encephalitis, intussusception and even death.
288
 Alternatively, highly purified 
recombinant molecules or synthetic peptides or sub-units of pathogens are recognized 
for offering the best safety profile. However, these safer antigens/vaccines lack strong 
immunogenicity and may require co-administration of immunological adjuvants and 
multiple administration for complete protection.
287
 Various adjuvants or strategies have 
been investigated as formulation components of vaccines to enhance the induction of 
immune responses against safer antigens. It is now generally accepted that for induction 
of a strong immunological response via both antigen-presentation pathways (MHC-I and 
MHC-II) against the antigens may require combination of various components/strategies 
such as use of particulate vaccine delivery systems, incorporation of safe immunological 
adjuvants in vaccine formulation and development of targeted vaccine formulations. 
3.1.1. Selection of pertussis toxin (PTX) as a model protein antigen 
Pertussis (whooping cough) is a prevalent cause of infant death worldwide 
and continues to be a public health concern especially in developing countries. 
Estimates from the World Health Organisation (WHO) suggest that, in 2003, about 
17.6 million cases of pertussis occurred worldwide and that about 279,000 patients 
died from this disease.
289
 Bordetella pertussis, the most common causative agent of 
pertussis, is a Gram-negative coccobacillus with exclusive affinity for the mucosal 
layers of the human respiratory tract. B. pertussis has evolved various mechanisms, 
known as virulence factors, for attachment, invasion and survival within eukaryotic 
cells such as epithelial and several phagocytic cells
290-293
. The important virulence 
factors which are considered to play a key role in the establishment of B. pertussis 
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infection are filamentous hemagglutinin (FHA), pertussis toxin (PTX), adenylate 
cyclase toxin (AC-Hly) and pertactin (P69). In addition to these key factors other 
factors such as fimbriae, dermonecrotoxin, tracheal cytotoxin, tracheal colonization 
factor, serum resistance factor and lipopolysaccharide also play roles leading to 
clinical manifestations of pertussis.
294, 295
 PTX acts as both an adhesion and a toxin 
therefore it is considered to be a major virulence factor of B. pertussis. Margaret 
Pittman introduced the term “Pertussis toxin” which is also known as lymphocytosis-
promoting factor, islet-activating factor and pertussigen. PTX (MW 105,060) is 
exotoxin composed of noncovalently associated subunits designated S-1, S-2, S-3, S-
4 and S-5 with Mrs of 26220, 21920, 21860, 12060 and 10940, respectively.
296, 297
 
The toxin contains one copy of each subunit except S-4, which is present in two 
copies. PTX plays an important role in the pathogenesis of whooping cough that 
might be used by B. pertussis to evade and impair the host immune and cells surface 
functions in vivo 
294, 298
. Inactivated pertussis toxin commonly known as pertussis 
toxoid (PTXd) is an important and essential component of commercial acellular 
DTaP (Diphtheria-Tetanus-acellular Pertussis) vaccine.  
Recent reports from the WHO and independent research conclude that 
protection following pertussis vaccination wanes after 6–12 years 289. As a result, 
symptomatic as well as asymptomatic pertussis is increasingly reported in older 
children, adolescents and adults even in communities with high immunization 
coverage 
289
. Many studies have highlighted the multiple causes for the resurgence of 
the disease, such as use of better diagnostic tools, different effectiveness of the 
vaccines used, differences in vaccine coverage and loss of vaccine efficacy due to 
the emergence of new B. pertussis strains overproducing PTX.
299-302
 It has also been 
previously reported that conventional adjuvants such as aluminium compounds 
failed to augment vaccines performances against whooping cough in some cases.
181, 
303
 The background importance of PTXd in the pertussis vaccine along with the 
resurgence of disease in highly immunized countries lead to the selection of PTXd as 
a model protein antigen for this thesis studies. 
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3.1.2. Selection of IgA as an immunological adjuvant with M cell 
targeting potential 
The introduction of immunological adjuvants in chapter 1 highlights the 
importance of investigations leading to development of novel immunological 
adjuvants for incorporation in vaccine formulations. Secretory immunoglobulin-A 
(SIgA) is essential in protecting mucosal surfaces by ensuring immune exclusion. 
SIgA exhibits the striking feature to adhere to the apical membrane of M-cells
304, 305
, 
promoting uptake of proportion of SIgA as reflected by the detection of gold-coated 
SIgA in the pocket of M-cells
306
. Further study of the interaction of M-cells with 
SIgA molecules demonstrated that IgA, with or without bound secretory component, 
but not IgG or IgM, bound selectively to murine and human M-cells.
307
 Adherence 
of IgA to M-cells required Cα1 and Cα2, suggesting that no known IgA receptor was 
involved in the interaction process.
308
 Recent studies indicated that SIgA exert the 
immunomodulatory and weak mucosal immunostimulant effects after being 
transported through M-cells of the Peyer‟s patch.308, 309  In a rather isolated study, 
Zhou et al
310
 prepared and evaluated IgA coated liposomes for rectal administration 
of ferritin antigen. They also compared M-cell targeting efficiency of IgA coated 
liposomes in Peyer patch tissues with uncoated liposomes. They concluded that IgA 
can significantly enhance the local secretory immune response to antigen in 
liposomes, apparently by increasing liposome uptake by at least 10 times via M cells. 
The studies on transportation of SIgA through M-cells, as well its 
immunological role and use of IgA as a potential M-cell targeting agent in some 
preliminary studies signify the potential of IgA as a novel immunological adjuvant. 
The endogenous nature of IgA, readily availability of antibody from industry, non-
pathogen origin and lack of inter-species variation in interaction between IgA and 
M-cells are some of the advantages IgA can offer as a vaccine formulation 
component. The conclusions of the studies highlighted above regarding IgA and lack 
of studies exploring IgA‟s suitability as an immunological adjuvant lead to the 
selection of IgA as a potential immunological adjuvant and M-cell targeting agent in 
this study.  
80 
 
3.1.3. Objectives of this section 
The broad objective of this part of research project was the development of 
an effective method for incorporation of PTXd and/or mouse IgA into optimized CS-DS 
nanoparticle formulation and characterization of these loaded formulations for in-vitro 
parameters.   
3.2. EXPERIMENTAL 
3.2.1. Materials 
Mouse IgA-Kappa from murine melanoma (Catalog no. M1421), 3,3',5,5'-
tetramethylbenzidine (TMB-2 liquid substrate system, Catalog no. T8665), tris 
bufferd saline powder (Catalog no. T6664), phosphate buffered saline (Catalog no.  
P4417), glutaraldehyde grade I (8% in water, catalog no. G7526) tween-20 
(Catalog no. P9416), bovine serum albumin (Catalog no. A3294), L-lysine 
(Catalog no. W384704), glycerol (Catalog no. 49767), and carbonate-bicarbonate 
buffer capsules (Catalog no.  C3041) were purchased from Sigma-Aldrich Ltd., 
Australia. Ham‟s F12 nutrient mixture (Catalog no. 11765-054), fetal calf serum, 
certified (Catalog no. 16000-036), trypsin-EDTA (Catalog no. 25200-056) and 
Opti-MEM-I reduced medium (Catalog no. 31985-062) were purchased from 
Invitrogen Australasia Pty Ltd, Australia. Lyophilized pertussis toxin (List 
Biological Laboratories Ltd., USA, Catalog no.181) was purchased from Sapphire 
Biosciences, Australia. All chemicals used for experiments were of molecular 
biology grade and used as received unless otherwise specified. 
Female Balb/c mice aged between 6-8 weeks were purchased from Animal 
Resource Center, Perth, Australia. All the animal purchase and studies were duly 
reviewed and approved by the Animal Ethics Committee of Curtin University of 
Technology. 
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3.2.2.  Methods 
3.2.2.1. Estimation of IgA  
Mouse IgA ELISA Quantitation kit (Catalog no. E90-103, Bethyl 
Laboratories, USA) was used for estimation of IgA for determination of loading 
and release of IgA from nanoparticles. Flat-bottom microtiter plates (Catalog no. 
442402, Nunc F96 MicroWell™ Plates, Thermo Scientific, Nunc A/S, Denmark) 
were coated with 10 µg/mL goat anti-mouse IgA affinity-purified antibody 
solution in carbonate-bicarbonate pH 9.6 coating buffer and incubated for 60 
minutes at 25 ± 2ºC. Plates were washed 4 times with wash buffer (Appendix 
7.1) and each well was blocked with 300 µL of blocking buffer (Appendix 7.1) 
for 30 minutes at 25 ± 2ºC. Plates were washed 4 times with wash buffer, 100 µL 
of test sample or standard was added per well, and incubated for 60 minutes at 25 
± 2ºC. Plates were washed 5 times with wash buffer and 100 µl of HRP-labeled 
goat anti-mouse IgA antibody solution in dilution buffer (0.02 µg/mL) was added 
to each well and incubated for 60 minutes at 25 ± 2ºC. Plates were washed 5 
times, developed for 30 min at 25 ± 2ºC with HRP substrate (3,3',5,5'-
tetramethylbenzidine), stopped with 1M HCl, and read at 450 nm with a 
microplate reader (Victor
3
V
™
 Wallac 1420 multilabel counter, PerkinElmer life 
and analytical sciences, Turku, Finland). Formula and preparation method of 
different buffers used in ELISA are included in Appendix 7.1. A standard curve 
was plotted and best fit model was derived using Graphpad Prism statistical 
software (v5 demo, Graphpad Inc., USA). The accuracy and precision of ELISA 
assay were determined from four 400 ng/mL IgA samples. Precision was 
calculated as percent relative standard deviation (RSD) and accuracy was 
calculated as percent ratio of measured experimental IgA concentration to 
theoretical expected IgA concentration (400 ng/mL). Analytical sensitivity 
(detection limit) for ELISA method
311
 of IgA quantification was calculated using 
the formula [average absorbance of the blank + 3 x (Standard Deviation for 
blank)]. Blank represents antigen and antibody free wells in the ELISA run. 
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3.2.2.2. Detoxification of PTX 
PTX was detoxified before its entrapment into nanoparticles using 
modification of method previously described by Munoz et al
312
. In brief, a 
solution of purified PTX was made in 20 mM sodium phosphate containing 0.5 
M NaCl (pH 7.6). A known volume of 0.2% w/v glutaraldehyde solution (made 
in the same buffer) was added to bring the final concentration of glutaraldehyde 
to 0.05% w/v. The mixture was incubated at room temperature for 2 h, and then a 
known volume of 0.2 M L-lysine solution (made in same buffer) was added to 
bring the final concentration of L-lysine to 0.02 M. The mixture was incubated 
for 2 h at room temperature and then dialyzed for 2 days against 250 mL of 
20mM sodium phosphate buffer containing 0.5 M sodium chloride. To 
incorporate PTXd in CS-DS nanoparticle formulation, the buffer was replaced 
with sterile water and volume was reduced using 10,000 molecular weight cut-
off (MWCO) membrane centrifugal filtration unit (Microsep, Pall Life Science, 
Australia). 
Detoxification of PTX was evaluated by Chinese Hamester Ovary 
(CHO) cell assay.
313
 In brief, confluent flasks of CHO cells were trypsinized and 
diluted in Ham‟s F12 nutrient mixture supplemented with 5% v/v fetal calf serum 
(FCS). A cell suspension containing 5 X 10
5
 of CHO cells was then added to 
each well of a flat-bottom 9-well tissue culture plate. PTX and PTXd in Opti-
MEM-I reduced medium (final concentrations in the volume of 2 mL was 0.07 
µg/mL and 2 µg/mL) were added, and clustering of cells was evaluated at 20 
hours. The phosphate buffer saline was used as negative control for comparison. 
The test was conducted in triplicate and photographs were captured at the end of 
test (20 hours) using Nikon inverted microscope. General details of cell-culture 
techniques and cell counting method are compiled in Appendix 7.2.  
3.2.2.3. Quantification of PTXd using protein estimation kit 
A fluorescent protein-probe based estimation method (Quant-iT
™
 
protein assay kit, Catalog no. Q33210, Invitrogen, USA) was used for initial 
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quantification of PTXd in solution obtained from detoxification procedure of 
PTX. A standard curve was prepared using bovine serum albumin as the model 
protein and all the assays were performed in triplicate. In brief, 200µl of working 
Quant-iT reagent solution was added in triplicate in individual wells of 96-well 
microplate followed by addition of 10µl of sample in each well. Flourescence 
was measured using a microplate reader (Victor
3
V
™
 Wallac 1420 multilabel 
counter, PerkinElmer life and analytical sciences, Finland) at excitation 
wavelength at 470 nm and emission wavelength at 590 nm. The accuracy and 
precision of assay were determined from four 30 µg/mL PTXd samples. 
Precision was calculated as percent relative standard deviation (RSD) and 
accuracy was calculated as percent ratio of measured experimental PTXd 
concentration to theoretical expected PTXd concentration (30 µg/mL). Analytical 
sensitivity (detection limit) for Quant-iT method of PTXd quantification was 
calculated using the formula [average flourescence of the blank + 3 x (Standard 
Deviation for blank)]. Blank represents sample free wells in the plate. 
The protein estimation kits only provide a non-specific method for 
protein estimation as the quantification is based on the reaction between common 
functional groups present in protein structure and the reagent. Therefore, these 
kits cannot be used when two or more proteins (e.g. PTXd and IgA) are present 
in any solution. This limitation of protein estimation kit prohibited the use this 
method for estimation of PTXd in entrapment efficiency and release studies. To 
solve this problem to the development of an ELISA method for PTXd was tried 
as described below. For comparison, PTX was also used along with PTXd in 
development of ELISA method. 
3.2.2.4. Estimation of PTXd and PTX by ELISA method 
The estimation of PTXd and PTX was conducted in three steps which 
are briefly described here, 
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3.2.2.4.1. Production of hyper-immunized anti-PTXd serum in Balb/c 
mice 
Twenty female BALB/c mice (Animal Resource Center, Perth, 
Australia) aged 8-10 weeks were immunized by the subcutaneous (s.c.) route 
with volume of 125 μl per mouse. Mice received four immunizations 
respectively at day 0 with 2 g, at day 10 with 4 g and at day 21 and day 28 
with 6 g of PTX adsorbed on alum (Imject
® 
alum, Catalog no. 77161, Pierce 
Biotec. Ltd, USA). Blood was taken from each animal one week after the last 
immunizaiton dose using cardiac puncture technique under deep anaesthesia 
(Intraperitoneal, ketamine/xylazine combination) and all the animals were 
then sacrificed by cervical dislocation. The animal study protocol was 
reviewed and approved by the Animal Ethics Committee, Curtin University of 
Technology, Perth, Australia. 
3.2.2.4.2. Purification of IgG antibodies from hyper-immunized serum 
and conjugation of purified IgG with horseradish peroxidase 
(HRP) 
Protein-G IgG purification kit (Catalog no. 89926, Pierce 
Biotec. Ltd, USA) was used for purification of IgG antibodies from serum 
collected from hyper-immunized mice. Protein G column was equilibrated 
with about five gel-bed volumes of IgG binding buffer followed by addition of 
diluted serum sample to the immobilized protein G column. The column was 
again washed with about five gel-bed volume of IgG binding buffer and 
purified antibodies were then eluted and collected using gentle Ag/Ab elution 
buffer (Catalog no. 21027, Pierce biotec. Ltd, USA). Elution of antibody was 
monitored using UV absorbance at 280nm (UV-Vis spectrophotometer, 
Hewlett-Packard instruments, USA). Eluted antibody solution was dialyzed 
against 0.1M carbonate-bicarbonate buffer and stored at -20°C in aliquots. 
The flow rate through column was maintained around 1 mL/minute during all 
steps. 
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For conjugation of HRP with IgG, SureLINK
®
 HRP conjugation 
kit (Catalog no. 840003, KPL Inc., USA) was used. In short, 150 µL of 1 
mg/mL antibody solution was mixed with activated HRP for 1 hour at room 
temperature followed by addition of 10 µL of reducing agent and incubation 
for 15 minutes at room temperature. Equal volume of storage buffer was then 
added in reaction vial and incubation at room temperature was provided for 15 
minutes. HRP-conjugated antibodies were stored at -20°C in aliquots. 
3.2.2.4.3. Sandwich ELISA method 
 Sandwich ELISA method similar to ELISA method used for 
estimation of mouse IgA (kappa) was used to estimate PTXd (and PTX) for 
determination of entrapment efficiency and release profile with the exception 
of using purified anti-PTXd IgG for coating and anti-PTXd IgG conjugated 
with HRP as secondary antibody. Formula and preparation method of 
different buffers used in ELISA are included in Appendix 7.1. 
The sandwich ELISA method developed only provided an 
accurate and reproducible estimation method for PTX and not for PTXd 
(explained in section 3.3.3). This led to the use of PTX in place of PTXd for 
entrapment efficiency and release studies. 
3.2.2.5. Preparation of IgA and PTX loaded CS-DS nanoparticles 
CS-DS nanoparticles containing mouse IgA and/or PTXd were prepared 
by adding 105 μl of PTXd and/or mouse IgA solution (containing 140μg of IgA 
or PTXd or IgA and PTXd each) into 105 μl chitosan solution (0.2% w/v in 0.4% 
v/v acetic acid solution) followed by dropwise addition of 70μl of dextran sulfate 
solution (0.1% w/v in milli-Q water) with high speed magnetic stirring at room 
temperature.  
For entrapment efficiency and release profile studies PTX was used in 
place of PTXd due to lack of accurate and reproducible method of estimation for 
PTXd.  
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3.2.2.6. Particle size and zeta potential of nanoparticles 
Particles size of nanoparticles in a formulation was determined using 
photon correlation spectroscopy using a Zetasizer 3000HS (Malvern Instruments, 
Malvern, Worcestershire, UK). The measurements were performed at 25ºC with 
a detection angle of 90°, and the raw data were subsequently correlated to Z 
average mean size using a cumulative analysis by the Zetasizer 3000HS software 
package. Each sample was measured 10 times. 
The zeta potential of particles was determined by laser Doppler 
anemometry using a Zetasizer 3000HS (Malvern Instruments, Malvern, 
Worcestershire, UK). The samples were injected into the flow cell chamber and 
measurements were carried out at 25ºC. For each sample, the mean ± SD of 3 
repeat measurements was established. 
3.2.2.7. Entrapment efficiency of PTX and/or IgA in nanoparticles 
 The quantity of PTX and/or IgA entrapped in the nanoparticles was 
calculated by the difference between the total quantity of protein added during 
the nanoparticle formation and the quantity of non-entrapped protein remaining 
in the aqueous filtrate. The latter was determined following the separation of 
protein-loaded nanoparticles from the aqueous medium by centrifugal-filtration 
using filtration units (Vivaspin
®
 500, Catalog no. KH-36228-12, Cole-Parmer, 
USA) fitted with membrane of one million Dalton cut-off at 2000 x g at 15 °C 
for 10 minutes. The particles were washed 3 times and filtration was repeated in 
between each washing. The PTX and/or IgA entrapment efficiency were 
calculated from the following equation (3.1): 
 
    
 (3.1) 
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3.2.2.8. In-vitro release study of PTX and/or IgA from nanoparticles  
The purpose of this study was to estimate the quantity of PTX which 
potentially could leak out of nanoparticles during the storage period. In addition, 
the release study may also help in understanding the corelation between 
pharmaceutical aspects of nanoparticulate vaccine delivery and induction of 
immune responses in-vivo. The CS-DS nanoparticles containing 10 µg of 
entrapped PTX and/or IgA (obtained from entrapment efficiency study as filtrand 
nanoparticles) were incubated with 2 mL of acetate buffer pH 5.1 medium. An 
acetate buffer acidic medium was used in release study to avoid agglomeration of 
CS-DS nanoparticles which could occur at basic pH as explained in chapter 2. 
The release studies were conducted at maintained temperature of 37°C. At pre-
determined time intervals, the 100 µl samples were withdrawn and centrifuged at 
16000 x g over 10 µl of glycerol bed to collect the supernatant for analysis. 
Glycerol bed has been previously used in studies
314
 during centrifugation for 
effective separation of nanoparticles from released ingredients. The 100 µl of 
fresh release medium was used to replace the sample volume collected from 
release medium. Results are shown as the distributive percentage of PTX or IgA 
released with respect to the total associated protein. 
3.2.2.9. SDS-polyacrylamide gel electrophoretic (PAGE) analysis of PTXd 
or IgA – loaded CS-DS nanoparticles 
The stability of PTXd and IgA in nanoparticles was investigated 
using SDS-PAGE analysis. The electrophoresis was performed with gels 
composed of 10% acrylamide, cast and run in Tris–glycine buffer. The sample 
bands were stained using silver nitrate staining method.
315
 All the samples were 
diluted with reducing sample buffer and diluted samples were heat treated for 5 
minutes. 20 µl of each diluted and heat treated sample (each containing 2 µg of 
PTXd or IgA) was loaded for electrophoretic analysis. The Gel electrophoresis 
was performed using a Mini-PROTEAN 2D electrophoresis system (Bio-Rad 
Laboratories, Inc., USA) at voltage of 75 V for initial 15 minutes followed by 
200 V for next 45 minutes. After electrophoresis, the pictures of gel were taken 
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using a digital camera (Sony Inc., Japan). The composition and preparation of 
SDS-PAGE gel mixtures are included in Appendix 7.3. 
3.2.2.10. Statistical analysis 
The raw data was processed to calculate mean with standard 
deviation using Microsoft excel 2007 (Microsoft Inc., USA). The experimental 
data was statistically analyzed using Graphpad Prism statistical software (v5 
demo, GraphPad Software Inc., CA, USA). 
3.3. RESULTS AND DISCUSSION 
3.3.1. Estimation of IgA 
Mouse IgA was quantified by sandwich ELISA method using a mouse 
IgA estimation kit (Catalog no. E90-103, Bethyl laboratories, USA). Mouse IgA 
solutions of known concentration were used to prepare calibration/standard curve. A 
non-linear correlation between concentration of IgA solutions and absorbance was 
observed in concentration range of 15.6 – 1000 ng/mL (Figure 3.1). The sigmoidal 
model - variable slope (equation 3.2) was selected as the best curve fit model for 
protein quantification on the basis of least sum of squares obtained for y-values and 
confidence intervals for each parameter value (Figure 3.2). 
 
       (3.2) 
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Figure 3.1. Standard (calibration) curve for IgA estimation using ELISA 
method.  
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Figure 3.2. Log scale calibration curve for IgA estimation using ELISA 
method. 
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Statistical and analytical parameters for the estimation of IgA by ELISA 
method were determined (Table 3.1) and used for further calculations in in-vitro 
characterization studies.  
  
 
Table 3.1. Statistical and analytical parameters for IgA estimation by ELISA 
method. 
 
Parameter Results 
Accuracy (400 ng/mL) 98.2 ± 12.3 % (n = 4) 
Precision (400 ng/mL) 4.3% (n = 4) 
Sensitivity (ng/mL) 4.3 
A  0.0491 
B  1.070 
C  220.1 
D  4.117 
Correlation of coefficient (R) 0.9997 
 
 
3.3.2. Detoxification of PTX  
Bordetella pertussis infections, associated with whooping cough, have 
been significantly reduced by the introduction of pertussis vaccines and 
immunization programs. Although whole-cell pertussis vaccines have been used for 
past many decades and are still being used particularly in the developing world, the 
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more recent development and introduction of acellular pertussis vaccines has both 
increased compliance with vaccination programs and reduced the severity of 
adverse reactions to the vaccine. These acellular pertussis vaccines are composed of 
the PTXd with or without inclusion of pertactin (PRN), filamentous hemagglutinin 
(FHA), and fimbriae (FIM2 and FIM3/6). Of the components used in the 
formulation of the acellular pertussis vaccine, only the PTX is the toxic component 
if administered at the doses required for effective vaccination,
316
 hence it is included 
in the detoxified form (PTXd) in the final formulation. Most of the commercial 
acellular pertussis vaccines contain chemically detoxified PTX with an exception of 
few using genetically detoxified PTX. In this investigation, glutaraldehyde was used 
for detoxification of PTX using modified method reported by Munoz et al.
312
 The 
glutaraldehyde treatment of pertussis toxin is reported to cause cross-linking of 
pertussis toxin structures and reduction of toxicity of toxin.
317
  
CHO cell agglutination assay is usually used testing for safety of 
acellular pertussis-containing vaccines.
313, 318, 319
 Agglutination of CHO cells is a 
reflection of PTX activity as it requires both the binding and enzymatic functions of 
the toxin.
320, 321
 The clustering of CHO cells was clearly observed (Figure 3.3 B1, 
B2) at both high (2 µg/mL) and low (0.07 µg/mL) doses of PTX which indicates the 
high sensitivity of assay as reported previously
320
. The absence of clustering of cells 
in results of CHO cell assay for PTXd (Figure 3.3 C1, C2) obtained by 
detoxification of PTX with glutaraldehye suggested PTX is detoxified and is 
suitable for use in in-vivo studies. 
93 
 
  
A1 - Buffer only A2 - Buffer only 
  
B1 - Pertussis toxin (2µg) B2 - Pertussis toxin (70ng) 
   
C1 - PTXd (2µg) C2 - PTXd (70 ng) 
 Figure 3.3 CHO cell assay for evaluation of detoxification of PTX. 
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3.3.3. Estimation of PTXd (or PTX) 
Two different methods were utilized for estimation and analysis of PTX 
and PTXd as explained previously in this chapter. Currently, there is no in-vitro 
specific standard quantitation method for PTXd which has been universally 
recommended and accepted in industrial or academic research. Non-specific protein 
estimation methods such as Lowry and Bradford methods have been widely used for 
estimation of proteins including PTXd. However, these estimation methods are 
general methods of protein quantification with no specificity for PTXd and have 
limited applicability in multi-protein studies such as ours. In addition, these methods 
usually need higher concentrations of protein (higher detection limit and lower 
sensitivity) for accurate quantification, which makes them unsuitable for studies 
involving very low dose of proteins (e.g. PTXd). Therefore, two different methods 
were used for estimation of PTXd (or PTX) in this study. The first method used a 
fluorescent reagent for non-specific protein quantification to estimate initial PTXd 
concentrations after detoxification before addition into any formulation. The second 
estimation method was pursued with an aim of specific sensitive quantification of 
PTXd using ELISA technique particularly for entrapment efficiency, release profile 
and other formulation experiments.  
For initial quantification of PTXd after detoxification process, a protein 
quantification kit (Quant-iT
™
 Protein Assay kit) was used. The solutions of bovine 
serum albumin (BSA) of known concentrations were used as standard protein 
samples. A non-linear correlation between concentration of BSA solutions and 
fluorescence was observed in concentration range of 0 – 100 µg/mL. Curve-fit 
statistical models were studied to select the best fit model using Graphpad Prism 5 
statistical software. Polynomial (second order) model (equation 3.3) was selected as 
the best curve fit model for protein quantification on the basis of least sum of 
squares obtained for y-residual values and confidence intervals for each parameter 
value (Figure 3.4). 
       (3.3) 
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Figure 3.4. Standard (calibration) curve and model fitting for PTXd using 
Quant-iT protein quantification kit method. 
 
 
Statistical and analytical parameters for the Quant-iT estimation method 
were determined (Table 3.2) and to avoid experimental and environmental errors, 
standard concentrations of BSA were run in each plate along with PTXd samples.  
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Table 3.2 Statistical and analytical parameters for Quant-iT protein estimation 
method 
Parameter Results 
Accuracy (30 µg/mL) 109.7 ± 9.5 % (n = 4) 
Precision (30 µg/mL) 8.12% (n = 4) 
Sensitivity (µg/mL) 10.79 
β0 4117.70 
β1 78.50 
β2 3.44 
Correlation of coefficient (R) 0.9992 
 
 
Corbel et al.
317
 have reviewed the issue of accurate determination of 
antigen content at the intermediate and formulation stages and reported that 
measurement of protein content has the disadvantage of not necessarily reflecting 
the quality or quantity of antigenically active material present. Moreover, non-
specific nature of Quant-iT
™
 protein assay method and lower sensitivity (higher 
detection limit) of this assay method (Table 3.2) limited its applicability in in-vitro 
characterization (particularly entrapment efficiency and release studies) of PTXd 
loaded CS-DS nanoparticles.  To tackle these problems, development of a sandwich 
ELISA method for quantitation of PTXd by induction and purification of anti-
PTXd-IgG antibodies from mouse serum collected from hyper-immunised animals 
was undertaken. However, the developed ELISA method did not provided accurate, 
sensitive and reproducible quantification of PTXd (raw data included in appendix 
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7.4) which led to the use of PTX in entrapment efficiency and release studies. The 
developed sandwich ELISA was used to quantify PTX using known concentration 
solutions of PTX as standards (Figure 3.5). The developed sandwich ELISA method 
showed acceptable accuracy, sensitivity and reproducibility of results for PTX 
(Table 3.3) which allowed the use of this method in entrapment efficiency and 
release studies where lower detection limit is important for obtaining correct results. 
Antigen free and antibody free wells were used as negative controls and mean 
absorbance value of negative controls were subtracted from each positive sample 
absorbance before plotting the graph.  
The curve fitting study revealed that correlation between concentration of 
PTX and absorbance is non-linear for the concentration range of 15.6 - 2000 ng/mL 
(Figure 3.5). Second order polynomial model (equation 3.4) was selected as best 
curve fit model on the basis of least sum of squares of y-value differences and 
confidence intervals for each parameter value (Figure 3.5).  
 
       
(3.4) 
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Figure 3.5. Standard (calibration) curve for PTX estimation using sandwich 
ELISA method. 
 
Statistical and analytical parameters for the estimation of PTX by 
sandwich ELISA method were determined (Table 3.3) and to avoid experimental 
and environmental errors, standard concentrations of PTX were run in each plate 
along with samples. The accuracy and precision of assay were determined from four 
400 ng/mL PTX samples. Precision was calculated as percent relative standard 
deviation (RSD) and accuracy was calculated as percent ratio of measured 
experimental PTX concentration to theoretical expected PTX concentration (400 
ng/mL). Analytical sensitivity (detection limit) for sandwich ELISA method
311
 of 
PTX quantification was calculated using the formula [average absorbance of the 
blank + 3 x (Standard Deviation for blank)]. Blank represents antigen and antibody 
free wells in the ELISA run.  
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Table 3.3. Statistical and analytical parameters for PTX estimation by 
sandwich ELISA method 
Parameter Results 
Accuracy (400 ng/mL) 96.1 ± 9.2 % (n = 4) 
Precision (400 ng/mL) 6.74% (n = 4) 
Sensitivity (ng/mL) 34.97 
β0 0.2862 
β1 0.0032 
β2 - 9 x 10
-7
 
Correlation of coefficient (R) 0.9975 
 
Isben
322
 has studied in detail the effect of chemical detoxification of PTX 
on epitope recognition by murine monoclonal antibodies using ELISA as evaluation 
technique. The author concluded that the detoxification procedures employed 
altered the level and pattern of epitope recognition in various degrees. The 
researcher also reported that modifications induced by chemical detoxifications 
clearly reduced or destroyed antibody recognition of some epitopes while increased 
binding of others. The research indicated that PTX detoxification using 
formaldehyde causes higher reduction in antibody recognition of epitopes compared 
to PTX detoxified using hydrogen peroxide or genetically detoxified. Moreover, it 
has been also reported that detoxification of PTX using aldehydes could modify 
both the B- and the A-subunits of PTX which potentially reduce its interaction with 
antibodies in ELISA assay.
323-325
 These reports and the study conducted for this 
thesis indicate unsuitability of ELISA as a reliable method of estimation for PTXd.  
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3.3.4. In-vitro characterization of antigen and/or IgA loaded CS-DS 
nanoparticles 
  As explained above, the developed sandwich ELISA method was 
reasonably reproducible and accurate for estimation of PTX whilst the same method 
was found highly non-reproducible and non-reliable for PTXd estimation (raw data 
included in appendix 7.4). In the absence of any standard method for in-vitro 
estimation of PTXd especially for in-vitro characterization of antigen (PTXd) and 
adjuvant (IgA) loaded CS-DS nanoparticles, PTX was used in place of PTXd for in-
vitro characterization (entrapment efficiency and release profile) of loaded 
nanoparticle formulation. It is important to mention here that detoxification of PTX 
may lead to increase in molecular size due to cross-linking which in turn may or 
may not affect entrapment and release process. Therefore, further exploration of 
quantifying methods for PTXd such as immuno-blotting to determine exact 
entrapment efficiency and release profile is warranted. Immunoblotting has been 
reported
326
 as a selective technique for the detection of different B. pertussis protein 
antigens but utility of this technique for accurate and sensitive in-vitro 
quantification of PTXd needs further research studies. 
Two different approaches were studied for incorporation of PTX or IgA 
into CS-DS nanoparticles and entrapment efficiency was used as an evaluation 
parameter. In first approach, PTX or IgA was added into chitosan solution before 
addition of dextran sulfate into chitosan solution whereas in second approach PTX 
or IgA was added into dextran sulfate solution before mixing of dextran sulfate with 
chitosan solution.  Significantly higher entrapment (p < 0.001, student t-test) was 
achieved when PTX or IgA was added into chitosan solution during preparation of 
nanoparticles compared to addition of PTX or IgA into dextran sulfate solution 
(Table 3.4).  
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Table 3.4. Entrapment efficiency of IgA or PTX into CS-DS nanoparticles 
prepared by two formulation approaches 
Formulation approach ↓ IgA entrapment 
efficiency (%) ± SD 
PTX entrapment 
efficiency (%) ± SD 
IgA into chitosan solution 94.19*** ± 0.06 - 
IgA into dextran sulfate 
solution 
8.54*** ± 0.31 - 
PTX into chitosan solution - 95.98*** ± 1.94 
PTX into dextran sulfate 
solution 
- 73.44*** ± 2.11 
*** Means are significantly different (p < 0.001), comparison of values in same 
column. 
 
The higher entrapment efficiency of proteins on addition into chitosan 
solution might be because of larger molecular structure of chitosan (~ 150K) 
compared to dextran sulfate (~ 5K) allow intermingling of PTX or IgA with 
chitosan before formation of nanoparticles. Huang et al.
327
 have also reported 
entrapment efficiency of higher than 80% in CS-DS nanoparticles for a protein 
(vascular endothelial growth factor) and hypothesized the mechanism of entrapment 
in two stages; first intermingling of protein with high molecular weight 
polysaccharide and then formation of nanoparticles on addition of low molecular 
weight polyelectrolyte by interation of two polyions. Gan et al.
257
 have 
systematically studied fabrication conditions for efficient loading of chitosan 
nanoparticles using BSA as model protein. The authors reported that since protein 
molecules are large macromolecules with complex 3-D structure, able to fold and 
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unfold at different solution conditions, their interactions with long cationic chitosan 
chain and the consequential encapsulation can be complicated, depending on 3-D 
conformation, electrostatic, and solution conditions. Further, the presence of a 
crosslinking agent such as aldehydes will chemically interact with free amine 
groups on both protein and chitosan molecules, resulting in more compact protein–
chitosan nanoparticles. Additional adsorption of protein molecules on the surface of 
the formed particles may occur in sequence, leading to additional protein loading on 
the particles.
257
 
 In the light of experimental results and previous reports, antigen (PTX) 
and/or adjuvant were added into chitosan solution during preparation of 
nanoparticles for all further experiments. The entrapment efficiency of CS-DS 
nanoparticles was also observed higher than 90% when both IgA and PTX were 
incorporated into CS-DS nanoparticles i.e. 93.97 ± 0.508 and 95.88 ± 0.53 
respectively for IgA and PTX. This indicates that two proteins and their quantity do 
not hinder the incorporation of each other into CS-DS nanoparticles and CS-DS 
nanoparticle formulation can be a potential delivery system for multiple proteins 
together.   
Table 3.5 tabulates the particle size and zeta potential results of IgA- or 
PTXd- or IgA and PTXd-loaded CS-DS nanoparticles. It is important to mention 
that PTX was used in place of PTXd only for entrapment efficiency and release 
studies (where quantification of antigen was needed) and for particle size, zeta 
potential and stability (SDS-PAGE) studies PTXd was incorporated in CS-DS 
nanoparticles as in further in-vivo studies (next chapter of thesis) only PTXd can be 
administered as safe antigen to animals (as explained in section 3.3.2).  
The incorporation of PTXd or/and IgA in CS-DS nanoparticles did not 
result in significant increase of particle size but, the zeta potential of CS-DS 
nanoparticles become less positive on incorporation of protein(s). This may have 
occurred because the carboxylic acid groups on the surface of a large protein 
molecule may interact with amine groups at certain sites at the spread chitosan 
chain, but still maintaining a compact 3-D protein structure without spreading.
328
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On the other hand, high positive zeta potential of loaded CS-DS nanoparticles 
indicate that still be a high proportion of free amine group on the chitosan chain 
remains unoccupied. 
 
Table 3.5. In-vitro characteristics of loaded CS-DS nanoparticle formulations  
 
 
Lack of significant increase in particle size of nanoparticles with limited 
reduction in zeta potential on IgA and/or PTXd incorporation and entrapment 
efficiency higher than 90% achieved for these proteins when added into chitosan 
solution indicate involvement of strong attractive force between these proteins and 
nanoparticle components. This may be explained using a “Guest-host model” 
resulting in a “core/shell” structure established for polyelectrolyte complexes.329 In 
brief, the model states that the polymer partners complex according to the „„zip‟‟ 
mechanism and form particles consisting in long host molecule sequentially 
complexed with shorter molecules of oppositely charged guest polyelectrolyte 
resulting in a hydrophobic core formed from the aggregation of complexed 
segments whereas excess component in the outer shell ensuring the colloidal 
stabilization against further coagulation.
278, 281, 330
 This model explains most of the 
Formulation  Particle size ± 
S.D (nm)  
Polydispersity 
index ± S.D  
Zeta potential ± 
S.D (mV)  
CS-DS 
nanoparticles  
314.7 ± 9.2  0.29 ± 0.21  +53.2 ± 4.4  
IgA-loaded 
nanoparticles  
290.8 ± 10.3 0.52 ± 0.07  +39.6 ± 4.1  
PTXd-loaded 
nanoparticles  
324.0 ± 3.1  0.45 ± 0.17  +41.6 ± 3.2  
IgA and PTXd 
loaded nanoparticles  
330.3 ± 1.1  0.39 ± 0.14  +40.1 ± 1.2  
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in-vitro characterstics observed in the studies conducted as part of this thesis for CS-
DS nanoparticles.  
The applicability of this model on CS-DS nanoparticles is further 
vindicated by the release profile of protein(s)observed in this study. All the loaded 
CS-DS nanoparticles showed less than 15% of initial rapid release followed by 
almost no release of protein(s) for long time period (Figure 3.6 and 3.7). This 
indicates quick desorption of loosely bound surface IgA and/or PTX from shell part 
of nanoparticles, followed by slow or no release from core of nanoparticles with 
dynamic adsorption-desorption continuously occurring during the later phase. 
Similar release profiles have been reported previously for chitosan nanoparticles 
incorporating different protein(s).
283, 331, 332
 The lack of high percentage release in 
short time period is important in making sure that most of the vaccine dose remains 
in nanoparticle at the time of administration. 
A small increase of less than 10% in protein(s) release was observed 
when both IgA and PTX were incorporated into CS-DS nanoparticles compared to 
nanoparticles loaded with only IgA or PTX. The increased release might have 
occurred due to a small increase in the proportion of protein bound to surface of 
nanoparticles in the presence of other competitive protein. 
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Figure 3.6. Release profile of PTX from CS-DS nanoparticle formulation in 
acetate buffer pH 5.1. All the data plotted is in the form of mean ± SD (n = 3). 
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Figure 3.7. Release profile of IgA from CS-DS nanoparticle formulations in 
acetate buffer pH 5.1. All the data plotted is in the form of mean ± SD (n = 3). 
 
 
To evaluate the integrity of protein(s) on entrapment into CS-DS 
nanoparticles, the SDS-PAGE bands of the nanoparticle containing IgA or PTXd 
were compared with that of native IgA or PTXd using the protein concentration of 
100µg/ml (2 µg in 20 µl) in each sample. The results of study (Figure 3.8) showed 
identical bands for the entrapped IgA (lane C) and native IgA (lane B), each with 
two bands representing heavy and light chains of structure. Similarly, for native 
(lane D) and entrapped PTXd (lane E) identical bands were observed. There were no 
additional bands which indicate that the molecular weight of IgA and PTXd was not 
significantly affected by the entrapment procedure. The relatively lighter (faded) 
bands for nanoparticle incorporated PTXd (lane E) and IgA (lane C) compared to 
native PTXd (lane D) and IgA (lane B) indicate shielding of significant proportion 
of PTXd and IgA inside CS-DS nanoparticles. The absence of distinct PTX 
structural unit bands (S1, S2, S3, S4 and S5) for PTXd in SDS-PAGE results 
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indicates structural modification of molecule by detoxification. It has been 
previously reported
317
 that SDS-PAGE results are of less value in characterization 
of PTXd obtained by chemical detoxification. However, the results of SDS-PAGE 
give sufficient information about molecular weight similarity of IgA and PTXd 
before and after incorporation into CS-DS nanoparticles. This is important for 
comparison of different loaded nanoparticle formulations against antigen solution 
formulations in in-vivo studies. 
 
 
Figure 3.8. Gel electrophoretic analysis of, (A) Molecular weight marker; 
(B) mouse IgA; (C) CS-DS nanoparticles loaded with mouse IgA; (D) PTXd; 
(E) CS-DS nanoparticles loaded with PTXd. 
To conclude, PTXd and/or IgA were efficiently incorporated into CS-
DS nanoparticles using a simple aqueous method and loaded nanoparticles were 
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characterized for in-vitro evaluation parameters. The method of estimation for IgA 
and PTXd (or PTX) were developed and used in the determination of entrapment 
efficiency and release profile for loaded CS-DS nanoparticles. The in-vitro 
characterization of IgA and/or PTXd loaded CS-DS nanoparticles suggests the 
potential of CS-DS nanoparticles as vaccine delivery system with the following 
important advantages: 
  High entrapment efficiency for protein antigen and adjuvant using simple 
preparation and incorporation method. 
  Nanoparticulate size and positive zeta potential, both of which can potentially 
lead to induction of higher immunological responses in-vivo. 
  Lack of significant release of incorporated protein(s) from nanoparticles 
during storage ensures that most of the protein(s) will be in nanoparticle 
incorporated form at the time of administration. 
These results warrant the further evaluation of PTXd and/or IgA loaded 
CS-DS nanoparticles in-vivo. 
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CHAPTER 4 
IMMUNOLOGICAL CHARACTERIZATION 
OF THE ANTIGEN AND/OR IgA LOADED  
CS-DS  NANOPARTICLE FORMULATIONS 
IN-VIVO 
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4.1. INTRODUCTION 
The immune system can be divided into innate and adaptive (acquired) immune 
systems although both of these immune systems work together as a complex integrated 
system.
333
 A cascade of events occurs when cells participating in innate immune 
defences recognize foreign structural motifs on pathogens to eliminate or contain the 
threat. Innate immunity comprises of a variety of hematopoietic and cellular factors 
including the complement system, phagocytic cells, natural killer cells, naturally 
occuring antibodies, γδ T cells, and anti-microbial peptides. The innate immune system 
recognize components of foreign invaders using relatively few molecules, these 
microbial associated components were described by Janeway and Medzhitov as 
pathogen-associated molecular patterns (PAMPs).
334
 Depending on the vigour of the 
innate immune response, the adaptive immune response may or may not be actively 
engaged.
188
 In contrast to innate immunity, adaptive or acquired immunity involves 
recognization of antigen-specific epitopes, in case of protein antigens, via specialized 
cell surface receptors (B cell or T cell receptor) resulting in an antigen-specific immune 
response.
188
  
There are two arms of acquired immunity, which have different set of 
participants but with one common aim of eliminating the foreign antigen. Of these two 
arms, one is mediated mainly by B cells leading to production of antibodies and referred 
to as antibody-mediated (humoral) immunity. The other is mediated by T cells (Th1 or 
Tc cells), which do not synthesize antibodies but instead synthesize and release various 
cytokines that affect other cells.
335
 Cell mediated immunity is particularly effective 
against intracellular pathogens, some cancer cells and foreign tissue transplants. 
Antibody-mediated immunity works mainly against antigens present in body fluids and 
extracellular pathogens. Antibody mediated immune responses against an antigen can be 
further classified into two main types based on the site of induction; first is systemic 
immune response which represent induction of antibodies in blood and lymph fluids, and 
second is mucosal immune response which offer antibody-mediated protection at the 
mucosal surfaces mostly through secretory immunoglobulins (SIgA). 
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 Induction of the appropriate immune response is essential determinant of 
vaccine efficacy/performance. One of the critically important innate immune cells 
involved with induction of immune responses are the dendritic cells. Dendritic cells are 
found in all body tissues and play a central role in stimulation and regulation of acquired 
immunity (cell mediated and humoral immunity).
336
 In the blood and tissues, dendritic 
cells are in an „immature‟‟ state, capable of phagocytosis, and express low levels of 
costimulatory molecules as well as molecules associated with antigen capture and 
cellular migration (pattern recognition receptors – PRRs) such as TLRs, DCIR, CCR7, 
DC-SIGN, DEC-205 etc.
337
 Upon activation via TLRs and/or other environmental cues, 
such as IL-8, dendritic cells undergo maturation. Following maturation, dendrtic cells 
lose much of their phagocytic capacity while increasing surface expression of migratory 
and costimulatory molecules, such as MHC I/II, CD80, CD86, and CD40. This process 
is accompanied by migration to the draining lymph node(s). Within the lymph node, 
dendritic cells continue maturation and serve as potent APCs to naive CD4+ and CD8+ 
T cells.
188
 
Dendritic cells process antigen either via the major histocompatibility complex 
(MHC) class-I or class-II pathways. This depends upon whether the antigens are 
endogenous or exogenous. Exogenous antigens taken up by APCs are contained within a 
phagosome or early endosome. The phagosome fuses with a lysosome generating a 
phagolysosome in which proteolytic enzymes are activated following changes in the pH 
that leads to degradation of the antigen into small peptide fragments in order to facilitate 
their presentation to T cells and B cells. Antigens within phagolysosomes of APCs 
representing exogenous antigens are displayed as MHC-II and then presented on the 
cellular surface for stimulation of CD4+ T cells.
338
  
Antigens of many viral and intracellular bacterial pathogens are presented by the 
endogenous pathway and processed in the cytosol. Processing of these antigens involve 
degradation in the proteasome and transport to the endoplasmic reticulum via TAP-I and 
TAP-2 encoded peptide transporters via the golgi apparatus as MHC class-I peptide 
complex to the surface of the APC for presentation to CD8+ T cells.
188, 338
 Upon 
recognition of the MHC peptide complex and costimulation from APC, naїve T-helper 
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(Th) cells differenciate into effector Th cells.
339
 These CD4+ T-helper (Th) cells can be 
further classified as Th1, Th17, and Th2.
340-342
 A Th2-type immune response is 
characterized by the production of IL-4, IL-5, IL-10, IL-13 and TGF-β and the secretion 
of IgG1 and IgE antibody isotypes. Th1-type responses are characterized by the 
production of cytokines such as IFN-γ, GM-CSF, TNF-α, IL-2, IL-12, IL-18 and TNF-β 
and IgG2a antibodies and are considered to be indirect indicators of cell-mediated 
immunity (CMI) involving activation of  macrophages and manifestation of delayed type 
hypersensitivity.
343
 Immune responses of the Th1-type are directed more towards the 
clearance of intracellular pathogens such as Mycobacterium tuberculosis and Shigella 
species, and most viruses, whereas a Th2-type response is generally associated with the 
induction of antibodies that effectively neutralize toxins, viruses, and/or bacterial 
adhesion.
344, 345
 Th17 responses are considered inflammatory in nature and are 
characterized by production of IL-17.
340
 The role of Th17 cells in vaccinology or 
infectious disease has yet to be fully elucidated although an association with 
autoimmunity has been suggested.
338
  
The induction of different arms of immune response depends on stimulation of 
particular antigenic processing pathway, which in turn is influenced by various factors 
such as formulation components of vaccine, nature of antigen and route of vaccine 
administration. Conventionally, nearly all the vaccines were administered through 
parenteral routes and such is the case with majority of the currently used commercial 
vaccines. However, interest in investigation of newer routes for vaccine delivery have 
resulted in various studies reporting possibility of vaccine delivery through different 
mucosal routes such as oral, nasal, pulmonary, sublingual and rectal routes. Mucosal 
administration of vaccines offers a number of advantages, including easier 
administration, reduced potential adverse effects and the potential reduction of the need 
for frequent boosters. In addition, mucosal immunization has been reported to induce 
both mucosal and systemic immune responses at least in some monogastric species. 
Table 4.1 compares the pros and cons of parenteral versus mucosal routes of 
administration for vaccine delivery.
346, 347
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Table 4.1 Comparison of the parenteral and mucosal routes of administration for 
vaccine delivery 
Comparison 
parameters 
Parenteral delivery Mucosal delivery 
Immunogenicity of 
antigen 
Higher Moderate or lower 
Dose of antigen 
required 
Lower Moderate or higher 
Acquired immunity Systemic antibodies;  
Cell mediated immunity 
may be induced using 
delivery system or 
adjuvants. 
Systemic and/or mucosal 
antibodies; 
Cell mediated immunity may 
be induced using delivery 
system or adjuvants. 
Compliance and 
ease of 
administration 
Lower compliance and 
injections are used. Medical 
expertise needed for 
administration 
Higher compliance and easy 
administration with self 
administration possible 
Examples of routes 
studied/used 
Subcutaneous, 
intramuscular, intradermal 
Oral, nasal, rectal, sublingual, 
pulmonary. 
 
A comparative in-vivo immunological evaluation of different antigen loaded CS-
DS nanoparticle formulations delivered via intranasal versus subcutaneous routes was 
undertaken due to the potential differences in type and level of induction of immune 
responses by a vaccine formulation administered through different routes of 
administration. The nasal mucosa is an attractive option for mucosal vaccine delivery 
because of the absence of acidity, lack of abundant secreted enzymes and small mucosal 
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surface area that result in a low dose requirement of antigen compared to oral vaccine 
delivery. Additionally, the most common causative agent of pertussis, Bordetella 
pertussis, has an exclusive affinity for the mucosal layers of the human respiratory tract. 
This makes intranasal vaccination attractive as induction of mucosal immune response in 
respiratory mucosa could be valuable in local protection against the infection. 
Furthermore, the presence of an organized lymphoid tissue (M cells incorporating 
NALT) in nasal mucosa could provide an efficient uptake pathway for nanoparticulate 
PTXd-loaded CS-DS formulations. The presence of M cells in nasal mucosa could also 
help to understand the effect of incorporation of a M cell targeting ligand (IgA) in PTXd 
loaded CS-DS nanoparticles on induction of in-vivo immune responses. The selection of 
IgA as a potential immunological adjuvant and M-cell targeting agent in this thesis work 
has already been included in chapter 3 section 3.1.2. 
4.1.1. Objectives of this section 
The goal of this part of project was to perform a comparative study of 
the immunological responses of antigen-loaded CS-DS nanoparticle formulations 
with or without IgA delivered via intranasal versus subcutaneous routes in a mouse 
model. The goal was accomplished by execution of the following studies: 
 Evaluation of nasal M-cell targeting efficiency of IgA loaded CS-DS 
nanoparticulate formulation. 
 Determining the immunogenic response of IgA as an immunological adjuvant 
for pertussis toxoid delivery via  mucosal and parenteral routes. 
 Determining the immunogenic response of CS-DS nanoparticluate 
formulation as vaccine delivery system through mucosal and parenteral routes. 
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4.2. EXPERIMENTAL 
4.2.1. Materials 
Lyophilized pertussis toxin (List Biological Laboratories Ltd., USA, 
Catalog no.181) was purchased from Sapphire Biosciences, Australia. Mouse IgA-
Kappa from murine melanoma (Catalog no. M1421), 3,3',5,5'-tetramethylbenzidine 
(TMB-2 liquid substrate system, Catalog no. T8665), tris bufferd saline powder 
(Catalog no. T6664), phosphate buffered saline (Catalog no.  P4417), 
glutaraldehyde grade I (8% in water, catalog no. G7526) tween-20 (Catalog no. 
P9416), bovine serum albumin (Catalog no. A3294), L-lysine (Catalog no. 
W384704), UEA-I conjugated with TRITC (Catalog no. L4889), goat anti-mouse 
IgA-FITC conjugated (Catalog no. F9384) and carbonate-bicarbonate buffer 
capsules (Catalog no.  C3041) were purchased from Sigma-Aldrich Ltd., Australia.  
Goat anti-mouse IgG1-HRP conjugated (Catalog no. A90-105P, Bethyl 
labs., USA), goat anti-mouse IgG2a-HRP conjugated (Catalog no. A90-107P, 
Bethyl labs., USA), goat anti-mouse IgG2b-HRP conjugated (Catalog no. A90-
109P, Bethyl labs., USA) and goat anti-mouse IgA-HRP conjugated (Catalog no. 
A90-103P, Bethyl labs., USA) antibodies were purchased from Sapphire 
Biosciences, NSW, Australia. BD OptEIA
™
 mouse interferon-γ (IFN-γ) ELISA set 
estimation kit (Catalog no. 555138, BD biosciences), sterile scalpel blades no. 20 
(Catalog no. 16827, BD biosciences) and ultra-fine needle insulin syringe (Catalog 
no. 16296, BD biosciences) were purchased from BD biosciences, Australia. The 
flat-bottom 96-well F96 maxisorp nunc immuno plates (Catalog no. 442404, 
Thermo Fisher scientific, Roskilde, Denmark) were obtained from in-vitro 
technologies, Australia. All other chemicals used for experiments were of molecular 
biology grade and used as received unless otherwise specified. 
Female Balb/c mice aged between 6-8 weeks were purchased from 
Animal Resource Center, Perth, Australia. All the animal purchase and studies were 
duly reviewed and approved by Animal Ethics Committee of Curtin University prior 
to the start of the animal study. 
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4.2.2. Methods 
4.2.2.1. Preparation of CS-DS nanoparticulate formulations for in-vivo 
studies 
Blank CS-DS nanoparticles were prepared as a negative control 
formulation for in-vivo studies by dropwise addition of 100μl dextran sulfate 
solution (0.1% w/v in milli-Q water) into 300μl of chitosan solution (0.1% w/v 
in 0.2% v/v acetic acid solution) at room temperature with high speed magnetic 
stirring to form nanoparticles.  
CS-DS nanoparticles incorporating mouse IgA and/or PTXd were 
prepared by adding 105μl of PTXd and/or mouse IgA solution (containing 
140μg of IgA or PTXd or IgA and PTXd each) into 105μl chitosan solution 
(0.2% w/v in 0.4% v/v acetic acid solution) followed by dropwise addition of 
70μl of dextran sulfate solution (0.1% w/v in milli-Q water) with high speed 
magnetic stirring at room temperature.  
Half of each formulation was used for subcutaneous immunological 
animal studies and another half for nasal immunological animal studies. All the 
formulations were prepared on the same day of their administration into 
animals. 
4.2.2.2. In-vivo uptake of IgA loaded nanoparticles in nasal epithelia 
Two female Balb/c mice (aged 6-8 weeks) were anaesthetized with 
isoflurane as inhalational anaesthetic in conjuncture with air using ventilator 
just before administration of formulation through nasal route. CS-DS 
nanoparticulate formulation loaded with IgA was administered into mice nares 
(10 µL per nostril) by a 20 µL pipette tip. The animals were kept at a controlled 
temperature condition for half an hour after administration of formulation. The 
animals were sacrificed 30 min after intranasal administration of the 
formulations under deep anaesthesia induced by administration of ketamine 
(80mg/Kg) in combination with xylazine (16mg/Kg) by intraperitoneal route. 
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The exposed nasal mucosa was gently washed by tris buffer saline. The nasal 
cavity of the mice was flushed with 4% (w/v) paraformaldehyde solution in 
PBS pH 7.4 and the septum along with nasal associated lymphoid tissue 
(NALT) situated at the posterior part of the nose were excised using dissecting 
microscope (Olympus SZ61, Olympus corporation, Philippines). The excised 
nasal tissues were immersed in the 4% (w/v) paraformaldehyde solution in PBS 
pH 7.4 for 45 minutes. The tissues were then gently washed with tris buffer 
saline. The tissues were stained with FITC labelled anti-mouse IgA, UEA-1 
conjugated with TRITC and Hoescht 33343 for 60 min and visualized by a 
confocal laser scanning microscope (Bio-Rad, Alphen a/d Rijn, The 
Netherlands). The confocal pictures were obtained by scanning the nasal 
epithelia in the x, y plane with a z-step. Another two female Balb/c mice (6-8 
weeks) were used as negative controls and administered with buffer only. The 
nasal tissues excised from negative control mice were stained with either UEA-
1 conjugated with TRITC or Hoescht 33343 and confocal pictures were 
obtained as described above. 
4.2.2.3. In-vivo immunological comparative evaluation of formulations  
Four groups of 6 female Balb/c mice aged 6-8 weeks each were 
used for in-vivo comparative evaluation of different formulations through 
subcutaneous route of administration for immunological responses. Alum 
(Imject Alum) adsorbed PTXd was used as a positive control in this study. In 
brief, PTXd was adsorbed over alum by dropwise addition of PTXd into alum 
suspension with continuous vortexing for 30minutes. Another five groups of 6 
female Balb/c mice aged 6-8 weeks each were used for in-vivo comparative 
evaluation of different formulations through intranasal route of administration 
for immunological responses. For the easier administration of formulations to 
animals through intranasal route, each animal was anaesthetized with isoflurane 
as inhalational anaesthetic in conjuncture with air using ventilator just before 
administration of 10μl formulation in each nostril.The details of the study are 
included in Table 4.2. 
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Table 4.2. Experimental design for comparative in-vivo evaluation of CS-DS nanoparticulate formulations against 
conventional antigen formulation. 
Animal 
group 
Route 
of adm. 
IgA dose 
(μg) 
PTXd dose 
(μg) 
Formulation Dosing 
frequency 
Sacrifice post 
first adm. 
End-point 
collection 
1 IN 0 10 PTXd solution Day 1, 14 and 
21 of study  
30 days Blood, 
spleen, lungs 
2 IN 0 10 CS-DS nanoparticles 
loaded with PTXd 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
3 IN 10 10 CS-DS nanoparticles 
loaded with IgA and PTXd 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
4 IN 0 0 Buffer only (control group 
1) 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
5 IN 10 0 Blank CS-DS 
nanoparticles with IgA 
(control group 2) 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
6 SC 0 10 PTXd adsorbed on imject 
alum 
Day 1, 14 and 
21 of study  
30 days Blood, 
spleen, lungs 
7 SC 0 10 CS-DS nanoparticles 
loaded with PTXd 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
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     SC = Subcutaneous administration; IN = Intranasal administration; adm. = administration 
 
 
 
8 SC 10 10 CS-DS nanoparticles 
loaded with IgA and PTXd 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
9 SC 0 0 Blank CS-DS 
nanoparticles (Control 
group 3) 
Day 1, 14 and 
21 of study 
30 days Blood, 
spleen, lungs 
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4.2.2.4. Collection and processing of blood and tissues from mice at the 
termination of immunological studies 
Blood from each animal was collected in sterile centrifuge tubes on 
30
th
 day of first immunizaiton dose using cardiac puncture technique under 
deep anaesthesia induced by administration of ketamine (80mg/Kg) in 
combination with xylazine (16mg/Kg) by intraperitoneal route. All the animals 
were sacrificed by euthanasia by cervical dislocation under deep anaesthesia. 
Lungs and spleen from each mouse were also excised after dissection and kept 
into 1mL of PBS containing 0.1% w/v BSA and 2mL of complete DMEM 
(CDMEM) nutrient medium respectively.  
The collected blood from animals was kept for half an hour on ice 
and then centrifuged at 4000 rpm (1500 x g) for 10 min to collect supernatant as 
serum. All the serum samples were kept frozen at -80ºC until tested by ELISA 
for anti-PTXd specific IgG, IgG1, IgG2a and IgG2b antibody isotypes and/or 
subclasses. Lungs collected from each mouse were homogenized in a glass tube 
with the help of a plunger and the homogenate was centrifuged at 13000 rpm 
(12000 x g) for 10 min to collect the supernatant which was kept frozen at -
80ºC until being tested by ELISA to determine antigen specific IgA. 
4.2.2.5. Preparation and culture of splenocytes 
The individual spleens collected from each mouse were 
homogenised using a syringe plunger and passed through cell strainer (sieve) to 
produce spleen cell suspension. These spleen cell suspension were pooled to get 
two pooled cell suspension per animal group i.e, three individual mouse spleen 
cell suspensions from same animal group were pooled. The pooled cell 
suspensions were centrifuged at 1000 rpm for 10 minutes and cell pellet was 
redispersed in ACK buffer followed by incubation for 5 minutes at room 
temperature. Cell suspension was again centrifuged at 1000 rpm for 10 minutes 
and cell pellet was redispersed in complete Dulbecco‟s Modified Eagle 
Medium (CDMEM) nutrient medium. Cells were washed three times and 
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finally redispersed in 1mL of CDMEM nutrient medium. The concentration of 
cells was measured using hemocytometer cell counting and appropriate dilution 
was made to get cell concentration of 10
7 
cells per mL. Using sterile 24-well 
flat bottomed tissue culture plates, 1mL of splenocyte suspension (1 X 10
7
 
cells/mL) from each pooled cell suspension was plated in triplicate along with 
20μl of the mitogen solution [Con A - 5μg (positive control) or PTX - 2μg or 
PBS only (negative control)]. The plates were incubated in a humidified 5% 
CO2 incubator for 72 hours at 37°C. The plates were centrifuged and the clear 
supernatants stored at -80ºC until being tested by ELISA to estimate IFN-γ 
concentration. General details of cell-culture techniques and cell counting 
method are compiled in Appendix 7.2. 
4.2.2.6. Estimation of anti-PTXd serum antibodies using ELISA 
Flat-bottom microtiter plates (Catalog no. 442402, Nunc immuno 
96 microwell plates) were coated with 2μg/mL PTX solution in carbonate-
bicarbonate pH 9.6 coating buffer and incubated overnight in fridge at 4 ± 2ºC. 
Wells were aspirated and plates were washed four times with wash buffer and 
each well was blocked with 300 µl of blocking buffer for 30 minutes at 25 ± 
2ºC. Plates were aspirated followed by washing four times with wash buffer, 
100 µl of diluted serum sample in dilution buffer was added per well, and 
incubated for 60 minutes at 25 ± 2ºC. Plates were aspirated followed by 
washing five times with wash buffer and 100 µl of diluted HRP-labeled goat 
anti-mouse IgG or HRP-labeled goat anti-mouse IgG1 or HRP-labeled goat 
anti-mouse IgG2a or HRP-labeled goat anti-mouse IgG2b antibodies in dilution 
buffer (0.4 μg/mL) was added to each well and incubated for 60 minutes at 25 ± 
2ºC. Plates were aspirated followed by washing five times, developed for 30 
min at 25 ± 2ºC with HRP substrate (3,3',5,5'-tetramethylbenzidine), stopped 
with 1M HCl, and read at 450 nm with a microplate reader (Victor
3
V
™
 Wallac 
1420 multilabel counter, PerkinElmer life and analytical sciences, Turku, 
Finland). Serial dilutions of each serum sample were made and run in ELISA 
for estimation of anti-PTXd titers for each animal of every group. At the end of 
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each washing set and before addition of next reagent, plates were inverted on 
absorbent paper to remove any residual buffer. Formula and preparation method 
of different buffers used in ELISA are included in Appendix 7.1. 
4.2.2.7. Estimation of anti-PTXd IgA in lung homogenates  
Flat-bottom microtiter plates (Catalog no. 442402, Nunc immuno 
96 microwell plates) were coated with 2 μg/mL PTX solution in carbonate-
bicarbonate pH 9.6 coating buffer and incubated overnight in fridge at 4 ± 2ºC. 
Wells were aspirated and plates were washed four times with wash buffer and 
each well was blocked with 300 µl of blocking buffer for 30 minutes at 25 ± 
2ºC. Plates were aspirated followed by washing four times with wash buffer, 
100 µl of diluted lung homogenate supernatant sample in dilution buffer was 
added per well, and incubated for 60 minutes at 25 ± 2ºC. Plates were aspirated 
followed by washing five times with wash buffer and 100 µl of diluted HRP-
labeled goat anti-mouse IgA antibodies in dilution buffer (0.4 μg/mL) was 
added to each well and incubated for 60 minutes at 25 ± 2ºC. Plates were 
aspirated followed by washing five times, developed for 30 min at 25 ± 2ºC 
with HRP substrate (3,3',5,5'-tetramethylbenzidine), stopped with 1M HCl, and 
read at 450 nm with a microplate reader (Victor
3
V
™
 Wallac 1420 multilabel 
counter, PerkinElmer life and analytical sciences, Turku, Finland). Serial 
dilutions of each lung homogenate supernatant sample were made and run in 
ELISA for estimation of anti-PTXd titers for each animal of every group. At the 
end of each washing set and before addition of next reagent, plates were 
inverted on absorbent paper to remove any residual buffer. Formula and 
preparation method of different buffers used in ELISA are included in 
Appendix 7.1. 
4.2.2.8. Estimation of splenocyte IFN-γ using ELISA 
Microwells of flat-bottom microtiter plates (Catalog no. 442402, 
Nunc immuno 96 microwell plates) were coated with 100μl per well of capture 
antibody diluted in coating buffer (carbonate-bicarbonate pH 9.6 buffer). Plates 
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were sealed and incubated overnight at 4°C. Wells were aspirated and washed 
four times with wash buffer. Plates were blocked with 300μl per well of 
blocking agent and incubated at 25 ± 2 °C for 1hours. Plated were aspirated 
followed by washing four times with wash buffer, 100 µl of splenocyte culture 
supernatant sample or recombinant mouse IFN-γ standard was added per well 
and incubated for 2hours at 25 ± 2ºC. Plates were aspirated followed by 
washing five times with wash buffer and 100 µl of working detector 
(biotinylated anti-mouse IFN-γ monoclonal antibody + streptavidin-horseradish 
peroxidase conjugate) was added to each well and incubated for 60 minutes at 
25 ± 2ºC. Plates were aspirated followed by washing five times, developed for 
30 min at 25 ± 2ºC with HRP substrate (3,3',5,5'-tetramethylbenzidine), stopped 
with 1M HCl, and read at 450 nm with a microplate reader (Victor
3
V
™
 Wallac 
1420 multilabel counter, PerkinElmer life and analytical sciences, Turku, 
Finland). Recombinant mouse IFN-γ standard solutions in the concentration 
range of 1000 pg/mL to 62.5pg/mL were run along with samples in the plate. 
At the end of each washing set and before addition of next reagent, plates were 
inverted on absorbent paper to remove any residual buffer. Formula and 
preparation method of different buffers used in ELISA are included in 
Appendix 7.1. 
4.2.2.9. Statistical analysis 
The normalized data was analyzed and processed to calculate mean 
with standard error of mean for each animal group using Microsoft excel 2007 
(Microsoft Inc., USA). All animal group results were statistically compared by 
one-way ANOVA followed by post Tuckey test and comparative graphs were 
plotted using Graphpad Prism statistical software (v5 demo, Graphpad Inc., 
CA, USA). Details of calculations done for titer dtermination are explained in 
appendix 7.6. 
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4.3. RESULTS AND DISCUSSION 
4.3.1. Selection of animal model for in-vivo studies 
Mouse is the most frequently used animal in the literature for investigating 
immune responses against Bordetella pertussis because it can closely, albeit not in 
entirety, resembles the human immune response. Although humans are the only 
natural host for this bacterium, mice can be infected with B. pertussis with the 
exception of the absence of cough after infection, and have been used and accepted 
as a model for studies on immunity against this pathogen.
348, 349
 As the animal 
experiments were designed to evaluate immune responses induced by 
nanoparticulate formulations, accompanied by the fact that the proposed work can 
not be carried out in vitro, mouse model was selected for the proposed studies. 
Female Balb/c mice were selected for all the in-vivo experiments because of their 
known less aggressive nature compared to the males of same breed which allows 
possibility of keeping a group of mice together in one cage without causing 
significant stress to any of the animals.   
4.3.2. CLSM visualization of IgA-loaded CS-DS nanoparticles in nasal 
epithelia 
To evaluate the site of uptake for IgA-loaded CS-DS nanoparticles on 
intranasal administration, a confocal laser scanning microscopy (CLSM) study 
using Balb/c mice as animal model was performed. First control animal nasal tissue 
was only treated with UEA-1 attached to TRITC flourescent marker for specific 
labeling of the M-cells in NALT as shown in Figure 4.1a. UEA-1 is a plant lectin 
reported to specifically bind with L-fucose present on the surface of M-cells in 
mice.
201, 350
 Second control animal nasal tissue was only treated with Hoechst 33342 
fluorescent marker for nonspecific labeling of every epithelial cell as Hoechst 33342 
labels nuclei of each cell (Figure 4.1b). Visualization of IgA loaded nanoparticles in 
nasal epithelia after administration of loaded formulation administered through the 
nasal route to Balb/c mice was performed using anti-mouse IgA-FITC conjugated 
based on the specific antigen-antibody reaction of IgA-loaded nanoparticles with 
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anti-mouse IgA-FITC conjugated. FITC, TRITC and Hoechst all have distinct 
excitation and emission wavelengths which allow their concomitant use on a single 
tissue sample without any significant interference. The nasal tissues of animals 
administered with IgA loaded CS-DS nanoparticles were treated with all three 
markers (Hoechst 33342, UEA-I attached to TRITC and anti-mouse IgA FITC 
conjugated). The presence of FITC (green) attached to anti-mouse IgA around 
UEA-I conjugated TRITC (red) was observed (Figure 4.1c). This co-presence of 
green and red colour in confocal microscopy pictures indicates the preferential 
uptake of IgA loaded CS-DS nanoparticles in nasal associated lymphoid tissue 
(NALT) probably by M-cells. The z-scan series pictures of each of nasal tissue are 
compiled in Appendix 7.5. 
 
 
126 
 
  
      (a)    (b)               (c) 
 
Figure 4.1. CLSM visualization of nasal epithelia, (a) specific labelling of M-cells in NALT with UEA-TRITC; (b) non-
specific labelling of epithelial cells in nasal mucosa with Hoechst 33342; (c) targeting of NALT by IgA-loaded nanoparticles.
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As early as in 1992, Porta et al
351
 reported that latex beads coated with 
sIgA instilled into mouse intestinal loops are taken up by M-cells present in Peyer‟s 
patch follicle-associated epithelial tissue. The group on the basis of their confocal 
study using fluorescent beads also stated that bead adsorption and uptake was 
greater at the edge compared with the apex of follicle domes. In an another study, 
Zhou et al
310
 used IgA-coated liposomes for rectal delivery of a soluble model 
antigen and reported that the presence of IgA on the liposome surface increased the 
uptake of liposomes into Peyer‟s patch mucosa, and the local mucosal rectalo-
colonic immune response to model antigen about 5-fold over uncoated liposomes. 
Inspite of these earlier studies through oral and rectal routes, any study reporting use 
of IgA loaded particulate delivery system for intranasal administration could not be 
found in literatue. The results of CLSM study carried out for this thesis support 
previous studies
310, 351
 and further broaden the potential of IgA as M-cell targeting 
agent through mucosal routes. It is important to mention here that various previous 
studies
30, 314, 352, 353
 have reported uptake of particulate delivery systems by M-cells 
situated in NALT on nasal administration of particulates. The confocal microscopy 
study in this thesis did not differentiate the contribution of nanoparticulate nature of 
delivery system and presence of IgA in nanoparticles on preferential uptake of IgA-
loaded CS-DS nanoparticles by M-cells on nasal administration. Further studies are 
warranted to separately estimate the contribution of particulate nature of 
nanoparticles and IgA in preferential targeting of NALT by IgA loaded CS-DS 
nanoparticles. 
4.3.3.  In-vivo immunological comparative evaluation of formulations 
through subcutaneous route of administration 
The developed PTXd loaded CS-DS nanoparticle formulations with or 
without mouse IgA were compared against a conventional alum adjuvanted PTXd 
formulation for induction of systemic, mucosal and cell-mediated immune 
responses through subcutaneous route of administration. Subcutaneous route is one 
of the parenteral routes normally used for vaccine administration and alum is the 
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regulatory approved as well as most commonly used adjuvant in vaccine 
formulations for parenteral administration.  
For the quantitative comparison of humoral immune responses (systemic 
and mucosal), the raw absorbances data was processed to calculate titers. All the 
titer values for every animal and every immune response parameter were calculated 
using same method as described in detail in appendix 7.6. In brief, the mean of 
blanks (antigen and antibody free wells) was subtracted from normalized 
absorbances of samples and graphs were plotted with absorbance on Y axis versus 
dilution factor for sample on the X axis. A linear regression fit was performed for 
the absorbance values between 0.1 and 1.0 and linear trendline was extrapolated to 
X-axis to find the corresponding dilution factor as antibody titer. In other words, the 
cut-off point was 0.1 optical density (Appendix 7.6). 
Table 4.4 and Figure 4.2 shows the comparative antigen-specific serum 
IgG levels induced by different formulations administered by subcutaneous route 
(raw data compiled in appendix 7.6). The PTXd loaded CS-DS nanoparticle 
formulations induced significantly higher serum IgG antibody levels compared to 
alum-adjuvanted PTXd formulation. The negative control group of animals 
administered with blank CS-DS nanoparticles showed negligible induction of serum 
IgG response. The level of significance in the difference between serum anti-PTXd 
IgG titer levels induced by IgA+PTXd loaded CS-DS nanparticles and alum 
adjuvanted PTXd formulation was higher (p < 0.001) compared to the difference 
between serum IgG titer levels induced by PTXd loaded CS-DS nanoparticles and 
alum-adjuvanted PTXd formulation (p < 0.05). Additionally, the level of 
significance for the difference between serum anti-PTXd IgG titers induced by 
PTXd loaded CS-DS nanoparticles formulation and alum adjuvanted PTXd 
formulation was found as p = 0.057. These results indicate that enhanced serum IgG 
response induced by IgA and PTXd loaded CS-DS nanoparticle formulation 
compared to alum adjuvanted PTXd formulation may be due to the synergistic 
adjuvant effect of CS-DS nanoparticles and IgA. However, lack of significant 
difference at p < 0.05 between serum anti-PTXd IgG titers induced by PTXd-loaded 
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CS-DS nanopaticle formulation and IgA+PTXd-loaded CS-DS nanoparticle 
formulation indicate that out of two contributing sources of adjuvant activity CS-DS 
nanoparticles may play a major role. 
Table 4.3. Antigen specific serum IgG antibodies titer induced in animals by 
different formulations administered by subcutaneous route 
Animal PTXd + alum 
PTXd in CS-DS 
nanoparticles 
PTXd and 
IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1 275.92 2276.67 1862.33 Negligible 
2 239.35 259.78 1665.25 Negligible 
3 138.00 452.54 1554.24 Negligible 
4 87.80 861.88 2141.17 Negligible 
5 439.80 1641.20 2091.50 Negligible 
6 794.43 1540.25 2020.50 Negligible 
MEAN  329.22 1172.05 1889.16 N/A 
SE 115.66 317.38 97.42 N/A 
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Figure 4.2. Comparative antigen specific serum IgG antibodies level induced by 
different formulations administered by subcutaneous route (* p < 0.05; *** p < 
0.001; error bar represents standard error) 
 
Production of immunoglobulin isotypes is associated with different T-
helper responses. The serum IgG subclass profiles are utilized as an indicative of 
Th1 or Th2 responses against an antigen.
248, 354, 355
 Th1 cells secrete IFN-γ and 
interleukin-2 (IL-2), promoting the production of IgG2a. Th2 cells secrete IL-4, IL-
5 and IL-10, promoting the production of IgG1.
356
  Table 4.5 and Figure 4.3 shows 
antigen specific serum IgG1 levels induced by different formulations administered 
through subcutaneous route (raw data compiled in appendix 7.6). The results for 
serum IgG1 are in accord with the results for serum IgG and indicate that CS-DS 
nanoparticle formulation with or without IgA induced significantly higher (p < 0.05 
or p < 0.01) IgG1 antibody immune response compared to alum adjuvanted 
conventional formulation. Similar to serum IgG results this can be interpreted from 
IgG1 results that CS-DS nanoparticle formulation/delivery system has major effect 
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in induction of enhanced serum IgG1 antibody levels with a minor synergestic 
effect in presence of IgA in the formulation. 
 
Table 4.4. Antigen specific serum IgG1 antibodies titer induced in animals by 
different formulations administered by subcutaneous route 
Animal PTXd + alum 
PTXd in CS-DS 
nanoparticles 
PTXd and IgA 
in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1 291.28 2179.25 2184.25 Negligible 
2 990.22 1888.40 982.87 Negligible 
3 154.00 287.16 988.60 Negligible 
4 514.81 2000.50 1220.87 Negligible 
5 522.00 1087.50 2034.40 Negligible 
6 240.39 1022.83 2270.50 Negligible 
MEAN 452.12 1410.94 1613.58 N/A 
SE 135.34 299.11 250.13 N/A 
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Figure 4.3. Comparative antigen specific serum IgG1 antibodies level induced 
by different formulations administered by subcutaneous route (* p < 0.05; ** p 
< 0.01; error bar represents standard error). 
 
 
The results obtained for antigen specific serum IgG2a antibody response 
are shown in Figure 4.4 and Table 4.6 (raw data included in appendix 7.6). There 
was no significant difference in the level of IgG2a antibody response induced by 
different PTXd formulations administered through subcutaneous route and overall, 
the serum IgG2a antibody response was lower compared to serum IgG1 antibody 
response for all PTXd formulations. Similar results were also obtained for IgG2b 
antibody response as shown in Figure 4.5 and Table 4.7. In addition, all the animals 
in the animal group administered with PTXd formulations did not show IgG2a and 
IgG2b immune response i.e, some of the animal(s) per animal group showed 
negligible or zero IgG2 immune response (Figure 4.4 and 4.5). 
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The results of IgG1 and IgG2a antibody response indicate induction of a 
predominant Th2 immune response by all PTXd formulations as the ratio of IgG2a 
to IgG1 antibodies in serum was found to be smaller than 1 for all PTXd 
formulations. On the other hand, the number of animals per group that showed 
IgG2a immune response was found higher in case of PTXd-loaded CS-DS 
nanoparticles compared to alum adjuvanted PTXd formulation as well as IgA and 
PTXd-loaded CS-DS nanoparticles formulation (Figure 4.4). This result suggests 
that the chitosan nanoparticulate formulation may have some adjuvant properties 
relating to Th1 cells.  
To further investigate the cell-mediated immune response induced by 
different PTXd formulations, IFN-γ in splenocyte culture supernatants of each 
animal group was estimated (data included in appendix 7.6). The IFN-γ ELISA 
results showed that in the presence of Con-A all the splenocyte cultures obtained 
from different animal groups (including negative control group) irrespective of the 
administration of any formulation secreted high concentration of IFN-γ. Contrary to 
Con-A treatment, all the splenocytes cultures incubated with PBS secreted very low 
concentrations of IFN-γ. Surprisingly though, all the splenocyte culture supernatants 
irrespective of the differences in immunization of different groups showed  
absorbances higher than 1 in IFN-γ ELISA when the splenocytes were incubated 
with PTX (appendix 7.6). The  results obtained from splenocyte cultures when 
incubated with PTX could be because of the use of PTX and not PTXd as stimulant 
in splenocyte culture incubation as PTX has been demonstrated as a strong mitogen 
for T-lymphocytes.
357-359
 Hence, for complete evaluation of the Th1 (cell mediated) 
immunological adjuvant properties of CS-DS formulations, further immunological 
studies with higher doses of PTXd, larger size animal groups and modified methods 
for cell-mediated immune response estimation are warranted. These studies could 
not be carried out because of time and financial constraints. 
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Table 4.5. Antigen specific serum IgG2a antibodies titer induced in animals by 
different formulations administered by subcutaneous route 
Animal 
PTXd + alum 
PTXd in CS-DS 
nanoparticles 
PTXd and 
IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1  Negligible 224.87  Negligible 
Negligible 
2 217.23 249.18  Negligible 
Negligible 
3  Negligible Negligible 117.50 
Negligible 
4 122.08 238.67 205.28 
Negligible 
5 77.62 57.84 201.09 
Negligible 
6 59.56 279.88 231.31 
Negligible 
MEAN 119.12 210.09 188.80 
N/A 
SE 35.24 39.12 24.69 
N/A 
 
135 
 
1
10
100
1000
PTXd+Alum PTXd in CS-DS
nanoparticles
PTXd & IgA in
CS-DS nanoparticles
Blank CS-DS
nanoparticles
4/6 4/6
5/6
0/6
A
n
ti
-P
T
X
d
 s
e
ru
m
 I
g
G
2
a
 t
it
e
r
 
Figure 4.4. Comparative antigen specific serum IgG2a antibodies level induced 
by different formulations administered by subcutaneous route (error bar 
represents standard error; fractional numbers in graph represent the number of 
animals in a group showed measurable antibody titer as numerator and total number 
of animals in a group as denominator). 
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Table 4.6. Antigen specific serum IgG2b antibodies titer induced in animals by 
different formulations administered by subcutaneous route 
Animal PTXd + alum 
PTXd in CS-DS 
nanoparticles 
PTXd and 
IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1  Negligible 394.18  Negligible Negligible 
2 204.81 241.26  Negligible Negligible 
3  Negligible Negligible 52.08 Negligible 
4 55.19 59.63 230.83 Negligible 
5 60.99 68.84 216.43 Negligible 
6  Negligible 50.95 233.00 Negligible 
MEAN 106.99 162.97 183.08 N/A 
SE 48.93 67.70 43.82 N/A 
 
 
137 
 
1
10
100
1000
PTXd+Alum PTXd in CS-DS
nanoparticles
PTXd & IgA in
CS-DS nanoparticles
Blank CS-DS
nanoparticles
3/6
5/6
4/6
0/6
A
n
ti
-P
T
X
d
 s
e
ru
m
 I
g
G
2
b
 t
it
e
r
 
Figure 4.5. Comparative antigen specific serum IgG2b antibodies level induced 
by different formulations administered by subcutaneous route (error bar 
represents standard error; fractional numbers in graph represent the number of 
animals in a group showed measurable antibody titer as numerator and total number 
of animals in a group as denominator). 
 
 
The quantification of anti-PTXd sIgA was performed on lung 
homongenate supernatants. The subcutaneous administration of the vaccine 
formulations was unable to induce the production of anti-PTXd IgA as expected
360
 
(raw data included in appendix 7.6).  
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It is noted that various studies in last two decades
361-363
 have investigated 
utility of chitosan based particles through mucosal routes for vaccine delivery but 
there are fewer studies
364, 365
 reporting chitosan particulate delivery systems for 
parenteral vaccine administration. Zhu et al
365
 developed the chitosan microspheres 
and used to deliver a fusion protein through subcutaneous route. The group reported 
that the fusion protein incorporated in chitosan microspheres elicited strong humoral 
and cell-mediated immune response. The authors have explained the enhancement 
in immune response as a result of readily uptake of chitosan microspheres with 
appropriate size (~ 1-10μm) by APCs and release of antigen within the cell when 
chitosan is degraded by the lysozymes. It is interesting to note here that though 
various studies have used particulate delivery systems for vaccine delivery and 
reported the effect of particle size on induction of immune responses, there is still a 
lack of clear understanding on this formulation parameter. Xiang et al.
23
 suggested 
that particles of different particles size ranges may follow different endocytic 
pathways and be preferentially taken up by different phagocytic cells. If uptake and 
processing of different sized particles occurs via different mechanisms, these may 
bias immune responses to generate a specific type of immunity. Particles in the size 
range of 20–200 nm are usually taken up by receptor-mediated endocytosis and 
elicit a cellular biased response, whereas particles with the size between 0.5 μm and 
5.0 μm are predominantly taken up by phagocytosis and/or macropinocytosis and 
elicit a humoral response.
23, 339
 
Borges et al
65
 studied the alginate coated chitosan nanoparticles adsorbed 
with hepatitis B surface antigen (HBsAg) through subcutaneous route as vaccine 
delivery system. The authors reported higher anti-HBsAg serum IgG titer compared 
to control group, with the majority of antibodies being of Th2 type, when animals 
vaccinated with HBsAg loaded onto coated nanoparticles. These authors further 
reported that the co-delivery of antigen-loaded chitosan nanoparticles with or 
without alginate coating in the presence of the immunopotentiator (CpG ODN 1826) 
resulted in an increase of anti-HBsAg IgG titers that was not statistically different 
from the group receiving HBsAg loaded alginate coated nanoparticles; however, an 
increase of the IgG2a/IgG1 ratio from 0.1 to 1.0 and an increase (p < 0.01) of the 
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IFN-γ production by the splenocytes stimulated with the HBV antigen was 
observed.  This study indicates that presence of an immunostimulator for Th1 cells 
in the formulation is probably crucial for induction of high cell-mediated immune 
responses except that the antigen itself has the Th1-inducing immunogenic 
properties. 
In addition, various studies
366, 367
 have reported efficient delivery of 
vaccines using chitosan solution or gel formulations administerd through parenteral 
route of administration. Interestingly, Gordon et al
53
 compared the chitosan gel 
formulation against chitosan nanoparticle formulation using ovalbumin as model 
protein antigen through subcutaneous route of administration. The research group 
reported that ovalbumin-loaded chitosan nanoparticles showed no significant in-vivo 
immunogenicity inspite of their ability to activate APCs in-vitro but formulations of 
ovalbumin in chitosan gel were able to stimulate both cell-mediated and humoral 
immunity in-vivo. These unexpected results are explained by the authors as a result 
of difference in release profile of antigen from nanoparticle and gel formulations 
and different in-vivo conditions for different route of administration. 
Overall, the in-vivo results of the study embodied in this thesis and the 
results of previously reported studies permit postulation of the hypothesis that depot 
formation by CS-DS nanoparticles at the site of injection with slow and sustained 
release of antigen from formulation as well as immunogenic properties of chitosan 
may have resulted in enhanced immune responses compared to alum-ajuvanted 
parenteral formulation. In addition, incorporation of IgA in CS-DS nanoparticulate 
formulation may have provided synergestic immune effect especially in induction of 
Th2 immune responses. However, futher investigations to test this hypothesis are 
warranted. 
4.3.4. In-vivo immunological comparative evaluation of formulations 
through intranasal route of administration 
The developed PTXd loaded CS-DS nanoparticle formulations with or 
without mouse IgA were compared against a PTXd solution formulation for 
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induction of systemic, mucosal and cell-mediated immune responses through 
intranasal route of administration. Intranasal route has been extensively studied in 
recent past as mucosal route of administration for vaccines with even few 
commercial successes (Flumist
®
 influenza vaccine). In this study, the intention was 
to assess the effect of incorporation of a M cell targeting ligand (mouse IgA) in CS-
DS nanoparticles on induction of immune responses against the co-administered 
antigen by intranasal route. 
Table 4.8 and Figure 4.6 shows comparative antigen specific serum IgG 
levels induced by different formulations administered through intranasal route. All 
the PTXd formulations showed significantly higher serum IgG immune response 
compared to negative control groups (administered with buffer only or IgA loaded 
CS-DS nanoparticles) but no significant difference was found in serum IgG levels 
induced by different PTXd loaded CS-DS nanoparticles compared to PTXd 
solution. In addition, the antigen specific serum IgG titers induced by intranasal 
administration of PTXd-formulations were found about 10 to 100 times lower 
compared to subcutaneous administration of similar formulations. Furthermore, the 
other serum and mucosal immune responses (serum IgG1, IgG2a, IgG2b and lung 
homogenate IgA) were found almost negligible (raw data included in Appendix 
7.6). 
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Table 4.7. Antigen specific serum IgG antibodies titer induced in animals by 
different formulations administered by intranasal route 
Animal 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd and IgA 
in CS-DS 
nanoparticles 
IgA in CS-DS 
nanoparticles Buffer only 
1 28.43 24.57 22.05 Negligible Negligible 
2 78.13 28.37 61.31 Negligible Negligible 
3 21.41 61.72 19.10 Negligible Negligible 
4 30.12 46.59 71.39 Negligible Negligible 
5 22.48 31.93 19.32 Negligible Negligible 
6 24.94 29.71 64.98 Negligible Negligible 
MEAN 34.25 37.15 43.03 N/A N/A 
SE 9.73 5.80 10.32 N/A N/A 
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Figure 4.6. Comparative antigen specific serum IgG antibodies level induced 
by different formulations administered by intranasal route (error bar represents 
standard error). 
 
The overall low immune responses and lack of enhancement in immune 
responses by PTXd-loaded CS-DS nanoparticle formulations may be explained as 
follows: 
 The same dose of PTXd (10μg per mouse) was used for both subcutaneous and 
intranasal administration and it is generally accepted that at same dose mucosal 
administration of vaccines induce comparatively lower immune responses than 
parenteral administration. It is very common with mucosal administration 
especially through intranasal administration that a proportion of dose either get 
swallowed in GIT or expelled out of noses which result in lower effective dose 
compared to parenteral administration where 100% of administered dose is 
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effective.
78, 368
 Newer delivery spray-devices (e.g. Optinose BD device
368
 and 
Becton-Dickenson Accuspray
TM
 device) have been developed and suggested to 
be used for improved efficiency in intranasal delivery in human beings. 
Currently, there is no commercial device available for an accurate dose 
administration to mouse model via the nasal route.  
 The ELISA method used estimation of immune responses may not be 
sufficiently sensitive for detecting small differences between different animal 
groups and techniques with higher sensitivity such as use of fluorescent 
substrates or radioimmuno assays might be useful in comparative 
immunological studies. 
 The slow and sustained release of PTXd from CS-DS nanoparticles may have 
been beneficial in case of subcutaneous administration because of the 
possibility of depot formation at the site of injection but in case of intranasal 
administration slow and sustained release of PTXd may have slowed 
substantial exposure of PTXd to immune system. Sharma et al
78
 reviewed the 
effect of release characterstics of a vaccine delivery sytem on induction of 
immune response and emphasized that the relationship between the rate of 
antigen availability and induction of immunogenic responses is inadequately 
understood. However, it has been suggested that antigen presentation by APCs 
to naïve and effector T-cells may only be required over the first few days for an 
efficient induction of T-cell expansion and differentiation, and that the 
prolonging of antigen presentation for weeks or months may lead to T-cell 
death, decreased effector expansion and decreased cytokine production by 
recovered effectors.
369
 
   
 To summarize, the in-vivo studies conducted in this investigation indicate 
that CS-DS nanoparticulate delivery system could be useful in the delivery of 
vaccines through subcutaneous route of administration as this system significantly 
enhances the Th2 type immune responses against antigen. In addition, IgA 
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incorporation along with antigen in CS-DS nanoparticles may further enhance the 
induction of humoral immune response. Studies embodied in this thesis signified the 
importance of route of administration and probably also the release profile of 
antigen from CS-DS nanoparticles in the induction of strong immune responses 
against antigen. Studies embodied in this thesis, along with previously reported 
studies
1, 132, 276, 370
 on the development of antigen delivery systems confirm the need 
to investigate both the pharmaceutical as well as immunological parameters such as 
release profile of antigen, the effect of the targeting ligands, route of administration, 
type of immune response desired and required antigen dose for particular routes of 
administration, for different vaccine candidate antigens. 
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CHAPTER 5 
GENERAL DISCUSSION AND SCOPE OF 
FUTURE RESEARCH 
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5.1. GENERAL DISCUSSION 
There is an ever increasing need for the development of delivery systems 
capable of meeting the challenge presented by the increasing proportion of new 
therapeutically active molecules of biological or biotechnology origin rather than 
conventional synthetic chemical entities. In addition there is a drive to replace the 
conventional injection with less invasive techniques that in the case of vaccines may also 
offer a broader immunological response. Research and development of particulate 
vaccine delivery systems, especially for newer sub-unit protein and nucleic acid based 
antigens has received significant attention recently due to their potential to co-deliver 
multiple active ingredients and induce a higher immune response compared to simple 
vaccine liquid formulations. 
 
In this research project, CS-DS nanoparticles were prepared using a complex 
coacervation (polyelectrolyte complexation) technique. Particle size and zeta potential of 
the nanoparticles were used as initial optimization parameters. The optimized 
nanoparticle formulation was loaded with a model protein antigen (pertussis toxoid) 
and/or a potential immunological adjuvant with M cell targeting prospective (IgA). This 
nanoparticle system was evaluated for in-vitro parameters using various techniques 
including photon correlation spectroscopy, ELISA and SDS-PAGE. In-vivo studies were 
performed to compare and evaluate the immune responses induced by the developed 
formulations administered via the nasal and subcutaneous route.  
 
CS-DS blank nanoparticles of size and zeta potential in the range of 150 - 400 
nm and -40 to +60 mV respectively, were obtained by the simple method of preparation. 
The effect of pH change on particle size and zeta potential of CS-DS nanoparticles was 
studied by adjusting the pH of final formulations and most of the CS-DS nanoparticle 
formulations were found to be unstable at basic pH values. The instability of CS-DS 
nanoparticles in a basic pH environment can be explained by neutralization of charge 
over nanoparticles with increase in pH. This increases the probability of agglomeration 
of the nanoparticles as electrostatic repulsive forces between the nanoparticles were 
reduced, as supported by the zeta-potential approaching zero. The ratio of CS to DS, 
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order of mixing and pH of nanoparticle formulation were identified as important 
formulation factors governing the size and zeta potential of nanoparticles, which in turn 
affect the stability of the formulation. An optimized blank CS-DS nanoparticle 
formulation with particle size 314.7 ± 9.2 nm, zeta potential +53.2 ± 4.4 mV and 
isoelectric pH 8.9 (prepared with CS to DS weight ratio of 3:1) was used to load the 
antigen and/or IgA. This choice was based on the pH stability study and potential 
immunological efficiency. The entrapment efficiency of IgA and model protein in the 
CS-DS nanoparticles was significantly higher on addition in CS solution compared to 
DS solution during the preparation procedure. This might be due to the higher molecular 
weight of the chitosan compared to dextran sulfate, resulting in an increased possibility 
of intermingling of macromolecules with the chitosan compared to dextran sulfate. All 
loaded nanoparticles showed an initial release of < 15% followed by no significant 
release of IgA or PTX. This is important in ensuring that most of the active ingredients 
in the formulation remain entrapped in nanoparticles at the time of administration. 
However it is also important to mention here that it is not clearly known what kind of 
release profile of antigen from particulate vaccine delivery systems is most suitable for 
induction of strong immune responses. Furthermore, the route of administration could be 
another factor which should be considered along with release profile because it is highly 
likely that a similar in-vitro release profile of an antigen may lead to different type or 
magnitude of immune response through a different in-vivo route of administration. The 
in-vitro studies highlight the importance of pharmaceutical factors in the successful 
formulation of a vaccine. But, further research is warranted in the possibility of large 
scale production; antigen protective ability and long term storage stability of the 
nanoparticulate formulations. Freeze drying (lyophilization) has been reported by 
various recent studies
371, 372
 as a promising technique for long-term stable storage of 
protein-loaded chitosan nanoparticle formulations. These research studies provide the 
platform on which scale-up technologies required for industrial production of 
nanoparticulate vaccines could be developed in future. 
Visualization of IgA loaded nanoparticles in nasal epithelia after administration 
through the nasal route to Balb/c mice was performed using confocal microscopy. The 
in-vivo uptake study of IgA-loaded nanoparticles in the nasal epithelia of Balb/c mice 
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indicated the preferential uptake of nanoparticles in nasal associated lymphoid tissue 
(NALT) probably by M-cells. The immunological evaluation of developed formulations 
in Balb/c mice groups showed that CS-DS nanoparticle formulations induced higher 
serum IgG and IgG1 titers compared to a conventional alum adjuvanted PTXd 
formulation, administered by the subcutaneous route. The absence of mucosal immune 
responses and induction of relatively weaker cellular immune responses indicated 
preferential enhancement of Th2 type immune responses by CS-DS nanoparticle 
formulations. Intranasal administration of various PTXd formulations (CS-DS 
nanoparticle or solution formulations) failed to induce immune responses comparable to 
subcutaneous administration of the same formulations incorporating the same quatities 
of PTXd. It can be speculated that this may be due to the lack of availability of efficient 
delivery techniques for intranasal administration of vaccines to small animal models. It 
is also hypothesized that the release profile of the antigen from the CS-DS 
nanoparticulate formulations may have played an important role in the magnitude of 
immune responses induced on intranasal vs sub-cutaneous administration of vaccine 
formulations. The results of the immunological studies also signifed the importance of 
the route of administration in induction of immune responses against antigen and 
pointed toward the need for individualised formulations for different antigens. But, this 
thesis did not explored the molecular or receptor level mechanisms involved with 
immunological adjuvant properties of CS-DS nanoparticles and IgA through different 
routes of administration which create a need of further investigations in this field. 
5.2. CONCLUSIONS 
This study highlights the potential of CS-DS nanoparticles as a simple and 
effective particulate delivery system for acellular subunit antigens. The particle size and 
zeta potential of CS-DS nanoparticles can be modulated by change in pH of formulation 
and ratio of CS to DS. The research embodied in this thesis also highlighted the 
importance of optimization of formulation and pharmaceutical factors such as 
entrapment efficiency, release profile and stability in the development of an efficient 
vaccine delivery system. The optimized positively charged nanoparticulate formulation 
loaded with IgA was preferentially taken up by the NALT area of the nasal mucosa. The 
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results indicate the potential use of IgA as a targeting agent for nanoparticulate vaccine 
delivery. The induction of enhanced humoral immune responses against antigen by CS-
DS nanoparticle formulations with and without IgA administered by the subcutaneous 
route indicated the potential of CS-DS nanoparticles as a vaccine delivery system with 
in-built immunological adjuvant properties. The route of administration could be 
enlisted as one of important determinants in induction of type and magnitude of immune 
responses against antigen based on the findings of this research project. The 
immunological studies also indicated the potential relevance of IgA as a novel non-
pathogen derived immunological adjuvant for particulate vaccine delivery systems. The 
previous reports
307,308
 and this study point toward IgA as a potentially useful formulation 
ingredient in vaccine delivery systems serving different purposes (M-cell targeting agent 
and immunostimulant) depending on route of administation. Notably, further studies 
with in-depth in-vivo immunological evaluations are required to make any conclusion on 
the real potential of CS-DS nanoparticles as a vaccine delivery system and IgA as an 
immunolgical adjuvant.  
5.3. SCOPE FOR FUTURE RESEARCH 
This research project has successfully explored some of the unknown areas in 
the field of vaccine delivery system and opens new research leads which could be 
investigated in future. The important research leads which could be followed in further 
studies are: 
 Development and validation of methods for in-vitro quantification of detoxified 
PTX with a view to analysing the immune responses using chemically and 
genetically detoxified PTX. Further investigations in the development of in-vitro 
quantification methods for PTXd would be important measuring antigen loading in 
nanoparticles. 
 The short term stability (about 48 hours) of CS-DS nanoparticles in aqueous 
environment presents a need of further exploration in lyophilisation or other type 
of solidification/drying methods to get long-term storage stability for CS-DS 
nanoparticulate formulations.  
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 Future investigations are required in evaluation of the duration of the immune 
response induced by nanoparticulate formulations through different route of 
administration. 
 Further immunological in-vivo studies through different routes of administration in 
larger size animal groups with higher doses of PTXd using CS-DS nanoparticles as 
vaccine delivery system. In addition, microbial challenge studies to see the 
protective efficacy of CS-DS nanoparticulate vaccine formulations should be 
undertaken in-vivo. In addition, quality of antibodies generated by the CS-DS 
formulations using neutralization assays is desirable. 
 Development and evaluation (in-vitro and in-vivo) of CS-DS nanoparticulate 
formulations using other antigens including different type of newer antigens such 
as other protein antigens, nucleic acid based antigens, synthetic peptides and 
carbohydrate antigens. 
 Further in-vivo studies to evaluate M-cell targeting and potential immunological 
adjuvant properties of IgA with different antigens with or without different 
particulate delivery systems. Further studies are warranted to investigate 
immunological adjuvant properties of IgA on parenteral administration with an 
emphasis on elucidation of mechanism of actions involved. 
 The effect of formulation factors such as particle size, surface charge, release 
profile and presence of different ingredients in formulation on the induction of 
immune responses against incorporated antigen need to be investigated with an 
emphasis on the understanding of molecular mechanisms involved.  
It is expected that the investigations in above research leads would result in 
the generation of sufficient information and knowledge that could guide in development 
of a successful vaccine product. Overall, this investigation has made a significant 
contribution to the knowledge base pertaining to the development of nanoparticle based 
vaccine formulations against infectious diseases. 
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7.1. COMPOSITION AND PREPARATION OF BUFFERS USED 
FOR ELISA 
The following buffer systems were used in estimation of IgA, PTX, PTXd, 
serum anti-PTXd IgG, serum anti-PTXd IgG1, serum anti-PTXd IgG2a, serum anti-
PTXd IgG2b and lung homogenate anti-PTXd IgA by ELISA method:  
 Blocking buffer 
Tris buffered saline (0.05M tris, 0.138M NaCl, 0.0027M KCl) 15.25 g 
(Catalog no. T6664, Sigma Aldrich, Australia)  
Bovine serum albumin (BSA) 10 g 
Dissolved in 900 mL of distilled water, pH adjusted to 8.0 and made to 1L 
with distilled water. 
 Wash buffer 
Tris buffered saline (0.05M tris, 0.138M NaCl, 0.0027M KCl) 15.25 g 
(Catalog no. T6664, Sigma Aldrich, Australia)  
Tween 20 0.5 g 
Dissolved in 900 mL of distilled water, pH adjusted to 8.0 and made to 1L 
with distilled water. 
 Dilution buffer 
Tris buffered saline (0.05M tris, 0.138M NaCl, 0.0027M KCl) 15.25 g 
(Catalog no. T6664, Sigma Aldrich, Australia)  
Tween 20 0.5 g 
BSA 10 g 
Dissolved in 900 mL of distilled water, pH adjusted to 8.0 and made to 1L 
with distilled water. 
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Note:  
For estimation of IFN-γ in splenocyte culture supernatant by ELISA, phosphate bufferd 
saline (0.1M phosphate buffer, 0.137M NaCl, 0.0027M KCl) was used in place of Tris 
buffered saline (0.05M tris, 0.138M NaCl, 0.0027M KCl; Catalog no. P4417; Sigma 
Aldrich, Australia) for making of blocking, wash and dilution buffers as amine group 
containing buffers cannot be used with biotinylated anti-mouse IFN-γ monoclonal 
secondary antibody and streptavidin-horseradish peroxidase conjugate. 
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7.2. ROUTINE CELL CULTURE AND STORAGE OF CELL 
LINES 
 Routine passaging / splitting of cells 
Cell lines were routinely maintained and sub-cultured aseptically. To 
passage the cells, 75 cm
2
 cell-culture flask containing 80-90% confluent cells were 
removed from the 37 °C CO2 incubator and placed in a bio-safety cabinet. The 
complete nutrient medium containing 100 µg/mL penicillin-streptomycin and 10% 
FCS was removed from the flask and cells were trysinized by addition of 2.5% 1 mL 
trypsin/EDTA followed by incubation at 37 °C in a CO2 incubator for 3-5 minutes. 
The trypsinized cells were pipetted up and down in the flask to loosen the cells. 50-
200 µL of the trypsinized cells were added to a new 75 cm
2
 flask containing 10 mL 
complete nutrient medium and incubated until next sub-culturing. 
 Freezing of cells 
One or more 75 cm
2
 flasks containing cells of 80% confluence were 
normally used for as a source of cells for freezing. The flasks were trypsinized and 5 
mL complete nutrient medium was added to each flask. The cell suspension from 
each flask was combined into a 15 mL centrifuge tube and centrifuged at 1000 rpm 
for 5 min. The supernatant medium was aspirated and cells were resuspended 
uniformly in 1 mL or appropriate volume of medium for cell counting. Cell counting 
was performed using a haemocytometer with conversion factor (CF) of 10,000 for a 
counting chamber of depth 0.1 mm. The 20 µL cell suspension aliquot was added to 
20 µL of 0.14% trypan blue. The mixture was added to the haemocytometer to fill 
the chamber. The chamber consists of 25 small squares separated by triple border 
lines in a large central square. The cells were counted in 25 small squares of the 
large square. The equation (equation 7.1) for viable cells per mL is,  
   (7.1) 
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 The cells were added with chilled complete nutrient medium to obtain 
approximately 10
6
 cells/mL. 900 µL of cell suspension was added to each Nunc 
cryotube containing 100 µL chilled DMSO. All the cryotubes were then placed in 
the cryo freezing container and stored at -70 °C for 24 hours followed by transferto 
liquid nitrogen for long term storage. 
 Thawing and culturing of cells 
The cryotubes containing cells were removed from liquid nitrogen and 
thawed in a 37 °C water bath. The contents of a cryotube were then transferred to a 
15 mL centrifuge tube containing 9 mL warm complete nutrient medium and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed and the cells were 
resuspended in 1 mL warm complete nutrient medium. 0.5 mL of cell suspension 
was added to each 75 cm
2
 flask containing 10 mL complete nutrient medium and 
incubated in a 37°C CO2 incubator. 
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7.3. COMPOSITION AND PREPARATION OF GEL MIXTURES 
USED FOR SDS-PAGE 
 Resolving Gel Mixture (10%) 
1.5M Tris HCl buffer, pH 8.8     4.0 mL 
10% w/v SDS solution      100 µL 
30% acrylamide/bis-acrylamide     3.3 mL 
10% ammonium persulfate     100 µL 
N, N, N', N'-tetramethylethylenediamine (TEMED)  10 µL 
Distilled water       4.0 mL 
The mixture was made up and degassed for 5 minutes at room temperature 
before the addition of ammonium persulfate and TEMED.    
 Stacking Gel Mixture (4%) 
0.5M Tris HCl buffer, pH 6.8     2.5 mL 
10% w/v SDS solution      100 µL 
30% acrylamide/bis-acrylamide     1.3 mL 
10% ammonium persulfate     100 µL 
TEMED        10 µL 
Distilled water       6.1 mL 
The mixture was made up and degassed for 5 minutes at room temperature 
before addition of ammonium persulfate and TEMED. 
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7.4. ESTIMATION OF PTXd USING SANDWICH ELISA 
METHOD (RAW DATA) 
It was tried to develop a sensitive, accurate and reproducible sandwich 
ELISA method for PTXd as explained in chapter 3. But the developed method failed to 
provide any reproducible data with a meaningful correlation with concentration of 
PTXd, necessary to develop a standard (calibration) curve. Table 7.1 represents 
variability in absorbances (raw data) for same PTXd concentration in different ELISA 
runs. Even runs with higher concentrations of PTXd (4 and 10 µg/mL) in sandwich 
ELISA could not produce reproducibility or correlation in absorbance and concentration. 
The results of sandwich ELISA for PTXd led to the use of PTX for entrapment 
efficiency and release studies as explained in chapter 3. 
 
Table 7.1 Representative raw data obtained for PTXd estimation by sandwich 
ELISA method. 
PTXd concentration (ng/mL) 
Average absorbance 
(Run 1) 
Average absorbance 
(Run 2) 
125 0.239 0.168 
250 0.294 0.207 
500 0.270 0.328 
1000 0.234 0.294 
2000 0.268 0.421 
Negative controls  
(Ag and Ab free wells) 
0.189 0.169 
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7.5. Z-SCAN CLSM PICTURE SERIES OF NASAL TISSUES 
   
   
   
   
Figure 7.1 Z-scan confocal pictures of nasal tissue treated with UEA-1 - TRITC 
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Figure 7.2 Z-scan confocal pictures of nasal tissue treated with Hoechst 33342  
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Figure 7.3 Z-scan confocal pictures of nasal tissue treated with Hoechst 33342, 
UEA-1 conjugated with TRITC and anti-mouse IgA conjugated with FITC 
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7.6. IN-VIVO IMMUNOLOGICAL DATA AND CALCULATIONS 
The mean of blanks (antigen and antibody free wells) was subtracted from 
normalized absorbances of samples and graphs were plotted with absorbance on Y axis 
versus dilution factor for sample on the X axis. A linear regression fit was performed for 
the absorbance values between 0.1 and 1.0 and linear trendline was extrapolated to X-
axis to find the corresponding dilution factor as antibody titer. If no two processed 
absorbace values (after subtraction of mean absorbance value for blanks) for any 
dilution of a sample were found above 0.1, then titer was assumed negligible (zero) for 
that particular sample. In other words, the cut-off point was 0.1 optical density. The data 
for all immunological parameters (serum IgG, serum IgG1, serum IgG2a, serum IgG2b, 
lung homogenate IgA and splenocyte culture supernatant IFN-γ) is attached below. The 
calculations for titer determination have been examplified here for serum IgG1 
responses induced by subcutaneous administration of PTXd formulations. Same 
calculation procedures have been followed for all parameters and final comparative 
graphs and tables are included in chapter 4. 
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Table 7.2 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG1 induced by subcutaneous administration of PTXd 
formulations  
Animal Dilution 
factor 
PTXd + Alum PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1 40 1.640 3.345 3.381 0.327 
100 0.854 3.388 3.016 0.285 
200 0.602 1.511 1.450 0.301 
400 0.401 1.111 1.103 0.26 
800 0.211 0.888 0.845 0.271 
1600 0.202 0.611 0.548 0.258 
2 40 3.445 3.415 2.376 0.388 
100 2.245 3.434 1.160 0.341 
200 1.112 1.700 0.988 0.310 
400 0.854 1.210 0.745 0.332 
800 0.540 0.808 0.580 0.320 
1600 0.310 0.584 0.401 0.305 
3 40 0.585 1.938 3.363 0.415 
100 0.480 0.734 2.204 0.354 
200 0.310 0.545 1.218 0.344 
400 0.258 0.408 0.858 0.324 
800 0.165 0.314 0.561 0.288 
1600 0.175 0.211 0.403 0.311 
4 40 2.373 3.436 3.411 0.285 
100 1.100 2.204 1.788 0.277 
200 0.805 1.917 1.106 0.215 
400 0.602 1.661 0.885 0.202 
800 0.405 0.845 0.588 0.189 
202 
 
 
 
 
 
 
 
 
 
 
 
 
  
Average absorbance for blanks (antigen free and antibody wells) = 0.378 
 
1600 0.301 0.512 0.405 0.178 
5 40 3.321 3.328 3.404 0.444 
100 1.708 2.101 2.458 0.405 
200 0.884 1.549 1.957 0.380 
400 0.555 1.081 1.257 0.354 
800 0.405 0.696 0.882 0.365 
1600 0.301 0.463 0.607 0.371 
6 40 2.173 2.599 3.414 0.361 
100 1.175 1.696 2.888 0.314 
200 0.602 0.943 1.854 0.325 
400 0.405 0.622 1.152 0.322 
800 0.401 0.526 0.888 0.345 
1600 0.388 0.410 0.620 0.323 
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Table 7.3 Corrected absorbance data for serum anti-PTXd IgG1 (obtained by subtraction of average absorbance for blanks) 
Animal Dilution 
factor 
PTXd + Alum PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1 40 1.262 2.968 3.004 -0.051 
100 0.476 3.010 2.638 -0.093 
200 0.224 1.133 1.072 -0.077 
400 0.023 0.733 0.725 -0.118 
800 -0.166 0.510 0.467 -0.107 
1600 -0.176 0.233 0.170 -0.120 
2 40 3.067 3.037 1.998 0.010 
100 1.867 3.057 0.782 -0.037 
200 0.734 1.322 0.610 -0.068 
400 0.476 0.832 0.367 -0.046 
800 0.162 0.430 0.202 -0.058 
1600 -0.068 0.206 0.023 -0.073 
3 40 0.207 1.561 2.985 0.037 
100 0.102 0.356 1.826 -0.024 
200 -0.068 0.167 0.840 -0.034 
400 -0.120 0.030 0.480 -0.054 
800 -0.213 -0.064 0.184 -0.090 
1600 -0.202 -0.167 0.025 -0.067 
4 40 1.995 3.058 3.033 -0.093 
100 0.722 1.826 1.410 -0.101 
200 0.427 1.539 0.728 -0.163 
400 0.224 1.283 0.507 -0.176 
800 0.027 0.467 0.210 -0.189 
1600 -0.077 0.134 0.027 -0.200 
5 40 2.943 2.951 3.026 0.066 
100 1.330 1.723 2.080 0.027 
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200 0.506 1.171 1.579 0.002 
400 0.177 0.703 0.880 -0.024 
800 0.027 0.319 0.504 -0.013 
1600 -0.077 0.086 0.229 -0.007 
6 40 1.795 2.221 3.036 -0.017 
100 0.797 1.319 2.510 -0.064 
200 0.224 0.566 1.476 -0.053 
400 0.027 0.244 0.774 -0.056 
800 0.023 0.148 0.510 -0.033 
1600 0.010 0.032 0.242 -0.055 
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Figure 7.4 A plot between corrected absorbances (0.1 - 1.0) and dilution factor with 
linear model fitting for calculation of titer for mice immunised with PTXd and 
alum by subcutaneous route. 
 
 
 
 
 
Figure 7.5 A plot between corrected absorbances (0.1 – 1.0) and dilution factor with 
linear model fitting for calculation of titer for mice immunised with PTXd-loaded 
CS-DS nanoparticles by subcutaneous route. 
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Figure 7.6 A plot between corrected absorbances (0.1 – 1.0) and dilution factor with 
linear model fitting for calculation of titer for mice immunised with PTXd and IgA-
loaded CS-DS nanoparticles by subcutaneous route. 
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Table 7.4 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG2a induced by subcutaneous administration of 
PTXd formulations 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.148 
Animal Dilution 
factor 
PTXd + Alum 
group 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
Blank CS-DS 
nanoparticles 
1 10 0.288 0.956 0.238 0.192 
40 0.257 0.648 0.238 0.170 
160 0.241 0.417 0.208 0.163 
2 10 0.586 0.521 0.283 0.203 
40 0.446 0.343 0.218 0.182 
160 0.299 0.301 0.204 0.179 
3 10 0.340 0.210 0.345 0.198 
40 0.301 0.210 0.302 0.213 
160 0.221 0.196 0.250 0.185 
4 10 0.263 0.537 1.106 0.202 
40 0.212 0.346 0.654 0.133 
160 0.209 0.299 0.414 0.129 
5 10 0.391 0.520 0.940 0.26 
40 0.305 0.314 0.544 0.202 
160 0.277 0.249 0.362 0.170 
6 10 0.760 1.616 0.550 0.224 
40 0.419 0.820 0.357 0.19 
160 0.291 0.512 0.298 0.185 
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Table 7.5 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG2b induced by subcutaneous administration of 
PTXd formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average absorbance for blanks (antigen free and antibody wells) = 0.228 
Animal Dilution 
factor 
PTXd + Alum 
group 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
Blank CS-DS 
nanoparticles 
1 10 0.358 3.300 0.281 0.312 
40 0.179 1.221 0.209 0.188 
160 0.178 0.888 0.186 0.198 
2 10 2.223 1.336 0.225 0.345 
40 1.183 0.851 0.191 0.182 
160 0.484 0.475 0.152 0.179 
3 10 0.282 0.224 0.574 0.288 
40 0.178 0.179 0.329 0.213 
160 0.174 0.175 0.247 0.185 
4 10 0.730 0.605 3.284 0.202 
40 0.396 0.376 1.222 0.133 
160 0.223 0.209 0.602 0.129 
5 10 0.815 0.758 2.370 0.350 
40 0.470 0.488 1.221 0.301 
160 0.311 0.219 0.545 0.245 
6 10 0.482 0.670 1.818 0.224 
40 0.251 0.345 0.942 0.190 
160 0.168 0.192 0.498 0.185 
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Table 7.6 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG induced by subcutaneous administration of PTXd 
formulations  
Animal Dilution 
factor 
PTXd + Alum PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-DS 
nanoparticles 
Blank CS-DS 
nanoparticles 
1 25 0.538 2.905 2.217 0.242 
50 0.430 2.104 1.498 0.170 
100 0.323 1.511 0.988 0.163 
200 0.298 1.111 0.597 0.161 
400 0.211 0.800 0.415 0.168 
800 0.233 0.611 0.345 0.154 
1600 0.222 0.482 0.285 0.144 
2 25 0.793 0.771 1.540 0.203 
50 0.655 0.632 1.235 0.182 
100 0.485 0.503 0.988 0.179 
200 0.320 0.335 0.745 0.165 
400 0.280 0.264 0.580 0.156 
800 0.202 0.244 0.401 0.155 
1600 0.154 0.211 0.301 0.156 
3 25 0.548 0.885 1.522 0.476 
50 0.405 0.684 1.110 0.213 
100 0.310 0.545 1.000 0.185 
200 0.258 0.408 0.858 0.170 
400 0.165 0.314 0.561 0.155 
800 0.175 0.211 0.403 0.158 
1600 0.161 0.170 0.338 0.154 
4 25 0.345 1.102 2.845 0.202 
50 0.282 0.888 2.057 0.133 
100 0.211 0.682 1.917 0.129 
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Average absorbance for blanks (antigen free and antibody wells) = 0.182
200 0.185 0.505 1.661 0.111 
400 0.142 0.410 1.294 0.112 
800 0.120 0.305 0.846 0.112 
1600 0.116 0.260 0.501 0.102 
5 25 0.854 2.584 2.804 0.329 
50 0.688 1.885 2.463 0.266 
100 0.528 1.549 1.957 0.224 
200 0.377 1.081 1.257 0.202 
400 0.296 0.696 0.882 0.184 
800 0.198 0.463 0.607 0.168 
1600 0.166 0.295 0.334 0.170 
6 25 0.982 0.943 2.888 0.185 
50 0.774 0.727 2.154 0.158 
100 0.534 0.692 1.184 0.144 
200 0.406 0.526 0.888 0.130 
400 0.354 0.458 0.62 0.134 
800 0.298 0.384 0.544 0.138 
1600 0.271 0.285 0.410 0.121 
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Table 7.7 ELISA data (absorbance at 450nm) for lung homogenate anti-PTXd IgA induced by subcutaneous 
administration of PTXd formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.259 
 
Animal Dilution 
factor 
PTXd + Alum 
group 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
Blank CS-DS 
nanoparticles 
1 5 0.338 0.345 0.363 0.334 
10 0.209 0.242 0.336 0.307 
2 5 0.277 0.214 0.333 0.285 
10 0.227 0.207 0.209 0.224 
3 5 0.297 0.310 0.488 0.295 
10 0.283 0.266 0.333 0.263 
4 5 0.330 0.377 0.293 0.315 
10 0.281 0.282 0.329 0.351 
5 5 0.252 0.237 0.208 0.233 
10 0.190 0.220 0.208 0.230 
6 5 0.411 0.430 0.456 0.466 
10 0.329 0.333 0.329 0.318 
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Table 7.8 Data (absorbances at 450nm) obtained from estimation of IFN-γ in 
splenocyte culture supernatants of subcutaneously immunized animal groups using 
ELISA method. 
 
 
Average absorbance for blanks (antigen free and antibody wells) = 0.305 
 
 
 
 
 
Table 7.9 Data (absorbance at 450nm) obtained for IFN- γ standards in ELISA 
method. 
  
 
 
 
 
 
 
 
Formulation used for 
immunization of 
animal group  ↓ 
Splenocytes 
stimulated with  
Con-A 
Splenocytes 
stimulated with 
PBS 
Splenocytes 
stimulated with 
PTX 
PTXd + Alum  2.979 0.695 3.304 
PTXd and IgA in CS-
DS nanoparticles 
3.374 0.622 2.344 
PTXd in CS-DS 
nanoparticles 
3.407 0.837 2.559 
Blank nanoparticles  3.345 0.633 2.750 
IFN- γ standards 
Conc. (pg/mL) Absorbance 
2000 3.233 
1000 2.385 
500 1.585 
250 1.124 
125 1.056 
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Table 7.10 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG1 induced by intranasal administration of PTXd 
formulations 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Average absorbance for blanks (antigen free and antibody wells) = 0.109 
Animal Dilution 
factor 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
IgA in CS-DS 
nanoparticles 
Buffer only 
1 10 0.271 0.185 0.158 0.130 0.167 
20 0.162 0.142 0.112 0.109 0.129 
2 10 0.186 0.157 0.170 0.200 0.119 
20 0.146 0.135 0.127 0.198 0.105 
3 10 0.168 0.193 0.148 0.100 0.101 
20 0.173 0.135 0.123 0.103 0.126 
4 10 0.208 0.134 0.117 0.126 0.122 
20 0.169 0.118 0.111 0.118 0.113 
5 10 0.171 0.148 0.243 0.121 0.116 
20 0.117 0.131 0.162 0.113 0.103 
6 10 0.158 0.258 0.238 0.104 0.224 
20 0.127 0.169 0.173 0.121 0.188 
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Table 7.11 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG2a induced by intranasal administration of 
PTXd formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.183 
Animal Dilution 
factor 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
IgA in CS-DS 
nanoparticles 
Buffer only 
1 5 0.170 0.139 0.168 0.156 0.188 
20 0.159 0.125 0.162 0.131 0.144 
80 0.171 0.126 0.134 0.148 0.148 
2 5 0.235 0.155 0.182 0.198 0.121 
20 0.177 0.139 0.156 0.188 0.112 
80 0.162 0.122 0.168 0.154 0.103 
3 5 0.169 0.156 0.153 0.185 0.145 
20 0.152 0.145 0.137 0.188 0.161 
80 0.169 0.146 0.162 0.145 0.125 
4 5 0.180 0.157 0.175 0.144 0.170 
20 0.137 0.133 0.161 0.121 0.162 
80 0.146 0.121 0.153 0.104 0.104 
5 5 0.161 0.152 0.141 0.112 0.145 
20 0.153 0.128 0.133 0.107 0.158 
80 0.137 0.130 0.133 0.109 0.128 
6 5 0.169 0.177 0.161 0.158 0.184 
20 0.152 0.154 0.148 0.148 0.158 
80 0.137 0.158 0.131 0.155 0.161 
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Table 7.12 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG2b induced by intranasal administration of 
PTXd formulations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.230 
 
Animal Dilution 
factor 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
IgA in CS-DS 
nanoparticles 
Buffer only 
1 5 0.312 0.425 0.160 0.172 0.420 
10 0.215 0.180 0.154 0.130 0.200 
2 5 0.598 0.463 0.413 0.158 0.310 
10 0.228 0.318 0.322 0.157 0.285 
3 5 0.170 0.526 0.172 0.175 0.245 
10 0.138 0.246 0.156 0.144 0.232 
4 5 0.498 0.356 0.411 0.246 0.202 
10 0.181 0.167 0.215 0.180 0.215 
5 5 0.388 0.528 0.380 0.266 0.354 
10 0.251 0.266 0.270 0.228 0.301 
6 5 0.342 0.487 0.335 0.254 0.314 
10 0.160 0.194 0.169 0.235 0.228 
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Table 7.13 ELISA data (absorbance at 450nm) for serum anti-PTXd IgG induced by intranasal administration of PTXd 
formulations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.151 
 
Animal Dilution 
factor 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
IgA in CS-DS 
nanoparticles 
Buffer only 
1 3 0.375 0.460 0.443 0.255 0.311 
12 0.297 0.331 0.306 0.222 0.247 
48 0.228 0.219 0.200 0.212 0.220 
2 3 0.482 0.393 0.590 0.188 0.238 
12 0.346 0.307 0.397 0.198 0.209 
48 0.275 0.216 0.252 0.154 0.131 
3 3 0.363 0.668 0.526 0.230 0.170 
12 0.260 0.417 0.317 0.202 0.134 
48 0.210 0.273 0.210 0.212 0.148 
4 3 0.463 0.352 0.521 0.301 0.195 
12 0.360 0.311 0.356 0.206 0.207 
48 0.250 0.226 0.272 0.199 0.161 
5 3 0.399 0.400 0.630 0.144 0.265 
12 0.285 0.323 0.366 0.137 0.233 
48 0.185 0.214 0.225 0.141 0.214 
6 3 0.553 0.408 0.519 0.193 0.171 
12 0.389 0.393 0.371 0.165 0.135 
48 0.246 0.232 0.252 0.150 0.128 
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Table 7.14 ELISA data (absorbance at 450nm) for lung homogenate anti-PTXd IgA induced by intranasal administration 
of PTXd formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average absorbance for blanks (antigen free and antibody wells) = 0.300 
 
 
Animal Dilution 
factor 
PTXd 
solution 
PTXd in CS-DS 
nanoparticles 
PTXd & IgA in CS-
DS nanoparticles 
IgA in CS-DS 
nanoparticles 
Buffer only 
1 5 0.276 0.284 0.265 0.310 0.288 
10 0.259 0.265 0.270 0.291 0.244 
20 0.231 0.260 0.234 0.248 0.248 
2 5 0.227 0.284 0.222 0.298 0.221 
10 0.202 0.242 0.207 0.288 0.212 
20 0.225 0.235 0.219 0.254 0.203 
3 5 0.306 0.313 0.262 0.285 0.292 
10 0.278 0.285 0.262 0.274 0.261 
20 0.199 0.246 0.262 0.245 0.225 
4 5 0.288 0.294 0.294 0.302 0.360 
10 0.215 0.267 0.351 0.300 0.334 
20 0.206 0.221 0.253 0.254 0.304 
5 5 0.207 0.208 0.221 0.233 0.237 
10 0.197 0.225 0.210 0.224 0.220 
20 0.177 0.212 0.203 0.190 0.177 
6 5 0.372 0.374 0.370 0.346 0.392 
10 0.301 0.354 0.314 0.331 0.358 
20 0.337 0.358 0.331 0.255 0.261 
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Table 7.15 Data (absorbances at 450nm) obtained from estimation of IFN-γ in 
splenocyte culture supernatants of animal groups immunized by intranasal route 
using ELISA method. 
 
Average absorbance for blanks (antigen free and antibody wells) = 0.305 
 
 
 
Formulation used for 
immunization of 
animal group  ↓ 
Splenocytes 
stimulated with  
Con-A 
Splenocytes 
stimulated 
with PBS 
Splenocytes 
stimulated with 
PTX 
Buffer only  3.327 0.781 3.367 
Blank nanoparticles  3.411 0.721 3.384 
PTXd solution  3.447 0.686 3.385 
PTXd and IgA in CS-
DS nanoparticles 
3.395 0.757 2.180 
IgA in CS-DS 
nanoparticles  
3.353 0.571 3.161 
PTXd in CS-DS 
nanoaparticles  
3.244 0.538 1.661 
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